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Peripheral Haemodynamic Studies In Patients With Cirrhosis And
Portal Hypertension.
Background & Objectives. Patients with liver cirrhosis and portal hypertension have
systemic vasodilatation and activated neurohumoral systems. These abnormalities
worsen with disease severity and are responsible for the development of its
associated complications. The aims of the present series of studies were to evaluate
the contribution of endogenous angiotensin II (ANG II) to the maintenance of basal
and sympathetically-stimulated peripheral vascular tone, to assess the contribution of
endothelin-1 and nitric oxide (NO) to the maintenance of basal peripheral vascular
tone; to determine the forearm vascular responses to exogenous ANG II, endothelin-
1, and noradrenaline; and to study the role of endogenous NO release in mediating
the peripheral vascular response to ANG II and to endothelin receptor antagonism.
Methods: In patients with cirrhosis and matched healthy controls, bilateral forearm
blood flow (FBF) was measured using venous occlusion plethysmography at
baseline, and after unilateral sub-systemic, intra-brachial infusions of incremental
doses of agonists or selective receptor antagonists, with or without the application of
lower body negative pressure (LBNP) or 'NO-clamp': a balanced co-infusion of L-
NMMA (a NO synthase inhibitor) and sodium nitroprusside (an exogenous NO
donor) to block endogenous NO release and restore normal basal blood flow
respectively. Baseline systemic haemodynamic parameters, and plasma hormonal
concentrations, were also measured using electrical bioimpedance and radioimmuno¬
assay respectively.
Results: Noradrenaline, angiotensin II, endothelin-1, BQ-788 (a selective endothelin
type B receptor antagonist), and L-NMMA reduced FBF and, whilst responses to
noradrenaline, BQ-788, and L-NMMA were similar across groups, those to ANG II
and endothelin-1 were greater in the healthy controls than in patients with cirrhosis.
Both losartan (a selective ANG II type 1 receptor antagonist) and BQ-123 (a
selective endothelin type A receptor antagonist) increased FBF, but responses to
losartan were enhanced only in patients with advanced cirrhosis, and those to BQ-
123 were enhanced in patients with pre-ascitic cirrhosis. LBNP caused similar
reductions in FBF during both saline and losartan infusions. Flowever, responses to
LBNP were less in patients with advanced cirrhosis only. In the presence of the 'NO-
clamp', the ANG II mediated vasoconstriction was enhanced in patients with
cirrhosis, unchanged in controls, and became similar in both groups. In contrast, the
BQ-123-induced vasodilatation was abolished in controls and attenuated in patients
during the 'NO-clamp', with FBF remaining significantly greater in patients with
cirrhosis.
Conclusions: These studies indicate that ANG II contributes to the maintenance of
basal peripheral vascular tone only in advanced cirrhosis, but not to sympathetically-
stimulated vascular tone. The impaired responses to ANG II and endothelin-1 are
apparent in early cirrhosis, whilst those to LBNP are impaired only in advanced
cirrhosis despite normal responses to noradrenaline infusion. In addition, the
enhanced BQ-123 vasodilatation suggests an activated endothelin system and a
greater contribution of endogenous ET-1 to the maintenance of basal forearm
vascular tone in patients with pre-ascitic cirrhosis. These findings suggest a
compensated vasodilated state and a role of ANG II, endothelin-1 and the
cardiopulmonary baroreceptors in the pathogenesis and perpetuation of the
haemodynamic derangements of early and advanced cirrhosis respectively.
Moreover, there is an important interaction between the endogenous tonic
vasopressor and vasodepressor systems since NO generation largely mediates the
vasodilatation response to ETA receptor antagonism, and, in patients with cirrhosis,
the impairment of ANG II vasoconstriction.
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CHAPTER 1
INTRODUCTION AND AIMS
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1. Haemodynamics of cirrhosis and portal hypertension
1.1. Historical background:
1.1.1. Liver cirrhosis:
Liver cirrhosis is a serious chronic disease that has been recognised for many
centuries. Hippocrates wrote "in cases ofjaundice, it is a bad sign when the liver
becomes hard" (Chadwick & Mann 1950). Matthew Baillie, a Lanarkshire-born
physician, has provided the earliest illustration of a cirrhotic liver in 1793. However,
Laennec was the first physician to use the term 'cirrhosis' early in the nineteenth
century. Later in the same century, William Osier wrote that in cirrhosis "the
prognosis is, as a rule, bad" (Osier 1892). At present, cirrhosis of the liver is known
to have a variety of causes, and is one of the greatest health problems worldwide.
1.1.2. Portal Hypertension:
Portal hypertension has also been recognised for a number of centuries, and was
identified as a potential cause of gastrointestinal bleeding by Vesaluis and Morgagni
(Sandblom 1993). Oesophageal varices were shown to be a site of communication
between the systemic and portal venous systems by Sappey in the nineteenth century
(Sandblom 1993). The term 'portal hypertension' was first used in 1906 (Gilbert &
Villaret 1906), and, until 1937, the increase in portal pressure could only be
measured directly at laparotomy (Sandblom 1993). Although under investigation for
50 years, the pathogenesis of portal hypertension remains poorly characterised and
incompletely understood.
1.1.3. Haemodynamics of portal hypertension:
The first evidence of increased total plasma volume in the patients with cirrhosis was
obtained in 1946 (Perera 1946). The association between portal hypertension and a
hyperdynamic circulatory state was first described by Kowalski & Abelmann in
1953, subsequently confirmed by others (Murray et al 1958; Kontos et al 1964), and
reviewed later by Martini et al in 1972. The presence ofmarked splanchnic
vasodilatation in patients with cirrhosis was reported by Kotelanski et al 1972.
However, in the early 1960s, many studies showed that the incidence of arterial
hypertension is 10 times less in patients with cirrhosis than the general population,
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and that arterial hypertension in these patients disappears with the development of
portal hypertension (Lowke 1962; Mashford et al 1962). Plevris and colleagues have
shown inverse correlation between the arterial blood pressure and the severity of
liver disease (Plevris et al 1990).
1.2. Description:
The haemodynamic changes of portal hypertension refer mainly to increased cardiac
output (CO), increased heart rate (HR), reduced systemic vascular resistance (SVR),
and splanchnic vasodilatation. The severity of these changes correlates with the
clinical indices of hepatic dysfunction (Braillon et al 1986; Schrier et al 1988;
Bendtsen et al 1990; Meng et al 1994). A list of the components of the hyperdynamic
syndrome in cirrhosis is shown in Table 1-1.
1.3. Importance and sequels
The hyperdynamic disturbances associated with portal hypertension are no longer an
academic curiosity. Indeed, it is influenced by the aetiology of liver disease, which is
most frequently alcohol-related in western countries. Moreover, many studies have
shown that certain haemodynamic characteristics, including the low arterial blood
pressure, have prognostic significance (Llach et al 1988, Gluud et al 1988). In
addition, the hyperdynamic disturbances may be responsible for the development of
the life-threatening complications of cirrhosis including ascites, hepatic
encephalopathy, variceal haemorrhage (Schrier et al 1988), and hepatorenal failure
(Epstein et al 1970; Badalamenti et al 1993). These complications, especially
variceal haemorrhage, are serious and may lead directly to death (D'Amico et al
1986). Therefore, a better understanding of the mechanism(s) underlying this
hyperdynamic circulation is essential for the development of therapeutic, and
possibly preventive, interventions.
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Table 1-1: The hyperdynamic circulatory syndrome of cirrhosis.
Organ Changes
Cardiovascular system T Cardiac output & T heart rate
>I Mean arterial pressure
i Systemic vascular resistance
-I Peripheral oxygen utilization
T Plasma volume
Cardiac dysfunction and ? heart failure
Lungs •I Diffusion capacity
i Partial pressure of oxygen
Hepatopulmonary syndrome
Kidney 4- —> Renal blood flow
•I Glomerular filteration rate
Na+ and water retention
Hepatorenal syndrome
Brain ■I —> Cerebral blood flow
? Encephalopathy
? Brain oedema
Liver and splanchnic circulation Portal hypertension
t Portal blood flow
4- —» T Hepatic blood flow
t Sinusoidal vascular resistance
opened portosystemic collaterals
Skin and muscle T—» Skin blood flow
T—» Muscle blood flow
•I = decrease. —> = normal, t = increased.
The haemodynamic changes are related to liver pathology as evidenced by the
significant rise in the mean arterial pressure (MAP) and SVR, and the reduction in
the cardiac index (CI) following orthotopic liver transplantation (Navasa et al 1993;
Gadano et al 1995). The nature of the relationship between liver pathology, portal
hypertension, SVR, and renal blood flow is unclear, although there is evidence of a
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hepatorenal reflex (Jalan et al 1997). However, the haemodynamic changes also exist
in association with pre-hepatic portal hypertension (e.g. due to portal vein thrombosis
or hepatic schistosomiasis) in the absence of cirrhosis (Bosch et al 1988), suggesting
an independent role of high portal pressure in the pathogenesis of circulatory changes
in cirrhosis.
1.4. Pathogenesis:
Portal hypertension is initiated by the increased hepatic vascular resistance within the
cirrhotic liver [the backward theory], and is exacerbated by the increase in portal
blood flow [the forward theory] (Vorobioff et al 1983; Benoit et al 1985; Bosch et al
1988; Grose & Hayes 1992; Figure 1-1).
Pressure = Resistance x Flow
The backward theory The forward theory
FIGURE 1-1: PATHOGENESIS OF PORTAL HYPERTENSION.
Over the last 4 decades, many theories have been proposed to explain the
pathogenesis of the hyperdynamic circulatory changes and its complications
especially ascites formation, in patients with cirrhosis. In general, these
haemodynamic changes have been linked to the development of portal hypertension
and liver dysfunction, but the exact mechanism remains controversial (Badalamenti
et al 1993, Wong et al 1997). The following theories have been proposed:
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1.4._1. The "Underfill Theory":
This theory suggests that the imbalance between hepatic sinusoidal hydrostatic and
oncotic pressures leads to the accumulation of hepatic lymph in the peritoneal cavity,
with a subsequent reduction in the effective arterial blood volume that stimulates the
vasoconstrictor systems, and triggers renal sodium and water retention (Figure 1-2).
However, this theory supposes that the plasma volume and CO would be low, which
is not the case even in the pre-ascitic stage of the disease (Witte et al 1971; Epstein
1979).
♦
Loss of intravascular fluids
Ascites Hypovolemia
I
FIGURE 1-2: DIAGRAM OF THE UNDERFILL THEORY
Chapter 1: Introduction & Aims 7
1.4._2. The "Overflow Theory":
This theory" proposes that renal sodium retention stimulated by liver dysfunction
and/or portal hypertension, perhaps via a humoral factor or the autonomic nervous
system, produces expansion of plasma volume and CO (Figure 1-3). This does not
explain the disproportionate increase in the vascular compartment, reduction in SVR,







High capillary hydrostatic pressure
I
Lymph formation > lymph return
I
Ascites formation
Low effective circulating volume
I
Activation of vasopressor systems
Sodium & water retention
I
Expansion of plasma volume and CO
FIGURE 1-3: DIAGRAM OF THE OVERFLOW THEORY.
CO, cardiac output.
1.4.3. The "Peripheral Arterial Vasodilatation Theory":
This theory (Figure 1-4) superseded and unified the strongest aspects of its
predecessors, and proposes that portal hypertension and other factors stimulate
peripheral vasodilatation leading to a reduction in the SVR and "effective"
hypovolemia. This results in compensatory activation of the vasoconstrictor system
including the renin-angiotensin system (RAS), the sympathetic nervous system
(SNS), and the anti-diuretic hormone (ADH), in an attempt to restore normal SVR.
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This usually succeeds in increasing the blood volume and restoring blood pressure in
patients with pre-ascitic cirrhosis and mild to moderate portal hypertension, and as a
result, inactivates the vasoconstrictor systems either partial or complete (Schrier et al
1988).
Portal Hypertension Impaired liver function
\ I
Portosystemic shunting High endogenous vasodilators
I I




Activation of SNS, RAS, Endothelin & vasopressin
I
Increased renal vascular resistance, Na+
& H20 retention
i i
Increased SVR & CO
I
Ascites formation
? Restoration of effective arterial
blood volume
FIGURE 1-4: DIAGRAM OF THE PERIPHERAL ARTERIAL
VASODILATATION THEORY
CO, cardiac output. RAS, renin angiotensin system. SNS, sympathetic nervous
system SVR, systemic vascular resistance.
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In patients with severe portal hypertension, however, the increase in blood volume is
not sufficient to normalise the SVR, the vasoconstrictor systems become more
activated with a continued renal fluid retention. Ascites then develop as a result of
fluid sequestration from the portal venous system into the peritoneal cavity (Rahman
et al 1992). Recently, the peripheral arterial vasodilatation theory has been
challenged (Wong et al 1997) following demonstrations in some patients that the
hyperdynamic syndrome is only evident when they are seated (Iwao et al 1997;
Bernardi et al 1992) and that the increase in CO precedes peripheral vasodilatation
(Lewis et al 1992). This suggests that primary arteriolar dilatation, followed by a
compensatory increase in CO, is not the main mechanism underlying the
development of the hyperdynamic circulation. Rather, the increase in CO, with a
compensatory reduction in SVR has been proposed to result from an increase in the
cardiac preload (Bernardi & Trevisani 1997).
1.5. Site of initial vasodilatation:
Traditionally, the cutaneous and muscular vascular territories have been proposed as
the main site of dilatation (Kontos et al 1964). However, this has recently been
challenged by in vivo studies, which showed that the brachial and femoral
components of the CO are actually reduced in patients with cirrhosis and ascites
(Fernandez-Seara et al 1989; Maroto et al 1993). Many studies in animals and
humans with cirrhosis have indicated that vasodilatation occurs mainly in the
splanchnic bed (Vorobioff et al 1984; Sato et al 1987; Maroto et al 1993; Iwao et al
1997), but cutaneous and muscular vasodilatation may also contribute to the
reduction in SVR (Bernardi & Trevisani 1997; Fernandez-Seara et al 1989; Steele et
al 1994). Teleologically, this makes sense, as one would believe that amongst the
first changes seen might be a direct attempt to increase blood flow to the liver, which
has been reduced due to the increased sinusoidal resistance.
1.6. Aetiology of the initial vasodilatation:
The exact cause of the initial vasodilatation remains unclear. Whatever the cause of
the hyperdynamic circulation, it is evident that SVR falls in patients with cirrhosis
and persists despite activation of the vasoconstrictor systems (Laragh 1962). This fall
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in SVR may result from impaired responses to the activated vasoconstrictor systems
(Lunzer et al 1975; MacGilchrist et al 1991) due to receptor or post receptor defects
and/or increased activity of vasodilators such as atrial natriuretic peptide (ANP; Iwao
et al 1997). Additionally, increased nitric oxide (NO) release (Battista et al 1997;
Martin et al 1998) secondary to either increased shear stress (Bomzon & Blendis
1994) or activation of inducible NO synthase (iNOS; Vallance & Moncada 1991)
may be involved.
/. 7. Then vasoconstricted territories in cirrhosis:
In the presence of low SVR, activation of the vasoconstrictor systems would be
expected in patients with cirrhosis, and is believed to contribute to renal arteriolar
constriction (Arroyo et al 1988), and ultimately to development of the hepatorenal
syndrome (Badalamenti et al 1993; Forrest et al 1996). In addition, cerebral
vasoconstriction has been reported in these patients (Aggarwal et al 1994; Dillon et
al 1995). Doppler ultrasound studies have also shown brachial and femoral
vasoconstriction (Fernandez-Seara et al 1989; Maroto et al 1993), and thermography
studies showed reduced peripheral blood flow (Steele et al 1994; Forrest et al 1995).
However, the presence of pulmonary vasodilatation that develops in the context of a
hepato-pulmonary syndrome (Matsubara et al 1984) indicates that the
vasoconstriction is not universal.
1.8. Circulating blood volume in cirrhosis:
Central blood volume is the volume of blood present in the central vascular
compartments, and is responsible for stimulation of the low-pressure
cardiopulmonary and arterial receptors. Studies measuring mean transit time of an
indicator calculated central blood volume and found that it is reduced in patients with
cirrhosis and ascites, but peripheral blood volume is significantly increased (Wong et
al 1994; Henriksen & Moller 1996). Moreover, central blood volume correlates
directly with total SVR and inversely with portal pressure and the activity of the SNS
(Henriksen & Moller 1996). Also, central blood volume is reduced in animals with
portal hypertension (Colombato et al 1996). In addition, central blood volume can be
assessed indirectly by measuring the activity of neurohumoral vasoconstrictor
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systems (Henriksen et al 1998). Indeed, most patients with cirrhosis and ascites have
activated vasoconstrictor systems, which can be suppressed by the administration of
vasopressor agents or by the expansion of the plasma volume (Wong et al 1979;
Shapiro et al 1985; Gines et al 1997; Jalan & Hayes 2000). These findings indicate
that arterial vasodilatation causes an abnormal distribution of the total blood volume
and a reduction in the effective arterial blood volume.
1.9. Haemodynamics and the stage ofcirrhosis:
1.9.1. Stage of pre-ascitic cirrhosis:
Patients in the pre-ascitic stage of cirrhosis have moderate portal hypertension,
increased total blood volume, increased CO, decreased SVR, and normal arterial
pressure (Bosch et al 1988; Bernardi & Trevisani 1997). The changes in CO and
SVR are more apparent in the supine position, and are probably caused by
misdistribution of total blood volume, with increased blood volume in the splanchnic
circulation that moves to the central circulation on lying down (Bernardi et al 1992;
Bernardi & Trevisani 1997). In addition, when patients with pre-ascitic cirrhosis are
given a high sodium diet, their central blood volume failed to increase, and the
activity of vasoconstrictor systems are not suppressed, confirming misdistribution of
total blood volume (La Villa et al 1992). Compared with healthy volunteers, patients
with pre-ascitic cirrhosis show increased mesenteric blood flow and normal femoral
blood flow, as measured by Doppler ultrasonography. This indicates the early onset
of splanchnic arterial vasodilatation and confirms total blood volume misdistribution
(Iwao et al 1997).
Despite their apparently normal renal function, these patients fail to escape the
sodium-retaining effect of mineralocorticoids, and are unable to excrete a sodium
load (Wood et al 1988; La Villa et al 1992; Gines & Schrier 1997). Moreover,
natriuresis in these patients is significantly less when they remain upright compared
with the supine position (Bernardi et al 1993) Also, in the upright position, patients
with pre-ascitic cirrhosis have higher plasma aldosterone concentrations than healthy
volunteers, and their plasma AMP concentrations are normal. On assuming the supine
position, however, the plasma concentrations of aldosterone become normal, and
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plasma ANP concentrations increase markedly (La Villa et al 1992; Bernardi et al
1993). Misdistribution of blood volume may be the cause of these hormonal changes,
and may explain the subtle sodium retention observed when these patients are supine.
1.9.2. Stage of cirrhosis and ascites;
Patients with cirrhosis and ascites have severe portal hypertension, markedly
increased intrahepatic vascular resistance, increased total blood volume, high CO,
low SVR, and low arterial pressure (Groszmann 1994; Moller et al 1997). These
haemodynamic changes are associated with persistent activation of the
vasoconstrictor systems including the RAS, the SNS, the endothelin system, and
vasopressin (Bichet et al 1982; Martin et al 1998). This activation is not affected by
postural changes (Bernardi et al 1995). Moreover, the use of pharmacological agents
to antagonise the effects of these vasoconstrictor systems produced marked reduction
in total SVR and systemic hypotension. This indicates that activation of the
vasoconstrictor systems in patients with decompensated cirrhosis constitutes a
compensatory mechanism to maintain integrity of the systemic circulation
(Schroeder et al 1976; Claria et al 1991; Esler et al 1992).
Patients with cirrhosis and ascites show elevated plasma ANP concentrations and
reduced renal responses to this peptide (Gines et al 1988). The combination of low
SVR, systemic hypotension, and marked activation of the vasoconstrictor systems is
consistent with the peripheral vasodilatation theory (Schrier et al 1988). Furthermore,
patients in the ascitic stage of cirrhosis have functional renal abnormalities. These
include: 1) sodium retention, secondary to increased tubular reabsorption of sodium,
with subsequent ascites and oedema formation; 2) progressive impairment in the
ability to excrete solute-free water; 3) renal arteriolar vasoconstriction. These
changes may lead to the development of dilutional hyponatremia, refractory ascites,
and hepatorenal syndrome (Gines et al 1997). Substantial improvement in renal
abnormalities is associated with increasing central blood volume and suppressing the
activity of the neurohumoral systems (Shapero et al 1985; Guevara et al 1998; Soper
et al 1996).
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2. The vasoconstrictor systems in cirrhosis
2.1. Mechanism ofaction of vasoconstrictors:
Vasoconstriction may result from sympathetic stimulation (noradrenaline; Nad),
endocrine hormones (ADH and angiotensin II; ANG II), locally produced hormones
such as ET-1 (Gurney 1994), or by the myogenic response to pressure (Meninger &
Davis 1992). In fact, plasma hormones (e.g., ANG II) may be produced locally, and
the locally produced ones (e.g., ET-1) may have a humoral role.
Despite the diversity of vasoconstrictor agonists and their receptors, their mechanism
of action is very similar. Binding of a vasoconstrictor agonist to its specific receptor,
which is located on the vascular smooth muscle cells (VSMC), induces a cascade of
second messengers leading ultimately to an increase in intracellular calcium, which
is the signal for smooth muscle contraction (Figure 1-5). Briefly, the binding of
vasoconstrictors to their G-protein coupled receptors causes hydrolysis of 4,5
phosphatidylinositol (4,5-PIns), resulting in the generation of two second
messengers, inositol triphosphate (InsPs) and diacylglycerol (DAG). The former
mobilizes intracellular Ca2+ to activate protein kinase subtype C (PKC), which is one
of the main transducers of the vasoconstrictor effects (Lee & Severson 1994), and
Ca21 calmodulin dependent kinases with subsequent phosphorylation of the myosin
light chain and initiation of vasoconstriction (Rasmussen et al 1987). DAG is an
endogenous PKC activator, which plays an important role in signal transduction of
the contractile responses of the VSMC. It is generally accepted that activation of
PKC, measured by its translocation from the cytosol to cell membrane, plays an
important role in agonist-induced contraction of VSMC not only through
phosphorylation ofmyosin light chains but also through modulating Ca2' channel
2+ • •
activity, Ca pump activity, and the sensitivity of the proteins involved in
controlling the contractile process, such as calponen and desmin, to Ca2' (Andrea &
Walsh 1992).
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Agonist Receptor Reference
Nad al Han et al 1987
ADH Via Schrier et al 1993
FIGURE 1-5: MECHANISM OF ACTION OF ASOCONSTRICTORS.
ADH, anti-diuretic hormone. ANGII, angiotensin II. DAG, diacylglycerol. ET-1,
endothelin 1. Gi2, G protein of the G; family. Gq/Gn, G protein of the Gq family.
lnsP3, inositol triphosphate. Nad, noradrenaline. 4,5 Pins, phosphatidylinositol 4,5-
biphosphate. PLC, phospholipase C. PKC, protein kinase subtype C. R, receptor. SR,
sarcoplasmic reticulum. VSMC, vascular smooth muscle cell.
2.2. The sympathetic nervous system (SNS):
2.2.1. The SNS in health:
The SNS has a central role in maintaining cardiovascular homeostasis (Hjemdahl
1990). This control system consists of peripheral receptors, which are responsive to
changes in cardiovascular stability, afferent, central, and efferent integrated
pathways, and neurohumoral effectors that ultimately modulate vascular tone
(Abraham & Schrier 1994).
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Baroreceptors represent an integral part of the regulatory system involved in the
maintenance of circulatory stability (Schrier 1990). High-pressure arterial
baroreceptors such as those found in the carotid sinus and aortic arch are present
within the arterial vascular tree and will respond to changes in arterial pressure,
which, in turn, is dependent on both CO and SVR (Abraham & Schrier 1994). Low-
pressure cardiopulmonary baroreceptors respond to changes in cardiac preload,
which is dependent on venous return to the heart and central blood volume (Mohanty
et al 1985).
The reduction in cardiac preload (Stevens et al 1965) or arterial pressure (Schrier
1988), which is sensed by the low-pressure cardiopulmonary or the high-pressure
arterial baroreceptors respectively, decreases the tonic inhibitory traffic in the
afferent glossopharyngeal pathways to the central nervous system. Consequently, an
increase in the efferent sympathetic activity occurs in a trial to preserve
cardiovascular stability (Schrier 1988). The peripheral effects of this increase in SNS
activity include: a) constriction of the arterial resistance vessels, b) an increase in the
SVR, c) stimulation of renin release from the kidney leading to the activation of the
RAS, and d) positive chronotropic and inotropic effects on the heart. The resultant
increase in ANG II production will further increase the tone of the arterial resistance
vessels. In addition, the SNS activity is also important in controlling the nonosmotic
release ofADH (Schrier 1988).
Adrenergic pathways that run from the glossopharyngeal baroreceptor nuclei to the
paraventricular and supraoptic nuclei in the hypothalamus terminate on neurons in
these nuclei, which synthesise the ADH (Renud et al 1985; Brooks et al 1986; Sladek
1985). Electrical activity of the supraoptic neurons correlates with vasopressin
release and is altered by changes in systemic blood pressure suggesting a role of
vasopressin in blood pressure control (Renud et al 1985). Thus, a decrease in cardiac
preload or arterial pressure inhibits baroreceptor activity and results in a
simultaneous activation of the vasoconstrictor systems, namely, the SNS, the RAS
and the nonosmotic release of ADH. Activation of these three systems is
interdependent, and has additive and synergistic effects on the VSMC (Ishikawa et al
Chapter 1: Introduction & Aims 16
1984). The immediate response to this integrated system involves the vascular effects
of the vasopressor hormones, but maintenance of the response is assisted by
vasopressin-induced water retention, and by SNS and ANG II-mediated increase in
the proximal renal tubular reabsorption of sodium (Schrier 1988).
Activity of SNS in humans can be assessed either by recording the sympathetic
action potentials with micro-electrodes applied to the peripheral nerves (Wallin et al
1981; Christensen et al 1986), or by measuring the plasma concentration of the
sympathetic neurotransmitters, which are secreted from the synaptic cleft into the
plasma (Christensen 1973; Cryer 1976; Hjemdal 1984; Christensen et al 1986).
Indeed, plasma concentrations ofNad in venous blood in the human forearm
correlated with muscle sympathetic nervous activity (Wallen et al 1981).
2.2.2. The SNS in cirrhosis:
Since the first report by Shaldon et al in 1961, evidence of increased plasma
concentrations of catecholeamines, in patients with cirrhosis and portal hypertension,
is accumulating (Henriksen et al 1981; Arroyo et al 1983; Bichet et al 1982a;
Bernardi et al 1983; Burghardt et al 1982; Nicholls et al 1985; Bendtsen et al 1990;
Henriksen et al 1991; MacGilchrist et al 1991; Henriksen & RingLarsen 1994;
Newby et al 1998a). Because the clearance ofNad is not significantly altered in
patients with cirrhosis, the increased plasma concentration ofNad is a reflection of
an increased release, rather than a decreased clearance (Zambraski & DiBona 1988).
The highest plasma concentrations ofNad and adrenaline occur in patients with a
high Child score, more pronounced portal hypertension, avid fluid and sodium
retention, and hepatorenal syndrome (Arroyo et al 1983; Burghardt et al 1982;
Gaudin et al 1991; Blends 1993; Fernandez-Rodriguez et al 1995), and shown further
increase during P-adrenergic blockade with propranolol (Bendtsen et al 1990).
Moreover, the plasma concentration of Nad is an independent prognostic factor in
cirrhosis (Tage-Jensen et al 1988; Gines et al 1993). Also, the sympathetic burst
frequencies recorded from skeletal muscle nerve fibres were enhanced in these
patients and correlate positively with the plasma concentrations ofNad (Floras et al
1991).
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Activation of the SNS in patients with cirrhosis is a homeostatic mechanism, which
maintains basal peripheral vascular tone, as demonstrated by the reduction of arterial
pressure following intravenous clonidine infusion (Willet et al 1986). However,
activation of the SNS plays an important role in the pathogenesis of sodium and
water retention. Indeed, a significant negative correlation was observed between
plasma Nad concentrations and renal blood flow, glomerular filtration rate, urinary
sodium and water excretion (Zambraski & DiBona 1988). Moreover, patients with
cirrhosis and ascites submitted to head-out water immersion showed a significant
increase in creatinine clearance (Zambraski & DiBona 1988).
Studies using selective catheterisation and tracer kinetic methods showed that SNS
overactivity and Nad spillover occur in many organs, including the kidney, the liver,
the prehepatic splanchnic areas, the heart, muscles and skin (Henriksen et al 1981;
Henriksen et al 1984; Willet et al 1985; Henriksen et al 1986; Henriksen et al 1987;
Henriksen et al 1991, Henriksen et al 1991a). Overactivity of the SNS in patients
with cirrhosis may be triggered centrally by mechanisms such as encephalopathy and
hypoxia, or peripherally by mechanisms such as low-pressure baroreceptor
unloading, volume receptor stimulation, hepatocellular dysfunction and metabolic
derangements (Henriksen et al 1998).
2.2.3. Lower body negative pressure (LBNP):
The technique of LBNP was first described to study responses to gravitational
change (Stevens & Lamb 1965; Brown et al 1966). LBNP causes blood pooling in
lower limbs, buttocks and pelvis, as demonstrated by pooling of plasma protein-
bound 1311 (Wolthuis et al 1974), leading to a decrease in central venous pressure
(CVP) and an increase in forearm vascular resistance at all degrees of LBNP.
Lower degrees of LBNP act through unloading the low-pressure cardiopulmonary
receptors resulting in reflex sympathetic vasoconstriction in forearm resistance
vessels. Higher degrees of LBNP unload both the low-pressure cardiopulmonary
receptors and the carotid baroreceptors (Wolthuis et al 1974). Low degrees of LBNP
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(<20 mm Hg) cause marked reduction in forearm blood flow (FBF) without affecting
arterial blood pressure or FfR (Zoller et al 1972; Johnson et al 1974). In contrast,
higher degrees of negative pressure (20 - 80 mm Hg) increase FfR, reduce the
systolic and diastolic blood pressure (Steven & Lamb 1965; Brown et al 1966; Ardill
et al 1967; Johnson et al 1974; Abboud et al 1979), decrease stroke volume (SV) and
CO (Stevens & Lamb 1965; Murray et al 1968), and increase renin release (Baylis et
al 1978; Mark et al 1978). These responses were blocked by propranolol (Mark et al
1978). Moreover, plasma concentrations ofADH increase only in subjects with
LBNP-induced syncope (Baylis et al 1978; Goldsmith et al 1982) that usually
develops during sustained LBNP of 30 mmHg or more (Murray et al 1968).
Sustained application ofLBNP increases both forearm muscle sympathetic nerve
activity (Sundlof& Wallin 1978) and plasma concentrations ofNad, which correlate
with the fall in CVP (Goldsmith et al 1982; Grassi et al 1985). The LBNP-induced
decrease in FBF can be abolished following sympathectomy (Ardill et al 1967) and is
reduced by intra-brachial infusion of bethanidine or beryllium tosylate infusion
(Brown et al 1966). These findings indicate that the SNS mediates the
vasoconstriction observed during application ofLBNP.
Patients with cirrhosis and ascites have reduced vasoconstrictor responses to the
application of ice (Lunzer et al 1975) and to LBNP (Ryan et al 1993; Newby et al
1998a). The vasoconstrictor response to LBNP do not appear to be mediated by
increased ANG II release, as they are not affected by concomitant infusion of
losartan, an ANG II type 1 receptor antagonist (Newby et al 1998a). This indicates
either impairment in the vascular smooth muscle cell contractile response especially
when accompanied by impaired responses to Nad infusion (Lunzer et al 1975; Ryan
et al 1993), or impairment in the low-pressure baroreceptor reflex when the vascular
responses to Nad infusion are normal (Newby et al 1998a). The latter could be due to
receptor down-regulation and/or defective neuronal transmission. In patients with
pre-ascitic cirrhosis, however, LBNP application reduces the CVP and FBF, and
increases plasma Nad concentrations and the renal sodium retention (Wong et al
1995, Wong et al 1998). These responses were similar in both patients and healthy
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controls (Wong et al 1995, Wong et al 1998). In addition, LBNP increased renal
concentrations of renin and ANG II in both groups, but this increase was
significantly higher in the cirrhotic group (Wong et al 1998).
2.2.4. Autonomic dysfunction in cirrhosis:
Evidence of autonomic dysfunction in patients with cirrhosis has emerged from
various studies utilising various tests, such as breath-holding, isometric exercise,
atropine blockade, heart rate variability, orthostatic, and Valsalva manoeuvres
(MacGilchrist & Reid 1990; Hendrickse et al 1992; Dillon et al 1994; Laffi et al
1996). These abnormalities are associated with the presence of liver failure, and are
markers of an adverse prognosis (Dillon et al 1994; Hendrickse & Tiger 1992;
Fleckenstein et al 1996). This autonomic dysfunction does not depend on disease
aetiology (Hendrickse & Tiger 1992), and also occurs in patients with portal vein
thrombosis (Voiget et al 1997). In addition, the autonomic dysfunction in cirrhosis
involves vagal neuropathy (Hendrickse et al 1992; Hendrickse & Triger 1994), and is
reversible after liver transplantation (Mohammed et al 1996). Also, blood pressure
responses to orthostasis are impaired, probably due to blunted baroreceptor function
(Bernardi et al 1982; Bernardi et al 1983; Iwao et al 1993). Moreover, sympathetic
responses to isometric exercise are impaired in patients with cirrhosis (Bernardi et al
1982; MacGilchrist & Reid 1990). ANG Il-mediated neuromodulation may be
involved in the pathogenesis of the autonomic dysfunction in patients with cirrhosis,
as evidenced by the correction of this dysfunction by captopril, an angiotensin
converting enzyme inhibitor (Dillon et al 1997). The pathophysiological basis of the
autonomic dysfunction is currently unknown, but it could occur within the central
nervous system, within the peripheral nerves, or at the level of the post-receptor
signal transduction pathways. On the basis of the available data, a multifactorial
aetiology for the hyporesponsiveness in cirrhosis is most likely.
2.3. The renin-angiotensin system (RAS):
2.3.1. The RAS in health:
Through the direct actions ofANG II, the RAS plays a fundamental role in
regulating blood pressure and body sodium and water balance. A reduction in arterial
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pres_sure or effective arterial blood volume activates the RAS (Schrier & Caramelo
1988; Badalamenti et al 1993). Plasma concentrations of ANG II depend on the
activity of renin, which is the rate-limiting step in converting angiotensinogen to
angiotensin I, and on the activity of the angiotensin converting enzyme activity. In
addition, the RAS can be manipulated at many levels including using enzyme
inhibitors and receptor antagonists. The enzymatic cascade leading to the generation
ofANG II is shown in Figure 1-6.
At least two main ANG II receptor subtypes have been identified: the ATi and AT2
receptors. The majority of the physiological actions of ANG II, including
vasoconstriction and aldosterone release, are mediated through the AT-1 receptor,
whereas the role of the AT2 receptor remains unclear (Matsubara et al 1998;
Matsubara 1998). ANG II stimulates both endothelial NOS messenger RNA
expression (Hennington et al 1998) and endothelial NOS activity (Olson et al 1997).
Moreover, ANG II has been shown to increase NO bioavailability in isolated rings
from rat carotid artery under static conditions (Boulanger et al 1995). Indeed,
although low in large vessels such as the aorta, surface AT2 receptor expression is
high in the microvasculature (Nora et al 1998). Genetic murine AT2 receptor
knockout models are associated with increased systemic blood pressure and
enhanced vasoconstrictor responses to ANG II (Hein et al 1995) whereas targeted
overexpression of AT2 receptor leads to an increased ANG II mediated cGMP
production and reduced ANG II mediated vasoconstriction (Tsutsumi et al 1999).
In addition to the regulation of renin release, the SNS has synergistic effects with
ANG II (Peach 1977). The magnitude of ANG 11-induced vasoconstriction is
enhanced during SNS inactivation, such as with sympathectomy or adrenergic
blockade. This interaction may be produced through ANG II-mediated facilitation of
Nad release or inhibition of its reuptake (Hjemdahl et al 1996). In addition, ANG II
augments sympathetically mediated arterioconstriction (Seidelin et al 1991) and
venoconstriction (Benjamin et al 1988) even when given at doses insufficient to
cause vasoconstrictor or vasopressor responses.
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2.3.2. The RAS in cirrhosis:
The RAS is activated in patients with cirrhosis with evidence of avid sodium
retention (Epstein & Norsk 1988). This was demonstrated by increased plasma renin
activity (PRA; Schroeder et al 1976; Bernardi et al 1982; Iwao et al 1994), and by
raised plasma concentrations ofANGII (Hayes et al 1992; Newby et al 1998a) and
aldosterone (Schroeder et al 1976). The elevated PRA in patients with cirrhosis is
mainly due to an augmented renal release of renin, although reduced hepatic
extraction may contribute (Arroyo et al 1979). Plasma ANG II and aldosterone
concentrations and PRA correlate directly with the severity of cirrhosis, and
inversely with both the MAP and the SVR (Aliaga et al 1995). In addition, PRA and
plasma ANG II concentrations have been shown to correlate directly with the
wedged hepatic venous pressure in patients with cirrhosis (Bosch et al 1980). This
suggests a role for the increased intrahepatic pressure in facilitating renin release, and
a role for ANG II in the altered hepatic haemodynamics. The former is supported by
the presence of a hepatorenal reflex (Jalan et al 1997), and the latter is supported by
several studies in animal and man, which showed an increase in the wedged hepatic
venous pressure and a decrease in hepatic blood flow following systemic or portal
infusion ofANG II (Segel et al 1963; Chiandussi et al 1963; Bashour et al 1963;
Kelly & Nyhus 1966).
Despite the increased activity of the RAS, it retains its ability to respond to
haemodynamic alterations (Iwao et al 1994; Bernardi et al 1983). Indeed, the
response of the RAS may even be enhanced in patients with cirrhosis (Iwao et al
1994), but remains insufficient to restore normal haemodynamics in decompensated
subjects (Schroeder et al 1976). Two weeks following orthotopic liver
transplantation, the activity of the RAS returns to normal (Navasa et al 1993).
Reduced renal perfusion, secondary to activation of the SNS, may represent the
primary stimulus for activation of the RAS in patients with cirrhosis. However, direct
stimulation of the RAS may occur due to the reduction in the effective arterial blood
volume as evidenced by the experiments of head-out water immersion (Epstein &
Norsk 1988). In these patients, plasma aldosterone concentrations correlated
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inversely with urinary sodium excretion (Wilkinson et al 1979). This suggests a
permissive role for aldosterone in the pathogenesis in sodium retention in patients
with cirrhosis (Arroyo et al 1988), as the majority of sodium retention, according to
Epstein 1988, is due to impaired distal delivery of the filtrate. However, the co¬
existence of normal concentrations of aldosterone and sodium retention may be
explained by the presence of high tubular sensitivity to aldosterone. This is
evidenced by the ability of spironolactone, an aldosterone antagonist, to reverse
sodium retention in these patients (Wilkinson et al 1979; Arroyo et al 1988).
Administration of saralasin (an ANG II-antagonist with partial agonist activity) or
captopril (an angiotensin enzyme; ACE inhibitor) causes marked hypotension in
patients with cirrhosis and ascites (Schroeder et al 1976; Pariente et al 1985; Wood et
al 1985). Also, intra-brachial infusion of losartan, a selective ATi receptor
antagonist, increases FBF in a similar group of patients (Newby et al 1998a). These
results indicate that endogenous ANG II is essential for the maintenance of basal
vascular tone in patients with cirrhosis and ascites. In addition, activation of the RAS
is a determinant for the maintenance of glomerular filtration rate (GFR) as evidenced
by the reduction ofGFR by low dose captopril in patients with cirrhosis and ascites,
without affecting arterial pressure (Gentilini et al 1993).
2.4. The endothelin system:
2.4.1. The endothelin system in health:
Endothelin-1 (ET-1), a potent vasoconstrictor, belongs to a 21-amino acid peptide
family (ET-1, ET-2, ET-3) with a range of biological effects (Yanagisawa et al 1988;
Spokes et al 1989; Masaki et al 1992). ET-1 was originally been identified in the
culture medium of porcine aortic endothelial cells (Yanagisawa et al 1988; Masaki et
al 1992), and is derived from a larger pre-pro-endothelin-1 (212 amino acids) which
is cleaved by endopeptidases to produce big endothelin-1 (38 amino acids), which is
then converted by specific endothelin converting enzymes to ET-1 (Figure 1-7;
Yanagisawa et al 1988; Masaki et al 1992).
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Molecular studies have, so far, identified two endothelin receptor subtypes in
mammalian species (Figure 1-8): endothelin-A (ETA) and endothelin-B (ETb). In
vascular smooth muscle cells, both receptors are expressed (Spokes et al 1989;
Davenport et al 1995), and these mediate vasoconstriction (Spokes et al 1989;
Tschudi & Luscher 1994; Davenport et al 1995; Haynes et al 1995). Only the ETB
receptors are found on endothelial cells, where they cause vasodilatation through the
release of endothelium-derived vasodilators, such as nitric oxide (NO; Takayanagi et
al 1991). ET-1 induced vasoconstriction is predominantly mediated by the ETA
receptor although ETb receptors may contribute under some circumstances
(Davenport & Maguire 1994).
2.4.2. The endothelin system in cirrhosis:
Patients with advanced cirrhosis and fluid retention have elevated plasma ET-1
concentrations (Moore et al; 1992; Uchihara et al 1992; Isobe et al 1993; Asbert et al
1993; Moller et al 1993; Matsumuto et al 1994; Gerbes et al 1995; Moller et al 1995;
Salo et al 1995a; Kitano et al 1996; Newby et al 1998a; Nolte et al 2000), which are
particularly high in patients with hepatorenal syndrome (Moore et al 1992;
Bachmann-Brandt et al 2000). The elevated plasma concentrations ofET-1 normalise
after liver transplantation (Bachmann-Brandt et al 2000), but remains elevated for up
to 15 months following TIPSS (Nolte et al 2000). However, normal levels were
shown in two earlier studies (Lerman et al 1991; Textor et al 1992). These two
studies are different possibly because they involved assays, which lack sensitivity
and specificity, and patients with early cirrhosis. The mechanisms underlying the
elevated ET-1 concentrations are unclear, and do not appear to be related to
hypovolemia or endotoxemia (Salo et al 1995a; Salo et al 1995b). Recent studies
have demonstrated that high plasma concentrations ofET-1 are due to both
decreased clearance by hepatocytes, and increased production by the gut and spleen
(Kuddus et al 2000; Nagasue et al 2000). Moreover, the plasma concentrations of
ET-1 correlate positively with the severity of liver disease as measured by Child-
Pugh score (Isobe et al 1993; Moller et al 1995; Gerbes et al 1995), the hepatic blood
flow as measured by D-sorbitol infusion, and the hepatic venous pressure gradient
(Moller et al 1995), and correlate negatively with liver cell mass as measured by
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galactose elimination capacity (Gerbes et al 1995), creatinine clearance (Uchihara et
al 1992; Moller et al 1993; Moller et al 1995), and the ability to excrete a given water
load (Hocher et al 1999). However, due to its paracrine and autocrine mode of action,
the majority ofET-1 is released abluminally to act on adjacent vascular smooth
muscle and endothelial cells and, as a consequence, plasma ET-1 concentrations may
not truly reflect the underlying activity of the endothelin system (Frelin & Guedin
1994). It should be noted that ET-1 might act as an endocrine hormone when its
plasma concentrations reach a large level (Haynes & Webb 1994). The increase in
plasma ET-1 concentrations correspond with up-regulation of preproendothelin-1
mRNA and elevated plasma concentrations of big ET-1 (Newby et al 1998a)
indicating that ET-1 levels reflect an increased production, rather than reduced
clearance, of the peptide.
A role for ET-1 in the vascular abnormalities of cirrhosis is indicated by the
demonstration that low concentration of bacterial lipopolysaccharide promote ET-1
release from endothelial cells (Ros et al 1997). Furthermore, the increased expression
of both ET-1 and ETA-receptors reported in the hepatic sinusoidal endothelial and
stellate cells of cirrhotic patients (Pinzani et al 1996) indicate that increased release
ofET-1 by the cirrhotic liver may account for the raised plasma ET-1 concentrations,
and contributes to the increased intra-hepatic resistance to flow. Interestingly, whilst
the increase in circulating ET-1 concentrations is expected to cause receptor down-
regulation (Rubanyi & Polokoff 1994), a preliminary investigation of intra-hepatic
vessels indicated that the ET-1-mediated contraction is not altered in cirrhosis
(Battaglia et al 1996). No studies have addressed the vascular responsiveness to ET-1
in vivo, or the role of endogenous ET-1 in the maintenance of basal peripheral
vascular tone, in patients with cirrhosis.
Experimental studies in the rat model of cirrhosis and portal hypertension have
shown reductions in splanchnic blood flow and portal venous pressure by the non¬
selective endothelin antagonists TAK-044 (Gandhi et al 1998), bosentan (Reichen et
al 1998; Sogni et al 1998) and SP206970 (Kojima et al 2000), and by the selective
ET]j receptor antagonist, IRL1038, while selective ETA receptor antagonism
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2.5. The anti-diuretic hormone (ADH; vasopressin):
The reduction in both arterial pressure and effective arterial blood volume increase
the non-osmotic baroreceptor-mediated secretion of vasopressin (Schrier &
Caramelo 1988; Badalamenti et al 1993). Plasma concentrations ofADH are
increased in patients with decompensated cirrhosis (Bichet et al 1982; Arroyo et al
1988). This increase is not related to plasma osmolarity as evidenced by the inability
of a water load to suppress ADH release in patients with cirrhosis and ascites (Bichet
et al 1982). Also, plasma concentrations of ADH correlate directly with disease
severity and inversely with both the MAP and SVR (Aliaga et al 1995), and return to
normal within two weeks of orthotopic liver transplantation (Navasa et al 1993).
Expansion of plasma volume by the insertion of a Le Veen shunt led to normalisation
of the circulating ADH levels (Reznick et al 1983). Administration of
demeclocycline, which interferes with the tubular actions of ADH, increases urine
flow and decreases urine osmolarity in patients with cirrhosis and ascites (Arroyo et
al 1988). Despite the increased activity ofADH, it responds to haemodynamic
changes (Iwao et al 1994; Bernardi et al 1983), although this response is insufficient
especially in advanced cirrhosis (Schroeder et al 1976). To our knowledge, the
contribution of vasopressin to maintenance of basal vascular tone in vivo has not
been investigated in patients with cirrhosis. However, Vi receptor antagonists cause
hypotension, and normalise the impaired water excretion in an experimental model
of cirrhosis (Claria et al 1991) suggesting that vasopressin may contribute to the
maintenance of arterial pressure in patients with cirrhosis.
3. Responses to the vasoconstrictor systems in cirrhosis:
In patients with cirrhosis, the increase in plasma concentrations of vasopressor
hormones is due to an increased release, rather than reduced clearance. In addition,
the vasoconstrictor systems are unable to prevent the development of peripheral
vasodilatation despite their activation, and their significant contribution to vascular
tone, especially as the disease worsens. Therefore, many in vitro and in vivo studies
have been performed to address the possibility of impaired responses to
vasoconstrictor agents.
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3.1. In vitro studies:
Studies on isolated vessels permit the assessment of vascular responses to
various stimuli in the absence of systemic hormonal and neuronal reflex effects.
Therefore, these studies can determine whether an impaired vasopressor response is
related to an alteration within the vascular wall. Studies using vessels from the
experimental models of cirrhosis have confirmed the presence of impaired responses
to a-adrenoceptor agonists, ET-1, and ANG II (Castro et al 1993; Hartleb et al
1994a; Hadoke & Hayes 1997). These studies have also shown normalization of the
vascular responses to vasopressor agonists after endothelial denudation and NOS
inhibition (Castro et al 1993; Hartleb et al 1994a; Sieber 1995) suggesting an
endothelial role in regulating these responses.
The difficulties in obtaining viable human vessels with intact endothelium from
patients with cirrhosis have restricted the use of in vitro techniques. However, in the
absence of endothelium, responses to selective ai-adrenoceptor agonists were
reduced in studies using isolated hepatic arteries (Smith et al 1993, Heller et al
1999), portal veins (Heller et al 1999), and radial veins (Ryan et al 1996) obtained
from patients with cirrhosis. Conversely, responses to ai-adrenoceptor agonists in
denuded hepatic arteries from cirrhotic patients and control subjects were similar in
another study (Hadoke et al 1998). Using isoprenaline to study the (32-adrenoceptor-
mediated vasodilatation showed enhanced relaxation of portal veins, but impaired
relaxation of hepatic arteries from patients with cirrhosis (Heller et al 1999). While
the latter is consistent with receptor down-regulation, secondary to the increased
plasma concentrations of Nad, the former suggests enhanced receptor function, and
indicates that the functional effects of cirrhosis differs from one vessel to another.
We are unaware of any studies of ANG Il-mediated contraction in arteries isolated
from patients with cirrhosis. Also, vasopressor responses to the ADH are
significantly impaired in denuded hepatic arteries from cirrhotic patients, whilst the
maximum response to 5-HT is slightly enhanced (Islam et al 2000). This indicates a
specific impairment of the Vi-receptor pathway, as the vasopressin-induced
contraction seems to be mediated by V)-receptor (Islam et al 2000).
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Initial studies using isolated hepatic arteries from patients with cirrhosis support a
role for the vasodilator NO in mediating the impaired responses to vasoconstrictor
systems (Smith et al 1993; Robinson et al 1995). Also, NO release was proposed as
the cause of impaired response to Nad in human radial veins (Ryan et al 1996).
However, other studies did not confirm this role (Schepke et al 1997). Despite the
fact that all isolated vessel studies share the limitation that all vessels had lost their
endothelium, they indicate that both endothelium-independent and endothelium-
dependent functional abnormalities develop in the vessels of patients with cirrhosis.
3.2. In vivo studies:
3.2.1. Systemic infusion of vasoconstrictors:
Most systemic studies have shown that the vasopressor response to ANG II (as
assessed by changes in BP, CO and/or SVR) is significantly reduced in patients with
cirrhosis with one exception (Lenz et al 1985). In contrast, responses to Nad are
reduced, unaltered, or enhanced in patients with cirrhosis (Table 1-2). Inter-study
variations are mainly due to methodological differences and variations in the patient
population, including their sodium status, menstrual status, alcohol intake,
concomitant diuretic therapy, severity of liver disease, and aetiology of liver disease.
For example, the patient group was significantly older than controls in one study
(Lenz et al 1985). Also, agonists were infused as a single bolus in some studies
(Johnston & Jose 1963; Pinzani et al 1991), whereas infusion was continuous in
others (Ames et al 1965; Laragh et al 1963; Lenz et al 1985; MacGilchrist et al
1991).
In addition, the dose of agonist infused and the parameters measured were variable
between studies. Concomitant diuretic therapy has been shown to reduce vascular
responses to Nad infusion (Oka & Manku 1981), effects, which may persist for
months (Alexsandrow et al 1959). Similarly, alcohol intake can reduce vascular
responses to Nad, but not to ANG II (Howes & Reid 1985). Therefore, the more
recent systemic studies ensured that patients had abstained from alcohol for a
minimum of 4 weeks (MacGilchrist et al 1991; Pinzani et al 1991). Furthermore, the
increase in total blood volume in patients with cirrhosis (Eisenberg 1956; Lieberman
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et al 1969; Wong et al 1994) with subsequent dilution of the infused doses of
agonists may reduce the responses to these vasopressor agents. However, this
hypervolemia does not influence FBF studies especially when comparing groups
with similar baseline FBF. These variations make interpretation of the results of the
systemic studies extremely difficult.
Although contributing to our understanding of the pathophysiology of portal
hypertension, systemic studies have the disadvantage of invoking neurohumoral
counter-regulatory mechanisms and having effects on a wide range of organs,
including the heart, brain and kidneys (Benjamin et al 1995; Webb 1995). Moreover,
previous studies investigating the role of the RAS in the maintenance of vascular
tone in patients with cirrhosis (Schroeder et al 1976; Arroyo et al 1981) are
weakened by the use of antagonists, such as saralasin, with partial agonist activity
(Case et al 1976; Anderson et al 1977; Anderson et al 1980), or the use of
angiotensin converting enzyme inhibitors (Pariente et al 1985), such as captopril,
which also inhibits the breakdown of bradykinin, which causes vasodilatation
through the release ofNO (Figure 1-6). The general conclusion from all systemic
studies is that an impaired response to exogenous vasoconstrictors does occur in
patients with cirrhosis. Whether this impairment is specific to ANG II, or also true
for Nad, ADH, and ET-1 requires further investigation. Also, from systemic studies
alone, the nature and mechanisms underlying the altered vascular responses can't be
clarified
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3.2.2. Local infusion of vasoconstrictors:
In the last decade, studies using local infusions in the isolated forearm resistance
vessels and dorsal hand veins are increasing, and those systemic infusions are
decreasing. The main reason for this shift towards local infusions in vivo is to avoid
invoking systemic neurohumoral effects or causing side effects. (Benjamin et al
1995; Webb 1995; Petrie et al 1998).
3.2.2.1. STUDIES USING DORSAL HAND VEIN COMPLIANCE:
Measurement of dorsal hand vein (DHV) compliance using the Aellig vein technique
is a method designed to assess vascular reactivity by measuring the alterations in the
distension capacity of a superficial dorsal hand vein held at a constant pressure
(Aellig 1981; Aellig 1994a; Aellig 1994b). According to this technique, changes in
vein diameter reflect changes in venous tone. This relatively non-invasive technique
involves intravenous infusion of at locally active and sub-systemic doses of agonists
and antagonists.
To my knowledge, only two controlled studies have utilized this technique in patients
with cirrhosis, and their results are contradictory (Table 1-3). Again, the use of
diuretics and the amount of salt intake may account for this variation. Indeed,
frusemide causes dilatation of the DHV, which may be mediated by the release of
PGL from the venous endothelium (Pickkers et al 1997). Also, the enhanced
response to Nad infusion occurred only in patients on a high salt diet (Wong et al
1995). In the non-controlled study (Calver et al 1994), infusion of L-NMMA, a
specific NO synthase (NOS) inhibitor, did not affect the DHV diameter. Also, Nad
induced venoconstriction was unaffected by co-infusion of L-NMMA.
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Table 1-3: Dorsal hand veins response to vasopressor agents in
patients with cirrhosis.
Reference Parameter Main results
Bierbrier et al 1994 DHV diameter • Unaffected basal venous tone.
• Reduced sensitivity to PE infusion,
but normal maximum contraction.
Wong et al 1995 DHV diameter • Reduced basal venous tone.
• Enhanced response to Nad infusion,
only during high sodium diet.
Calver et al 1994 DHV diameter • Unaffected basal venous tone.
• Unaffected response to Nad infusion
DHV, dorsal hand vein. PE, phenylephrine. Nad, noradrenaline.
3.2.2.2. STUDIES USING VENOUS OCCLUSION PLETHYSMOGRAPHY:
The combination of sub-systemic and locally active intra-brachial artery infusions
with FBF measurements using venous occlusion plethysmography represents a
powerful and reproducible method of assessing in vivo vascular responses in an
isolated circulation without invoking systemic effects (Benjamin et al 1995; Webb
1995; Petrie et al 1998). This technique is described in detail in Chapter 3.
• Basal FBF:
A precise conclusion about basal FBF in patients with cirrhosis cannot be made from
previous studies, as some studies (Rodriguez-Perez et al 1993; Calver et al 1994;
Albillos et al 1995; Wong et al 1996) have shown increased basal FBF in patients,
and a further increase with disease progression (Campillo et al 1995; Albillos et al
1995), while others reported similar basal FBF in both patients and controls (Lunzer
et ai 1975; Ryan et al 1993; Wong et al 1995; Ryan et al 1996; Newby et al 1998a).
• FBF responses to exogenous vasopressor agents:
ANG II and Nad are the most frequently studied vasopressor agents in the forearm
circulation (Table 1-4). Conflicting results have been reported. For example, the
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responses to Nad were either reduced (Ryan et al 1993; Ryan et al 1996; Campillo et
al 1995; Albillos et al 1995) or unaltered (Calver et al 1994; Newby et al 1998a) in
patients with cirrhosis. However, two of theses studies (Ryan et al 1993; Newby et al
1998a) have shown that the vasopressor responses to ANG II are reduced. One study
has combined the use of venous occlusion plethysmography to measure FBF and the
systemic infusion ofNad (Lunzer et al 1975). However, it is difficult to compare the
results with recent studies for two reasons: 1) FBF was measured without exclusion
of the hand despite the fact that circulation in the hand occurs mainly through
cutaneous vessels and contains a high proportion of arterio-venous shunts, and gives
variable FBF; 2) systemic infusion of agonists have the disadvantage of invoking
neurohumoral counter-regulatory mechanisms and having effects on a wide range of
organs, including the heart, brain and kidneys (Benjamin et al 1995; Webb 1995). In
deed, systemic infusion ofANG II produced systemic vasodilatation, and increased
calf blood flow (Motwani & Struthers 1992).
• Reasons of the conflicting results:
The conflicting results obtained by these investigations may be related to the
differences either in the disease severity, disease aetiology, methodology, or in a
combination of all. Therefore, standardisation of future studies is needed. As
discussed in Chapter 3, several precautions should be taken when performing a study
using venous occlusion plethysmography in order to avoid its limitations. Only three
studies have controlled their experiments by measuring blood flow in both arms. As
a consequence, two of these studies reported similar results (Calver et al 1994;
Newby et al 1998a), whilst the third did not include a healthy control group
(Campillo et al 1995). In addition, variations in diuretic therapy, dietary sodium
intake, and alcohol intake may also affect the results. For example, some studies
have included patients who were not on any diuretic therapy (Ryan et al 1993; Wong
et al 1995), others selected groups containing some patients receiving diuretics
(Lunzer et al 1975; Campillo et al 1995), and others stopped diuretics for 1 day
(Newby et al 1998a), 5 days (Ryan et al 1996), or 14 days (Albillos et al 1995)
before performing the investigation. It is generally advised that if the effects of
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diuretic therapy on systemic haemodynamics are to be avoided, diuretics should be
stopped for at least 5 times the half-life of the drug-used.
• Endogenous vasopressors and basalforearm vascular tone:
Infusion of losartan, a selective ATi receptor antagonist caused a significant
increased in FBF in patients with diuretic-responsive ascites but not in controls
(Newby et al 1998a). This is consistent with responses to saralasin infusion in whole
body studies (Schroeder et al 1976). These findings indicate that although the
vasopressor responses to ANG II are impaired, endogenous ANG II contributes
significantly to the maintenance of basal vascular tone in patients with cirrhosis and
ascites. However, this role needs to be assessed in the earlier stages of cirrhosis, and
in patients who were not on diuretic therapy.
• Nitric oxide and basalforearm vascular tone:
Compared to healthy controls, the contribution ofNO to the maintenance of basal
vascular tone in patients with early (Calver et al 1994; Ryan et al 1996) and
advanced (Newby et al 1998a) cirrhosis was studied using L-NMMA. All these
studies have shown that L-NMMA produces a similar reduction in FBF in both
patients and controls. Therefore, increased basal NO production is not responsible for
the impaired vasopressor responses in these patients, at least in the forearm bed. The
possibility that increased agonist stimulated NO release in this territory has never
been investigated before, and is tested in Chapter 4. To date, it is not clear whether
the impaired response to the vasopressor agonists is a generalised phenomenon or
specific to ANG Il-mediated vasoconstriction. To our knowledge, the reactivity to
ET-1 infusion has not been examined in patients with cirrhosis before, and will be
tested in Chapter 5.
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4. Mechanisms of vascular hyporesponsiveness
In patients with cirrhosis, the balance between vasodilators and vasoconstrictors
tends to be towards vasodilatation especially as the disease progresses (Figure 1-9 ).
FIGURE 1-9: THE BALANCE OF VASCULAR MEDIATORS IN CIRRHOSIS -
PREDOMINANT VASODILATATION.
The exact mechanism underlying the impaired responses to vasoconstrictor
mediators is still under debate. However, the reduced responsiveness could be
explained by either vascular smooth muscle (receptor and/or post-receptor) defects or
the presence of excess vasodilators or both. Many studies have shown that reduced
a-adrenergic responsiveness or sensitivity (Gerbes et al 1986; Bierbrier et al 1994;
Karatapanis et al 1994), while others suggest that the decrease in vascular
contractility is mainly a post-receptor defect (Murray et al 1985; Gopalakrishna et al
1993; Masuda et al 1993; Jeremy et al 1994; Groszmann 1994; Moreau et al 1994).
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5. The vasodilator systems in cirrhosis:
5.1. Mechanism ofaction of vasodilators:
Vasodilatation is induced by endothelium-derived factors such as NO, prostacyclin
(PGI2) and the endothelium-derived hyperpolarizing factor (EDHF). In addition,
endocrine hormones, such as glucagon, and peptides released from non-sympathetic
neurones, such as the calcitonin-gene-related peptide (CGRP) and the vasoactive
intestinal peptide (VIP). Many, but not all, vascular territories have a dilator basal
tone (Collier & Vallance 1991; Pickkers et al 1997). Vasodilator factors oppose the
effects of vasoconstrictor mediators and reduce intracellular calcium influx via their
action on cGMP and cAMP, which are formed in the smooth muscle cytosol from the
actions of guanylate cyclase and adenylate cyclase on guanosine triphosphate and
adenosine triphosphate respectively (Figure 1-10). Indeed, studies on vascular
smooth muscle have shown that cGMP-dependent kinases can depress the rise in
cytosolic calcium that occurs in response to ANG II (Lincolin et al 1996). The
second postulated action of cGMP is stimulation of calcium pumps leading to
calcium outflux from the cell through activation of calcium-ATP-ase activity
(Lincolin et al 1996). The other major route, whereby vascular smooth muscle tone is
modulated, is the transmembrane potassium channel. To date, 4 classes of potassium
channels have been identified on the VSMC membrane (Brayden & Nelson 1992).
Opening of potassium channels hyperpolarises the VSMC membrane, opposes
calcium influx, and decreases the vascular tone. The yet un-identified EDHF is
thought to produce vasodilatation through this mechanism (Barrier et al 2000).
Studies into the relationship between potassium channels, calcium, and the regulation
of vascular tone in patients with cirrhosis are warranted.
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5.2.-Nitric oxide (NO).
5.2.1. NO in health:
Twenty years ago, Furchgott & Zawadzki (1980) demonstrated that an endothelium-
derived relaxing factor (EDRF) mediated the acetylcholine-induced vasodilatation.
Many studies have subsequently shown that this EDRF is NO (Khan & Furchgott
1987; Ignarro et al 1987; Palmar et al 1987). NO is a gas with a short half-life which
regulates many pathophysiological processes, including smooth muscle relaxation,
central and peripheral neuronal transmission, platelet function, cytotoxic activity of
the immune cells, septic shock and atherosclerosis (Moncada et al 1991; Moncada &
Fliggs 1993; Hobbs et al 1999). NO is released from the amino-acid L-arginine, by
the enzyme NO synthase (NOS; Palmar et al 1988) by different stimuli including the
increase in blood flow, shear stress, endotoxins, and endogenous vasodilators such as
bradykinin, TNF-a, and adrenomedullin (Khoruts et al 1991; Richards et al 1996).
NO synthesized in the endothelial cells diffuses towards the underlying smooth
muscle cells and mediates relaxation through the activation of the soluble guanylate
cyclase enzyme which increases guanosine cyclic monophosphate (cGMP)
concentrations (Arnold et al 1977). Three isoforms ofNOS have been identified and
shown, by molecular cloning, to share 50-60% homology (Hobbs et al 1999). The
first is a constitutive isoform (nNOS or NOS I), whose activity is Ca2+/calmodulin
dependent and is mainly present in neuronal tissues. The second is a Ca2t
independent isoform (iNOS or NOS II) that has been isolated from different cells
after induction with bacterial products or inflammatory mediators. The third is
Ca2+/calmodulin requiring constitutive isoform found in the endothelial cells (eNOS
or NOS III), which plays an important role in vascular homeostasis (Hobbs et al
1999).
The genes encoding for NOS isoforms have been localized on human chromosomes
12, 17 and 7, respectively (Nathan & Xie 1994). Cytokines (mainly TNFa) and
bacterial lipopolysaccharides can induce de novo synthesis of iNOS in both the
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endothelium and the VSMC (Rees et al 1990; Radomski et al 1990). The activity of
NOS in tissues or cells is determined by the conversion of 14C- or 3H-L-arginine to
14 C- or 3H-L-citrulline respectively (Cahill et al 1993; Laffi et al 1993). Specific
inhibitors ofNOS have been developed, such as L-arginine analogues C-lSr -
monomethyl-arginine (L-NMMA), A°-nitro-L-arginine (L-NNA), and L-A°-nitro-
arginine methyl ester (L-NAME) (Moncada et al 1991; Hobbs et al 1999).
5.2.2. NO in cirrhosis:
A decade ago, it was hypothesized that NO may be have a role in he pathogenesis of
the hyperdynamic circulatory abnormalities of patients with cirrhosis (Vallance &
Moncada 1991). In support of this hypothesis, many studies in patients with cirrhosis
have provided evidence of this role (Martin et al 1998). In some studies (Table 1-5),
the hyperdynamic circulation has been reversed by blockade of the NO system,
whereas others have concluded that NO can only be partially responsible for the
vasodilatation in cirrhosis (Fernandez et al 1995; Kanwar et al 1996; Ryan et al
1996). The proposed haemodynamic consequences ofNOS inhibition and the
hypothetical role ofNO in the pathogenesis of portal hypertension in patients with
cirrhosis are shown in Figures 1-11 and 1-12.
FIGURE 1-11: THE HAEMODYNAMIC CONSEQUENCES OF NITRIC OXIDE
SYNTHASE INHIBITION.
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FIGURE 1-12: THE HYPOTHETICAL ROLE OF NITRIC OXIDE IN THE
PATHOGENESIS OF PORTAL HYPERTENSION.
5.2.2.1. NITRIC OXIDE IN THE ANIMAL MODELS OF CIRRHOSIS:
While many studies in experimental cirrhosis indicate that increased vascular
production ofNO contributes to arterial vasodilatation, probably due to increased
eNOS activity (Martin et al 1996; Morales-Ruiz et al 1996), others failed to do so
(Sogni et al 1992; Karatapanis et al 1994). Therefore, the role of NO is still unclear.
Up-regulation of eNOS precedes the onset of ascites formation in cirrhotic rats, as
does increased NO production (Niederberger et al 1995; Niederberger et al 1995a;
Ros et al 1995). Normalisation ofNO synthesis produces beneficial effects on
systemic haemodynamics (Pizcueta et al 1992), with suppression of the
vasoconstrictor systems and improvement of renal function (Martin et al 1998).
5.2.2.2. NITRIC OXIDE IN PATIENTS WITH CIRRHOSIS:
In patients with cirrhosis, evidence of increased NO synthesis is also accumulating,
suggesting a role in the pathogenesis of the hyperdynamic circulation (Table 1-5).
However another study does not suggest so (Forrest et al 1995). Increased production
NO starts before the onset of ascites formation, and contributes to the vasodilatation
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observed in advanced cirrhosis by reducing the vascular responses to vasopressor
agents (Martin et al 1998). The initial cause ofNO overproduction is unknown.
However, portal hypertension may contribute by increasing shear stress leading to
up-regulation of eNOS. Also, splanchnic production ofNO, mediated by either
eNOS or iNOS, may also have a role. The role ofNO in the pathogenesis of
haemodynamic and renal abnormalities in patients with cirrhosis remains unclear.
Table 1-5: Evidence supporting increased nitric oxide synthesis in
patients with cirrhosis and ascites.
Evidence Reference
Increased plasma concentrations ofNO
metabolites."
Increased exhaled NO in patients with hepato-
pulmonary syndrome.
Normalisation of arterial responses by NOS
inhibitors.
Increased NO in exhaled air. "
Increased NOS activity in neutrophils &
monocytes.
Enhanced vasodilatation to NO-dependent
vasodilators such as acetylcholine. "
Increased plasma concentrations ofNO "
The enhanced No production in the splanchnic
vascular bed following L-arginine infusion.
* This evidence is controversial to Ryan et al 1996 and Newby et al 1998a.
# Also shown in pre-ascitic cirrhosis. * Does not include a healthy control group.
Guarner et al 1993.
Barak et al 1999.
Mavoral et al 1994.
Campillo et al 1995.*
Matsumoto et al 1995;
Sogni et al 1995a.
Laffi et al 1995; Criado-
Jimenez et al 1995.
Albillos et al 1995.
Battista et al 1997.
Kakumitsu et al 1998
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5.3.'Other vasodilators in cirrhosis:
5.3.1. Atrial natriuretic peptides (ANPs):
The family of natriuretic peptides include at least three members: the atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP), and the weaker
endothelial C-type natriuretic peptide (CNP), which play a role in volume
homeostasis (De Bold 1985; Sudoh et al 1988; Suga et al 1992). ANPs produce
vasodilatation, natriuresis, and diuresis via the guanylate cyclase and cGMP pathway
(Luk et al 1994). Patients with cirrhosis and ascites showed elevated plasma
concentrations of, and blunted renal responses to, ANP (Gines et al 1988; La Villa et
al 1995; Wong et al 1995; Bandi et al 1997). Also, plasma concentrations ofANP
and cGMP are increased in patients with pre-ascitic cirrhosis (Trevisani et al 1995;
Iwao et al 1997, Iwao et al 2000). However, plasma levels ofBNP have been shown
to be normal in these patients (La Villa et al 1992a). The increase in ANP and cGMP
correlated inversely with PVR (Iwao et al 1997), and is more evident in the supine
position (Bernardi et al 1992; Iwao et al 1997). These controversial results of studies
in patients with pre-ascitic cirrhosis may be related to variations in the sodium intake
(Rector et al 1990), or the daily fluctuation in plasma ANP levels (Trevisani et al
1995). The cause of such high concentrations ofANP is unknown, because the atrial
pressure is normal, and the central blood volume is reduced. A study in a rat model
of cirrhosis showed that the ventricle is the main site of ANP synthesis (Poulos et al
1995). The subtle sodium retention, which precedes ascites formation, may be due to
blunted renal responses to ANP (Wong et al 1995).
5.3.2. Calcitonin-gene-related peptide (CGRP):
CGRP, a 37-amino acid neuropeptide, is a neurotransmitter with powerful
vasodilator effects (Rosenfeld et al 1983; Zaidi et al 1987; O'Halloran & Bloom
1991), which are important in the control of regional blood flow (Struthers et al
1986). Infusion of CGRP produces pronounced hypotension through a direct effect
ofCGRP rather than the release of other neurotransmitters (Struthers et al 1986;
Zaidi et al 1987; O'Halloran & Bloom 1991). Plasma concentrations ofCGRP are
elevated in patients with cirrhosis (Bendtsen et al 1991; O'Halloran & Bloom 1991;
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Gupta et al 1992; Moller et al 1995), and correlate directly with disease severity
(Bendtsen et al 1991; Gupta et al 1992) and CO, and negatively with SVR (Moller et
al 1996). These results support the hypothesis that CGRP may be implicated in the
systemic vasodilatation in cirrhosis. Moreover, increased CGRP may also contribute
to the abnormal distribution of the blood volume, in concert with other vasodilators
like NO and ET-3. Better understanding of the role of CGRP in the pathogenesis of
the haemodynamic alterations in cirrhosis requires use of its specific antagonists.
5.3.3. Glucagon:
Glucagon is 29-amino acid peptide secreted mainly by the a-cells of the islets of
Langerhans in the pancreas and primarily inactivated by the liver. Glucagon
promotes vasodilatation by direct, cAMP-mediated, VSMC relaxation or indirectly
decreasing the sensitivity to vasopressor agents (Richardson & Withrington 1976;
Pizcueta et al 1990; Nakahara et al 1997). Hyperglucagonemia occurs in portal
hypertensive animals and humans, and results from portosystemic shunting,
decreased hepatic clearance, and more importantly increased secretion (Sherwin et al
1974; Silva et al 1990; Lin et al 1996). Portal vein-stenosed rats with normal liver
function also had marked hyperglucagonemia, suggesting that elevated glucagon
levels do not depend on the presence of hepatocellular disease (Sherwin et al 1978).
However, another study showed that hyperglucagonemia is mainly related to the
liver function (Lewis et al 1991). Glucagon significantly decreases splanchnic
vascular resistance (Benoit et al 1984) and increases splanchnic blood flow in
patients with well-compensated cirrhosis (Lee et al 1988). In addition, an anti-serum
directed against glucagon ameliorates the hyperdynamic circulation in portal
hypertensive animals (Benoit et al 1986).
Somatostatin also constricts the splanchnic arterioles and reduces both the circulating
glucagon levels and portal pressure, suggesting a role for glucagon in the modulating
mesenteric blood flow (Kravetz et al 1988). In this study, somatostatin infusion
decreased portal venous inflow, but not down to normal. In addition, plasma
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glucagon levels did not correlate with portal venous inflow (Sikuler & Groszmann
1986), indicating that additional factors must also be involved.
5.3.4. Prostacyclin (PGI2):
Prostacyclin is an endogenous vasodilator of an endothelial origin that relaxes the
vascular smooth muscle cell by activating adenylate cyclase and increasing the
intracellular cAMP levels (Smith 1986). The cyclo-oxygenase (COX) enzyme, which
exists in a constitutive (COX-1) and an inducible (COX-2) isoforms, is involved in
the biosynthesis of PGI2 (Smith 1986; Masferrer et al 1990). Several studies have
shown elevated plasma concentrations of prostacyclin in both human (Arroyo et al
1983; Rimola et al 1986; Guarner et al 1992) and experimental cirrhosis (Sitzmann et
al 1989). The inhibition of prostaglandin biosynthesis by indomethacin has resulted
in a decrease in prostacyclin levels and significant amelioration of the hyperdynamic
circulation in patients with cirrhosis and portal hypertension (Bruix et al 1985), and
in the rabbit model of portal hypertension (Sitzmann et al 1991), an effect, which has
not been reported in the rat model (Blanchard et al 1985). Moreover, indomethacin
infusion has been shown to normalise the increased gastric blood flow in portal
hypertensive rats, but not in sham-operated controls (Pique et al 1988). This supports
a role for prostaglandins in the pathogenesis of the hyperdynamic circulation of
portal hypertension.
5.3.5. Adrenomedullin:
Adrenomedullin, a 52-amino acid peptide, is primarily released from the adrenal
medulla and induces relaxation of the vascular smooth muscle via specific receptors
(Eguchi et al 1994; Richards 1996). Plasma concentrations of adrenomedullin are
elevated in patients with cardiac, renal, and liver failure (Cheung & Leung 1997;
Fabrega et al 1997 Fernandez-Rodriguez et al 1998). In patients with cirrhosis, the
circulating levels of adrenomedullin appear to be higher in decompensated patients,
and correlate with the plasma concentrations of the vasopressor agents such as ET-1,
vasopressin, and Nad (Guevara et al 1998). The potential role of this vasodilator
peptide in the haemodynamic abnormalities in cirrhosis needs to be evaluated.
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5.3.6. Bile acids:
Bile acids, which possess vasodilator properties, circulate in increased levels in
patients with cirrhosis and portal hypertension and correlate with disease severity and
the blood levels of liver function tests (Ohkubo et al 1984). Reduction of circulating
bile acid levels to normal in portal vein-ligated rats did not ameliorate the
hyperdynamic circulation (Genecin et al 1990). However, in a different model, bile
acid depletion significantly decreased the splanchnic hyperaemia (Thomas et al
1991). Hence, the role of bile acids in mediating the hyperdynamic circulation is not
well defined.
Many other vasodilators, including neuropeptides, bradykinin, histamine, adenosine
and endotoxin have also been studied (Table 1-6). However, available evidence is
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6. Aims of the thesis
We have concentrated upon the RAS and The SNS in patients with pre-ascitic
cirrhosis, patients with diuretic-refractory ascites, and age- and sex-matched healthy
controls. The aims of these studies, which are included in Chapter 3 were to:
1. evaluate the baseline FBF, PRA, and plasma concentrations ofANGII, Nad,
and adrenaline, and their relation to disease severity.
2. determine the role of endogenous ANG II in the regulation of basal and
sympathetically-stimulated forearm vascular tone.
3. assess the forearm vascular responses to exogenous ANG II and Nad, and
whether these responses are dose-related.
4. assess the forearm vascular responses to reflex sympathetic stimulation by
low-pressure baroreceptor unloading.
5. study the relationship between the vascular abnormalities, if any, and disease
severity.
Because the most powerful vasoconstrictor peptide, ET-1, has not been studied
before in patients with cirrhosis, we have expanded our studies to investigate the
peripheral vascular reactivity to endogenous and exogenous ET-1 in cirrhosis in
Chapter 4. The aims of these studies - in patients with pre-ascitic cirrhosis and
matched healthy controls - were to:
1. measure the baseline plasma concentrations of ET-1 and big ET-1 in
patients with cirrhosis and its relation to disease severity.
2. determine the forearm vascular responsiveness to exogenous ET-1, and
3. assess the role of endogenous ET-1 in the maintenance of basal forearm
vascular tone using the selective ETA and ETB receptor antagonists, BQ-
123 and BQ-788 respectively.
The most important finding while studying the RAS was the impaired
vasoconstrictor responses to exogenous ANG II starting from the pre-ascitic stage of
cirrhosis. However, the mechanism of this hyporesponsiveness is not clear. In
addition, evidence of increased NO production in the animal models and in humans
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with cirrhosis is accumulating. Therefore, the aims of the study presented in Chapter
5 - in patients with pre-ascitic cirrhosis and healthy control subjects - were to:
1. evaluate the contribution of endogenous NO release to the maintenance of
basal peripheral vascular tone and,
2. assess the relationship between the vascular responses to ANG II and
endogenous NO release.
The main findings of the studies presented in Chapter 4 were the impaired forearm
vasoconstriction in responses to exogenous ET-1, and the enhanced vasodilatation in
responses to the ETA receptor antagonist, BQ-123. The mechanism underlying these
responses are unknown Therefore, the aims of the study presented in Chapter 6, in
patients with pre-ascitic cirrhosis and healthy controls, were to:
1. determine the relationship between the vascular responses to ETA receptor
blockade and endogenous NO release.
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CHAPTER 2
SUBJECTS, MATERIALS, AND METHODS
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1. Subjects
1.1. Subject recruitment:
All patients who participated in the studies were approached during their attendance
at the Royal Infirmary ofEdinburgh for further management of their chronic liver
disease. All healthy control subjects were recruited from the community by
advertisement or from the volunteer's data bank of the Clinical Research Centre at
the Western General Hospital. None of the control subjects had clinically significant
illness in their past history or on physical examination, and none was receiving
regular medication. Details of characteristics of subjects included in each study are
mentioned in the relevant chapter.
1.2. Ethics committee approval and consent:
All studies were conducted with the approval of the Health Volunteer and the
Medicine and Clinical Oncology Sub-Committees of the Lothian Health Board
Research Ethics Committee. Each subject was provided with a study information
sheet to read at least one week before the first study day. After a verbal explanation,
subjects then gave written, witnessed consent. All studies were undertaken in
accordance with the Declaration ofHelsinki (1989) of the World Medical
Association.
1.3. Standard experimental conditions:
All studies were performed in the Clinical Research Centre at the Western General
Hospital. Studies were performed in a quiet clinical laboratory maintained at a
constant temperature between 22 and 24°C.
1.4. Patients inclusion criteria:
All patients were ambulant and had biopsy-proven cirrhosis, endoscopically-proven
oesophageal varices, normal serum creatinine (<100 pmol/L), and no clinical
evidence of systemic circulatory disturbances, apart from the group of patients who
had diuretic-refractory ascites (Chapter 3). Patients were classified as having pre-
ascitic cirrhosis if they did not have ascites, either at the time of the study or before,
as assessed by both clinical and ultrasonographic examinations.
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/. 5. Exclusion criteria:
The main exclusion criteria included the presence ofmalignancy, encephalopathy,
portosystemic shunt (surgical or TIPSS), previous gastrointestinal bleeding, or any
significant cardiovascular disease, such as diabetes mellitus and hypertension.
1.6. Precautions:
To avoid the depressive effect of ethanol on vascular responses (Howes & Reid
1985), patients with alcoholic liver disease were abstinent from alcohol for at least
one month as confirmed by history and random blood ethanol testing. In addition, all
subjects were allowed a normal sodium diet of 150 mmol/day unless otherwise
stated, in order to avoid the possibility of altering the activity of endogenous
vasopressor systems (Rankin et al 1981; Stein et al 1995). None of the subjects
received vasoactive or non-steroidal anti-inflammatory drugs in the week before, and
all subjects abstained from food, tobacco and caffeine-containing drinks for a
minimum of 4 hours prior to each study. All female subjects were post-menopausal,
both for safety and to avoid the variability in vascular responses that may be
associated with cyclic hormonal changes (Hashimoto et al 1995).
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2. Pharmacological materials
2.1. Vehicle:
Physiological saline (0.9%; Baxter Ltd, Thetford, UK) was used as a vehicle to
dissolve peptides and drugs for all studies, except where Nad was used (see below).
All pre-dose measurements were made during infusion of this vehicle solution. Use
of isotonic solution avoided problems with hyperosmolar solution, which can cause
substantial vasodilatation (Overbeck & Grega 1970; Bank et al 1992).
2.2. Endothelin-1:
Human endothelin-1 (ET-1, MW 2492; C109H159N25O32S5), a 21 amino acid peptide,
is generated from big endothelin, the 38 amino acid precursor through the action of
endothelin converting enzymes (ECE). It is one of the most potent vasoconstrictors
yet identified. Among the three isoforms (ET-1, ET-2, and ET-3), ET-1 appears to be
the major form produced by the vascular endothelial cells, with a wide variety of
vascular and extra-vascular effects. Pharmaceutical grade, sterile, and pyrogen-free
ET-1 (Clinalfa AG, Laufelfingen, Switzerland) was dissolved in saline 0.9%, filtered
(Millipore 0.2 pm filter), and divided into aliquots under sterile conditions in the
Royal Infirmary of Edinburgh, and then frozen at -20°C until used. All ET-1 vials
used in the studies included in this thesis were from a single batch.
2.3. BQ-123 Sodium salt:
BQ-123 (MW 632.7; CsiH^NsO.Na) is synthetic cyclopentapeptide (Cyclo-[D-Asp-
L-Pro-D-Val-Leu-D-Trp]-Na) with potent and highly selective ETA-receptor
antagonist properties (lhara et al 1992). The specificity of BQ-123 as an endothelin
receptor antagonist has been shown in vivo in animals, where it dose not affect
vascular responses to potassium, Nad, phenylephrine, acetylcholine and nitro¬
glycerine (lhara et al 1992; Douglas et al 1994; Bazil et al 1992). Pharmaceutical
grade, sterile, pyrogen-free BQ-123 (Clinalfa) was dissolved in 0.9%saline, filtered
(Millipore 0.2 pm filter), and divided into aliquots under sterile conditions in the
Royal Infirmary of Edinburgh, and then frozen at -20°C until used. BQ-123 vials
used in the studies included in this thesis were from a single batch.
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2.4. BQ-788 Sodium salt:
BQ-~788 (MW 663 .7; C34H5oN507.Na) is a synthetic derivative of a tripeptide (N-cis-
2,6 dimethylpiperidino-carbonyl-y-MeLeu-D-Trp-DNle-OH.Na). It is a potent and
highly selective ETe-receptor antagonist, with a selectivity ratio of 200 relative to the
ETa receptor. BQ-788 infusion produces forearm vasoconstriction and increases
peripheral vascular resistance in healthy men (Strachan et al 1999). Pharmaceutical
grade, sterile, and pyrogen-free BQ-788 (Clinalfa) was dissolved in 0.9% saline,
filtered (Millipore 0.2 pm filter), and divided into aliquots under sterile conditions in
the Royal Infirmary ofEdinburgh, and then frozen at -20°C until used. All BQ-788
vials used in the studies included in this thesis were from a single batch.
2.5. Noradrenaline:
Noradrenaline (Nad; acid tartrate; MW337) is a catecholamine, derived from the
amino acid L-tyrosine, released from sympathetic post-ganglionic nerve terminals.
Nad is a potent agonist at a-adrenoceptors, causing constriction of vascular smooth
muscle (Weiner & Taylor 1985). Parenteral Nad acid tartrate (Levophed, 1 mg/mL)
was obtained from Sanofi-Winthrop Ltd, Guildford, UK. All vials ofNad used in the
studies included in this thesis were from a single batch.
2.6. Losartan:
The first clinically available AT-1 receptor antagonist was losartan, a phenyl
tetrazole substituted imidazole. Losartan has a 30 000-fold selectivity for the AT-1
receptor compared to the AT2 receptor (Johnston 1995). Losartan (Dupont-Merck,
Wilmington, USA) was dissolved in 0.9% saline, filtered (Millipore 0.2 pm filter),
and divided into aliquots under sterile conditions in the Royal Infirmary of
Edinburgh, and then frozen at -20°C until used. Pyrogen testing was negative. All
losartan vials used in the studies included in this thesis were from a single batch.
2. 7. Human angiotensin II:
Human angiotensin 11 (ANG II; MW 1046.2; C50H71N13O12), is an octapeptide
derived from angiotensin I by the action of angiotensin converting enzyme (ACE).
ANG II is a powerful vasoconstrictor that has other biological actions including
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stimulation of aldosterone biosynthesis, vasopressin release, thirst, glucose activation
and facilitation of sympathetic neurotransmission. ANG II (Clinalfa) was dissolved
in 0.9% saline, filtered (Millipore 0.2 pm filter), divided into aliquots under sterile
conditions in the Royal Infirmary ofEdinburgh, and frozen at -20°C until being used.
Pyrogen testing was also negative. ANG II vials used in the studies of Chapter 3
were from a single batch, while those used in Chapter 5 were from another patch.
2.8. Sodium nitroprusside dihydrate:
Pharmaceutical grade sodium nitroprusside (SNP) was obtained from David Bull
Laboratories, Victoria, Australia, and was administered at titrated doses (80-600
ng/min) prepared using sterile 0.9% saline. Due to its light sensitivity, SNP was
prepared and infused in syringes covered by opaque aluminium foil.
2.9. L-Ng monomethyl arginine acetate:
L-Vg monomethyl arginine (L-NMMA, C7Hi6N402.CH3C00H; MW 188.2) is an
endogenous methylated derivative of the amino acid L-arginine. L-NMMA is a
specific and dose-dependent substrate analogue inhibitor of nitric oxide synthase in
animals (Palmar et al 1988) and man (Vallance et al 1989a, Vallance et al 1989b).
Because nitric oxide is continuously generated in the resistance vessels, L-NMMA
causes peripheral vasoconstriction (Vallance et al 1989a), and increases blood
pressure in both healthy humans (Haynes et al 1993) and patients with cirrhosis
(Forrest et al 1995). Actions ofL-NMMA can be reversed by L-arginine in a dose-
dependent manner. Sterile and pyrogen-free L-NMMA (Clinalfa) was kept frozen at
-20°C. Before each study, L-NMMA at a concentration of 4 pmol/min was prepared
using sterile 0.9 % saline.
2.10. Vitamin C:
Vitamin C (Ascorbic acid, Evans Medical, Horsham, UK), at a final concentration of
10 pg/mL, was added to all diluent solutions for the studies using Nad to prevent its
oxidation (Collier et al 1978).
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Doses of all the previously mentioned pharmacological agents are mentioned in the
relevant chapter. However, it should be emphasised that all were locally active (in
the forearm circulation) and sub-systemic, and were chosen on the basis of previous
studies as indicated in the corresponding chapters. Also, no local or systemic side
effects were encountered with the use of any of these agents in any of the subject
included.
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3. Methods
3.1.'Measurement offorearm bloodflow:
This technique involves the combination of unilateral intra-brachial artery
administration of vasoactive agents and measurement of FBF by strain gauge venous
occlusion plethysmography (Figure 3-1). Using this technique, one can measure
baseline FBF, study the function of blood vessels in health and disease, characterise
the vascular properties of new drugs, and examine many physiological mechanisms
using specific pharmacological probes (Webb 1995; Webb & Hand 1995). Over the
last three decade, forearm venous occlusion plethysmography has been used
extensively in physiological, pharmacological, and clinical studies on vascular
smooth muscle and endothelial cell function and in the assessment of drug effects on
the arterial vascular bed (Collier et al 1972; Collier & Robinson 1974; Collier et al
1978; Webb et al 1989; Webb et al 1988; Benjamin et al 1989; Vallance et al 1989a;
Panza et al 1991; Cockcroft et al 1994, Verhaar et al 1998, Newby et al 1998,
Strachan et al 1999).
In this thesis, we have used this technique to evaluate the response of the forearm
resistance vessels to exogenous vasoactive agents such as ANG II, Nad, and ET-1,
and study the contribution of endogenous ANG II, ET-1 and NO to the maintenance
of basal vascular tone via infusing their selective antagonists such as losartan, BQ-
123, BQ-788, and L-NMMA respectively. We have also combined this technique
with the application ofLBNP to assess the FBF responses to reflex sympathetic
stimulation both in the basal state and during losartan infusion. In addition, we have
also used venous occlusion plethysmography to measure FBF responses to ANG II
and BQ-123 with and without the application of 'NO-clamp': a method of studying
the contribution of endogenous NO release to the vascular responses of vasoactive
agents.
In general, changes in local blood flow in response to vasoactive agents will reflect
the changes in arteriolar tone if the arterial blood pressure remains constant, although
effects on pre-capillary sphincters, or smaller arteries, may also contribute (Folkow
et al 1971). In addition, responses to vasoactive agents in the
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FIGURE 2-1: THE SET-UP OF BILATERAL FOREARM BLOOD FLOW
MEASUREMENT USING VENOUS OCCLUSION PLETHYSMOGRAPHY AND
UNILATERAL INTRA-BRACHIAL ARTERY INFUSION.
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forearm parallel those in other resistance beds (Collier et al 1978), and are therefore
apphcable to most of the vessels that contribute to systemic vascular resistance and
systemic blood pressure. Moreover, the changes in hepatic venous pressure gradient
in response to propranolol treatment correlated with FBF in patients with cirrhosis
(Albillos et al 1997).
3.1.1. Intra-brachial artery administration of drugs:
3.1.1.1. BACKGROUND:
The first description of arterial cannulation to assess responses of skeletal muscle to
the local administration of drugs was described in 1946 (Allen et al 1946; Barcroft &
Konzett 1949) in the form of adrenaline infusion into the femoral artery. However,
most studies nowadays use the brachial artery, as it is easy to reach, and is more
convenient. Also, femoral arteries can't be used in combination ofLBNP.
3.1.1.2. TECHNIQUE:
Cannulation of brachial artery of the non-dominant arm was performed using a 27-
standard wire gauge (SWG) steel needle (Cooper's Needle Works, Birmingham, UK)
attached to a 16G epidural catheter (Portex Ltd, Hythe, Kent, UK) under 1%
lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley, UK) local
anaesthesia. Patency was maintained by saline infusion at a constant rate of infusion
(1 ml/min), via an IVAC PI000 syringe pump (IVAC Ltd., Basingstoke, UK), in
order to prevent interpretation of the results being confounded by alterations in the
flow rate causing changes in FBF; this is particularly important to avoid during
infusion of vasoconstrictor substances.
3.1.1.3. SAFETY:
The extremely fine steel needle used to cannulate the brachial artery produces little
local trauma and enables repeated studies in the same subjects. This technique has
been in use at the Western General Hospital in Edinburgh for the last 10 years, with
no serious adverse events associated with its use. This is consistent with the safety of
long-term use of larger brachial and radial artery cannulae in clinical practice
(Gardner et al 1974; Moran et al 1988). The fine gauge needle technique is also well
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tolerated, allowing studies to be repeated up to 6 times in the same subjects at weekly
intervals. Although some researchers use cannulae of a size sufficient to allow direct
measurement of arterial blood pressure, we did not apply such a technique because
these cannulae produce tissue trauma and are therefore less well tolerated and
difficult to justify ethically. In addition, a recent study has shown that cannulation of
the forearm has a small effect on local baseline FBF and on the vasoconstrictor
responses to intravenously infused Nad (Kamper & Chang 1999). Alternatively, we
have used a non-invasive method to measure blood pressure at the brachial artery of
the non-infused arm for safety purposes and to exclude a systemic drug effect.
In studies that involve infusion of powerful vasoconstrictors or vasodilators, it is
critical to consider carefully, and be guided by, the data from previous animal
pharmacology and human studies especially when deciding the dose and duration of
each vasoactive substance. The doses chosen in the studies described in this thesis
have proved remarkably safe in previous forearm studies, avoiding the potential
hazards that might be associated with studies undertaken in other vascular beds, such
as the coronary circulation, or with systemic administration. Indeed, none of the
subjects included in these studies have experienced any side effects related to the
doses of the drugs. Theoretically, vessel occlusion is possible (Ashton et al 1963),
but this has not been observed in practice even with major reductions in local blood
flow caused by ANG II (Benjamin et al 1989) and ET-1 (Clarke et al 1989).
3.1.1.4. COMPLICATIONS:
A dull ache around the elbow or in the forearm may occur for up to 48 hours after
cannulation, and is probably related to immobilisation. After each experiment,
pressure is applied to the artery for at least 5 min to reduce the likelihood of bleeding
or haematoma formation. Only two patients had localized bruises that resolved
spontaneously. Occasionally the subject experiences pain in the hand if the median
nerve, which is adjacent to the brachial artery in the anticubital fossa, is stimulated
during cannulation. This is rare and immediately reversible when the needle is
withdrawn.
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3.1.2. Venous occlusion plethysmography:
3.1.2.1. HISTORICAL BACKGROUND:
Plethysmography, which means measurement of volume changes in a part of the
body, was first used in humans as early as 1875 (Mosso 1875). It was then proposed
as a method to measure blood flow in limbs and digits through the use of venous
occlusion by Brodie & Russell in 1905. Venous occlusion water plethysmography
was first shown to be suitable for measuring FBF and venous compliance by Hewlet
& van Zwaluwenburg in 1909. In this technique, a proximal limb cuff is rapidly
inflated to greater than the venous pressure but lower than the arterial pressure so
that the increase in limb volume with time gives a measure of blood flow because the
venous return is halted but arterial inflow continues unimpeded. In this system, the
limb was sealed in a rigid jacket and volume changes of the limb following inflation
of an upper arm venous occlusion cuff are measured by the displacement water or air
in the jacket. The main difficulties related to this method were the establishment of
fluid-tight seals, which did not impede blood flow or venous return, the bulk of the
equipment, and the need of considerable preparation. Therefore, alternative air-filled
plethysmographs have been used, but this was sensitive to temperature changes
(Vanhuyse & Raman 1971). The venous occlusion water and air plethysmographs
have been superseded by the introduction of strain gauges (Whitney in 1953), in
which changes in limb circumference are detected as a change in electrical resistance
of the gauge. Both the changes in limb circumference and electrical resistance were
proportional with negligible error (Whitney 1953; Ensink & Hellige 1981). The
original mercury-in-latex strain gauge was acting as a resistor in a Wheat stone
bridge circuit, and FBF measured using such temperature compensated strain gauges
was not only similar to that measured by the water displacement method, but also
with a lower variance in results of repeated measurements (Clarke & Flellon 1957;
Dahn & Flallbrook 1970; Paulev et al 1974). Recently, the mercury-in-latex gauges
have been replaced by indium/gallium-in-silastic gauges, which are more rapidly
applied and calibrated. The advantages of the strain gauge method include: 1) it
eliminates the need for water and air seals, 2) the strain gauges are small and
lightweight, 3) the strain gauges can be used for long periods, 4) subjects can move
their limbs between recording periods without disturbing the equipment or
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subsequent recordings, and 5) the time taken to apply and calibrate the gauges is
short. Throughout the years, this method has been standardized and computerized,
making it easier to carry out and reducing analysis bias (Chang & van Brumellen
1987; Chang et al 1988; Petrie et al 1998).
3.1.2.2. TECHNIQUE:
FBF measurements were made in both arms i.e. the infused and the control arms by
venous occlusion plethysmography using mercury in-silastic strain gauges applied to
the widest part of the forearm. Flands were excluded by rapid inflation ofwrist cuffs
to a pressure of 220 mmHg using E20 Rapid Cuff Inflators (D.E. Flokanson Inc,
Washington DC, USA). Upper arm cuffs were inflated up to 40 mmHg for 10
seconds (s) in every 15 s to achieve venous occlusion and obtain blood flow
measurements. Recordings of forearm blood flow were made every 3 min unless
otherwise stated. Voltage output from a dual channel Vasculab SPG 16 strain gauge
plethysmograph (Medasonics lnc, Mountain View, CA, USA) was transferred to a
Macintosh personal computer (Classic II, Apple Computer Inc, Cupertion, CA) using
a MacLab analogue-digital converter and Chart v4 software (both from AD
Instruments, Castle Hill, Australia).
3.1.2.3. REPRODUCIBILITY:
Between-day intra-subject reproducibility of baseline FBF measurements had a
coefficient of variation (CV) ranging from 7.8% to 15.6%. However reproducibility
of responses to systemic exercise ranged from 13% to 29% (Roberts et al 1986).
Another study of between-day intra-subject reproducibility of unilateral FBF showed
a CV of 25% and concluded that unilateral FBF measurements are: "poorly suitable"
for pharmacological trials (Altenkirch et al 1990). Also, poor within-day unilateral
baseline FBF reproducibility was reported by a third study (Egan et al 1988).
Simultaneous bilateral measurement of FBF as a method of reducing variability was
first proposed over 40 years ago (Greenfield & Patterson 1954), and has been
adopted thereafter by many investigators. In theory, measurements are adjusted for
systemic changes unrelated to the local stimulus by expressing flow in the infused
arm as a ratio of concurrent flow in the non-infused (control) arm (Webb 1995;
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Benjamin et al 1995). In contrast, FBF ratios are more reproducible than unilateral
FBFmeasurements both at rest (CV 19% vs 39%) and in responses to intra-arterial
infusions of vasoconstrictor substances (Petrie et al 1998). Also, forearm vascular
resistance may have a very small reproducibility advantage (CV 14%; Petrie et al
1998).
3.1.2.4. PRECAUTIONS:
The use of venous occlusion plethysmography has been shown to be both accurate
(Norton et al 1982) and reproducible when used in clinical studies (Robertson et al
1986; Petrie et al 1998). However, some precautions need to be considered:
1. Non-experimental stimuli can cause significant and misleading changes in
measured responses if unilateral measurements are used. Therefore, it is highly
recommended that responses to intra-arterial infusions should be measured using
bilateral forearm plethysmography with the results expressed as FBF ratios
(Benjamin et al 1995; Webb 1995; Petrie et al 1998).
2. The pressure in the arteries distal to an upper arm compression cuff is not
affected by inflation of the cuff to a sub-diastolic pressure (Wilkins & Bradley
1946). The amount of blood flow through bone (Edholm et al 1946) is small and
is not detected by this technique. Therefore, it is easy to select a suitable upper
arm collecting cuff pressure, which can temporarily stop venous return (apart
from those in bone), but does not affect arterial inflow.
3. Compared with the forearm, the hand has less distension capacity (Greenfield et
al 1963). Thus, inclusion of the hand may result in non-linear flow tracings,
which are difficult to analyse. In addition, blood flow to the hand is
predominantly through skin rather than muscle, and so is more sensitive to
changes in temperature (Spearman 1945) and emotions (Blai et al 1959;
Abramson & Ferris 1940). Moreover, skin blood flow has a different physiology
and exhibits different responses to vasoactive drugs (Webb 1995). Therefore, the
hand should be excluded during measurements by the application of a high-
pressure occlusion cuff at the wrist.
4. The rate of blood flow into the forearm arteries is disturbed during the first
minute after inflation of the high-pressure occlusion cuff at the wrist (Kerslake
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1949). Therefore, FBF recordings should be made for 3 min and the recordings
made in the first minute following wrist cuff inflation should never be used in the
analysis.
5. Venous occlusion plethysmography measures the total blood flow through all
tissues of a limb segment. The relative contribution of muscle to FBF at rest, as
estimated using adrenaline iontophoresis to abolish skin blood flow, was "75% of
blood flow less than, and "50% of blood flow higher than 6 mL/100 mL/min
(Cooper et al 1955; Zelis et al 1960; Katz & Folz 1983).
6. Using the strain gauge technique, FBF is given in mL per 100 mL of tissue per
min as calculated from the stretch of the gauge around one segment of the
forearm during a period of venous occlusion. Values obtained by the strain gauge
technique are similar to those obtained by volume methods (Whitney 1953;
Paulev et al 1974). Measurement of the absolute flow requires knowledge of the
forearm volume by water or air displacement. This introduces inaccuracy because
the blood flow in bone is low, causing an underestimate of muscle blood flow.
7. FBF varies with temperature, and it is important to maintain a constant
temperature to within ± 1°C throughout each study day.
3.1.2.5. STRENGTHS AND WEAKNESSES:
1. These studies enable the vascular responses to vasoactive mediators and drugs to
be assessed in vivo in humans. Therefore, it has the advantages of an in vivo
vascular technique especially when the vessels are exposed to physiological
pressures, have physiological dimensions, have intact nervous mechanisms,
bathed in the physiological medium ofblood, exposed to local and circulating
vasoactive and growth factors, and have not been exposed to general anaesthetic
agent or to potentially significant vessel trauma or hypoxia.
2. Because the dose of drug administered is small, the forearm technique can be
used early in the clinical evaluation of novel endogenous hormones or
cardiovascular drugs.
3. Because the effects of infused drug are restricted to the forearm, it is possible to
construct full dose-response relationships for the effects of drugs on FBF.
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4. Baseline FBF and the forearm vascular response to intra-arterial infusion of
vasoconstrictor agents, such as Nad, are not affected by left or right arm
dominance (Kamper & Chang 1999).
5. Most in vivo human vascular studies use systemic doses, which can influence the
neurohormonal reflexes and cause effects on other organs such as the brain, heart
and kidneys through changes in systemic haemodynamic parameters. Thus, the
direct vascular effects of systemic drug doses could not be readily attributed to
the infused drug alone. In contrast, intra-brachial artery administration of sub-
systemic and locally active doses of drugs together with measuring the FBF
responses allows the direct vascular actions of the vasoactive drugs to be studied.
Because FBF approximates to 20-50 mL.min"1, and the CO is "5000 mL/min,
doses of 100-1000 fold lower than the systemically active doses can be used
effectively within the forearm circulation. Therefore, the active amount of drug
reaching the systemic circulation with brachial artery infusion of locally active
doses is insignificant, unless the drug was given for very long periods or has a
long half-life. In addition, vasoactive peptides are rapidly inactivated in the
circulation.
6. Fluctuations in FBF occur in association with changing levels of alertness.
However, because these fluctuations affect both arms similarly, blood flow in the
control arm can serve as a contemporaneous control for drug effects in the
infused arm, thereby reducing the variability of the measurement (Greenfield &
patterson 1954).
7. The validity of the technique relies on some assumptions, such as arterial
pressure remaining stable during the study period. There is much between-
subjects variability in the forearm vascular response to changes in arterial
pressure, and there is no simple way of distinguishing the autoregulatory
response from the direct effect of a drug under these circumstances (Robinson
1990). However, provided that patients were comfortable and relaxed in a warm
calm environment, were given sufficient time to settle, and were given sub-
systemic doses, arterial pressure remains stable for considerably longer than is
required to observe the response to a drug.
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3.1.2.6. PITFALLS:
Thefforearm technique is most powerful when used for within-subject comparisons.
However, between-group comparisons such as between patients and healthy controls
are often performed. In this situation, several potential pitfalls may occur:
1. Patients and control subjects need to be well matched with respect to age and sex;
blood pressure; FBF, forearm volume & length; renal function; serum cholesterol
& glucose.
2. Results should be interpreted with caution if either the baseline blood pressures
or FBF differ between the groups. Whether changes in absolute flow or
calculated vascular resistance are used, normalising the results for initial
differences between the groups is inherently unsound (Robinson 1990).
3. Differences in vessel wall geometry pose a major problem, and increases in wall :
lumen ratio enhance the responses to both vasodilators and vasoconstrictors
(Folkow 1982). Thus, enhanced responses to a wide range of vasoconstrictors
(Doyle et al 1959; Egan et al 1987; Calver et al 1992) and vasodilators (Hulthen
et al 1985) in patients with hypertension can be explained by differences in vessel
geometry. This problem can be overcome by comparing dose-response
relationships to different vasoactive drugs within each group separately. For
example, by carefully selecting the dose of drugs, overlapping dose-response
curves to a range of vasoactive drugs can be produced in the forearms of normal
subjects and compared with responses in hypertensive subjects (Robinson et al
1984; Calver et al 1992). Based on the changes in vessel geometry,
vasoconstrictors are likely to produce greater vasoconstriction in the patients with
hypertension. However, if the effects of one agent among several tested was
relatively much greater than for the other vasoconstrictors it might be reasonable
to assume that there was a specific abnormality of this pathway in essential
hypertension.
4. Finally, there is the question of whether the observed responses in the FBF
(absolute or ratio or resistance) should be correlated with the doses or
concentrations of the drugs infused. The majority of FBF studies have used the
mass of drug delivered per unit time (min). However, a minority have suggested
that a correction should be made for the drug induced increase or decrease in
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blood flow (Angus & Lew 1992) or by limb volume (Chin-Dusting et al 1999). In
reality, no correction is necessary (Benjamin et al 1995; Webb et al 1995).
3.2. The nitric oxide clamp 'NO-clamp' technique:
3.2.1. Definition:
'NO-clamp' is a balanced co-infusion ofL-V'"monomethyl arginine (a selective NO
synthase inhibitor) and sodium nitroprusside (an exogenous NO donor) to block
endogenous NO production and restore normal NO-mediated basal blood flow
respectively.
3.2.2. Importance:
NO is continuously released by the endothelium, and relaxes the underlying vascular
smooth muscle. Brachial artery administration of L-NMMA (a selective NOS
inhibitor) causes forearm vasoconstriction and a reduction in basal blood flow
(Vallance et al 1989a). When assessing the contribution ofNO to the actions of a
given vasoactive agent, these L-NMMA-induced changes in vessel geometry and
blood flow may confound the interpretation of subsequent responses (Benjamin et al
1995; Webb 1995). However, co-infusion of sodium nitroprusside (SNP, an
exogenous NO donor) with L-NMMA can be used to restore the baseline blood flow
and vessel geometry by replacing endogenous NO with exogenous NO: the 'NO-
clamp' (Stroes et al 1997). This technique establishes a stable baseline forearm blood
flow (FBF) that can be maintained for at least 120 min (Verhaar et al 1998) and
permits the assessment of vascular responses in the absence of endogenous NO
synthesis (Stroes et al 1997; Verhaar et al 1998; Dijkhorst-Oei et al 1999).
3.2.3. Technique:
L-NMMA (Clinalfa AG, Laufelfingen, Switzerland) was continuously infused at a
rate of 4 pmol/min for 20 min to achieve maximal inhibition of local NOS activity.
This dose has previously been shown to produce a maximal vasoconstrictor response
in the forearm circulation (Vallance et al 1989a; Calver et al 1994). Thereafter, SNP
(David Bull Laboratories, Victoria, Australia) was co-infused at titrated doses (80-
600 ng/min) until FBF had been restored to within 10% of baseline flow and was
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sustained for at least 2 consecutive FBF measurements (variable duration). The drugs
were dissolved in 0.9% saline (Baxter Healthcare Ltd., Thetford, England). Due to
its light sensitivity, SNP was prepared and infused in syringes covered by opaque
foil.
3.3. Lower body negative pressure (LBNP):
LBNP was applied using a previously described method (Brown et al 1966). Subjects
rested supine within a plastic-covered steel cage, which enclosed the lower body
from waist downwards and sealed above the level of the anterior superior iliac spines
(Figure 2-3). A constant negative pressure of 15 mmHg was achieved using an
industrial strength vacuum cleaner regulated by a pressure control unit (Medical
Physics Department, Edinburgh University, Edinburgh, UK). Alterations to and
from atmospheric pressure were attained within 1-2 seconds. This negative pressure
causes selective forearm vasoconstriction, through pre-junctional release of Nad,
without affecting systemic blood pressure or heart rate and without activating carotid
baroreceptors (Seidelin et al 1991).
The combination of LBNP and intra-arterial infusion of local doses of drugs, agonists
or selective receptor antagonists (such as the use ofLBNP and losartan in Chapter 3)
are usually used to study the potential interaction between these vasoactive agents
and local sympathetic activity.
None of the subjects experienced any adverse effects during or after the application
of LBNP apart from our observation of a transient increase in the lower limb oedema
in two patients with advanced liver disease.
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FIGURE 2-2: THE SET-UP OF BILATERAL FOREARM BLOOD FLOW
MEASUREMENT AND THE APPLICATION OF LOWER BODY NEGATIVE
PRESSURE.
Chapter 2: Subjects, Materials, andMethods 71
3.4. Measurement ofsystemic haemodynamics:
3.471. Cardiac parameters & systemic vascular resistance (Electrical
bioimpedance method):
Baseline cardiac functions including heart rate, stroke volume and cardiac output
were measured using a non-invasive bioimpedance methodology (BoMed NC-
COM3, BoMed Medical Manufacturer Ltd) as previously described (Apple et al
1986). Figures 2-3 and 2-4 show the sites of attachments of the electrodes and an
example of the printouts of systemic haemodynamic results respectively.
Absolute cardiac output measured by electrical bioimpedance has been validated
against thermodilution measurements with correlation coefficients ranging from 0.83
to 0.90 and differences ranging from 2% to 12% (Apple et al 1986; Salandin et al
1988; Northridge et al 1990; Thomas et al 1992). In addition, electrical
bioimpedance measure of changes in cardiac output after drug intervention is not
only in close agreement with simultaneous thermodilution measurements, but also
has a lower within-subject coefficient of variation as well.
Cardiac index (CI), stroke index (SI), and total peripheral vascular resistive index
(TPVRI) were calculated according to the formulae:
• CI (mL.min"1. m"2) = CO (mL.min"1) / body surface area (BSA; m2).
• SI = stroke volume (mL) / BSA (m2).
• TPVRI (mm Hg. mL"1 min.m2) = MAP (mm Hg) / CI (mL.min"1. m"2).
• BSA (m2) = Square root (Hight (cm) x Weight (kg) / 3600).
3.4.2. Blood pressure & heart rate: (Semiautomated oscillometric
method):
Both blood pressure and HR were measured in the non-infused arm using a non¬
invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc,
Tokyo, Japan) at intervals throughout each study. This methodology has been
validated against intra-mercury sphygmomanometer (Wiinberg et al 1988) and the
Hawkesley random-zero mercury sphygmomanometer (Evans et al 1989; Jamieson et
al 1990).
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FIGURE 2-3: THE SITES OF ATTACHMENTS OF THE BOMED NC-COM3





ID# 06 19 55
height 167 cm
weight (1.13) 082 kg
VEPT 06340 ml
BSA 1.89 msq
CO SV EDV PF EF HR TFI IC ER STR ACI TIME
:04.1 069 122 042 56 060 30.0 033 33 037 071 01:01
:04.1 069 121 042 56 060 30.0 033 33 037 070
:04.1 069 122 042 56 060 30.0 033 33 037 070
:04.1 069 121 042 56 060 30.0 033 33 037 070
FIGURE 2-4: AN EXAMPLE OF SYSTEMIC HAEMODYNAMIC
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The MAP was calculated according to the formula: MAP (mm Hg) = diastolic
arterial pressure + 1/3 pulse pressure (systolic arterial pressure - diastolic arterial
pressure). Venous congestion due to pressures at or above mean diastolic pressure
cause reflex vasoconstriction lasting ~1 minute (Patterson & Shepherd 1954). For




After 30 min of supine rest, and before any drugs were administered, venous blood
sample was withdrawn from the non-infused arm. Ten mL were admixed with each
of the following: 1 mL of 5% disodium EDTA/ 2% sodium metabisulphite for
measuring Nad and Ad concentrations; 0.5 mL of 0.45% O-phenanthroline/ 4.65%
disodium EDTA for measuring ANG II concentration; and 1 mL of 1% disodium
EDTA and 1000 KIU aprotinin (Bayer AG, Germany) for measuring plasma renin
activity (PRA), ET-1 and big ET-1 concentrations. The samples were placed on ice
and immediately centrifuged at 1500 g for 20 min. Plasma was then frozen and
stored at -80°C until assayed. The relative centrifugal force (RCF) or g (gravity
force) was calculated using the formula:
RCF = 1.118 x 10"5 xrxn2
Where r is the radius of the centrifuge in centimeter (cm), and n is the speed of
rotation in rotindper minute (rpm).
3.5.2. Endothelin assay:
Baseline plasma concentrations of ET-1 (Peninsula Laboratories INC, Belmont, CA,
USA) and big ET-1 (Peninsula Laboratories INC) concentrations were measured by
radioimmunoassay (RIA) following extraction using Bond Elut® columns (Varian,
Harbor City, CA, USA) as described previously (Rolinski et al 1994) Briefly, each
2.5 mL plasma was diluted with 2.5 mL of 20% acetic acid and loaded onto a
column; these were washed, and eluted with 20% ammonium bicarbonate : 80%
ethanol (2x1 mL). The eluates were evaporated under nitrogen in a waterbath at
37°C, and reconstituted in phosphate buffer of pH 7.4 (0.25 mL). Duplicate extracted
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samples and standards containing 1-64 pg/ml endothelin-1 (each 100 pL) were
incubated with rabbit polyclonal antibody raised against ET-1 (Peninsula
Laboratories INC) for 24 hours at 4 °C and 125I-ET-1 (NEN Life Science Products,
Hounslow, UK). After vortexing, tubes were incubated for 18-24 hours at 4°C.
Amerlex Donkey anti-rabbit gamma globulin (200 pL) bound on magnetic particles
was added to all tubes, except the total-count tubes, and the tubes were then
incubated for 30 min at room temperature. Tubes were, then, centrifuged for 20 min
at 2000g at 4°C. The amount of radioactivity in the antibody-bound fraction was
determined by gamma counting for 1 min. The recovery of added ET-1 was 84%.
The intra-assay coefficients of variation for ET-1 and big ET-1 were 7.0% and 7.2%
respectively, and the inter-assay coefficients of variation were 9.0% and 9.3%
respectively. The cross reactivities of the ET-1 assay were ET-1 (100%), ET-2 (7%),
ET-3 (7%), C-terminal fragment (0%), big ET-1 (10%), angiotensin I (ANG I; 0%),
and ANG II (0%); and for the big ET-1 assay were ET-1 (0%), ET-2 (0%), ET-3
(0%), C-terminal fragment (100%), and big ET-1 (100%).
3.5.3. Angiotensin II assay:
Addition ofEDTA/O-phenanthroline to the venous blood samples inhibits the
converting and angiotensinase enzymes and therefore, inhibits the breakdown of
plasma ANG II (Dusterdieck & MaElwee 1971). Plasma ANG II concentrations
were measured by RIA following extraction using Bond Elut® columns (Varian,
Harbor City, CA, USA) as previously described (Morton & Webb 1985). Briefly, the
method of ANG II extraction was identical to that ofET-1, apart from the use of 4
mL of plasma. The extracts were then dried and re-dissolved in Tris buffer (50
mmol; PH 7.5) for the RIA (Peninsula Laboratories, Belmont, CA, USA). The intra-
assay and the inter-assay coefficients of variation for ANG II were 7.2% and 9.3%
respectively. The cross reactivities of the ANG II assay were ANG-II (100%),
angiotensin I (0.5%), ANP (0%), and renin substrate (0.9%).
3.5.4. Plasma renin activity assay:
PRA was measured under standard conditions through the generation ofANG I using
RIA as previously described (Haber et al 1969). PRA was estimated using RIA of
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angiotensin I generated from plasma after a 1-hour incubation at pH 5.5 and at 37°C
in conditions inhibiting the further conversion of angiotensin I (Rianen assay system
Angiotensin I [125I] kit; NEN Life Science Products). The intra-assay and the inter-
assay coefficients of variation for PRA were 4% and 7% respectively. The cross
reactivities of the angiotensin I assay were ANG 1 (100%), angiotensinogen (1%),
ANG II (0.9%), and angiotensin III (0.1%).
3.5.5. Catecholamines assay:
Plasma catecholamines were measured by dual-electrode coulometric detection after
separation on a reverse phase high performance liquid chromatography column as
described previously (Goldstein et al 1981). A simple solvent extraction system was
used for the selective and quantitative isolation ofNad and adrenaline from plasma.
Data handling and acquisition was carried out using a JCL 9000 Chromatography
Data System (Jones Chromatography Ltd, UK). The limits of detection were < 5 pg
per injection for Nad and adrenaline, with inter-assay coefficients of variation of
1.6% for Nad, and 2.0% for adrenaline. The average recovery of
dihydroxybenzylamine, which was used as the internal standard, was 88% (n=100).
3.5.6. Other assays:
• Serum creatinine:
Serum creatinine was assayed in the Department of Clinical Chemistry, Royal
Infirmary ofEdinburgh, using a Kodak Ectachem System E700 XRC analyser
(Kodak Diagnostics Ltd, UK).
• Urinary sodium excretion:
Urine of the 24 h preceding the morning of the study were collected and Na '
concentrations were determined by flame photometry.
3.6. Data management and statistical analysis:
3.6.1. Data extraction:
Plethysmographic data were extracted from the Chart1M (AD Instruments, Castle
Hill, Australia) data files and forearm blood flows were calculated for individual
venous occlusion cuff inflations using a template spreadsheet (Excel v5.0;
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Microsoft). Recordings from the first 60 s following wrist cuff inflation were not
included in the analysis because of the variability in blood flow this produces
(Kerslake 1949). Usually, the last 5 flow recordings in each 3 min measurement
period were calculated and averaged for each arm. Figures 2-5 & 2-6 shows
examples of the plethysmographic recordings before and after infusions of a
vasodilator and a vasoconstrictor respectively. In order to reduce the variability of
blood flow data, the ratio of flows in the 2 arms was calculated for each time point,
thereby using the non-infused arm as a contemporaneous control (Patterson &
Shepherd 1954; Benjamin et al 1995; Webb 1995; Chin-Dusting et al 1999).
3.6.3. Calculations:
The percentage change in FBF was calculated as follows:
% change in FBF = 100 x [(It/ NIt) - (Ib / NI„)] / ( Ib / NIb)
where /, andNIt are the bloodflows in the infused and non-infusedforearms
respectively at a given time point (t) andh andNh are the bloodflows in the infused
and non-infusedforearms respectively at baseline (b); time 0.
Unlike intra-arterial drug infusions, LBNP affects both arms, and therefore, the
changes in FBF during LBNP and either saline or losartan infusions were calculated
in the infused arm separately for every subject as % change from the flow during the
same infusion without LBNP as follows:
% change in FBF during LBNP = 100 x [(FBFlbnp - FBFsofl) / (FBFsorc)]
where FBFs or l is the blood in the infused arm during saline (S) or losartan (L)
infusion without LBNP, and FBFlbnp is the bloodflow in the infused arm during the
same infusion with LBNP, and then the results were averaged in each group.
To compare between the response curves without and during the application of the
'NO-clamp', a single-point data summary of the data set from each curve was
obtained separately as area under the curve (AUC; Matthews et al 1990). The
percentage change in area AUC was calculated according to the formula:
% change in AUC = 100 x [(AUCnoc - AUCfno) / (AUCfno)]
where NOC and FNO are the presence of the 'NO-clamp' andfree NO respectively.
FBF'was expressed in mL.100 mL' of tissue,min1 (Whitney 1953).
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In Chapter 6, the % attenuation in AUC following application of the 'NO-clamp' was
calculated according to the formula:
% change in AUC = 100 x [(% changepc - % changeAc) / (% changeAc)]
where PC andAC are the presence and absence of the 'NO-clamp' respectively.
3.6.2. Coefficient of variation:
The coefficient of variation in the ratio of basal infused to non-infused FBF was
nearly two-fold less than that for basal absolute FBF (Table 2-1). This was true
whether inter-subject, intra-subject (inter-study) or intra-subject (intra-study)
coefficients were examined. The lower variability of the ratio data reflects the fact
that small symmetrical variations in FBF occur continuously, most probably due to
variations in sympathetic outflow.
Table 2-1: Mean intra-subject (inter-study), intra-subject (intra-study),
and inter-subject coefficients of variation for basal forearm blood flow
and basal ratio of FBF (infused arm / non-infused arm).
The coefficient of variation



















Each individual coefficient of variation was calculated from the mean and the
standard deviation of 6-8 baseline observations obtained from studies presented in
this thesis.
3.6.4. Data analysis:
Data were expressed as mean ± standard error of the mean (SEM) and examined by
two-factor analysis of variance (ANOVA) with repeated measures (Chin-Dusting et
al 1999), the Pearson's correlation coefficient and two-tailed paired and un-paired t-
tests as appropriate. Statistical significance was taken at the 5% level.
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CHAPTER 3
STUDIES ON THE RENIN-ANGIOTENSIN AND
SYMPATHETIC NERVOUS SYSTEMS
Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in
regulation of basal and sympathetically-stimulated vascular tone in patients with
early and advanced cirrhosis. Gastroenterology 2000;1 18:565-572.
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1. Summary
Background/Aims: The renin-angiotensin and sympathetic nervous systems are
activated in cirrhosis. In this chapter, we aimed to establish the role of angiotensin 11
in the regulation of basal and sympathetically-stimulated vascular tone in pre-ascitic
cirrhotic patients, and diuretic-refractory ascites patients compared with age- and
sex-matched healthy controls.
Methods: Forearm blood flow (FBF) responses to lower body negative pressure
(LBNP) and to sub-systemic, intra-brachial infusions of losartan, an angiotensin II
type-1 receptor antagonist, noradrenaline and angiotensin II were measured using
venous occlusion plethysmography.
Results: In all groups, angiotensin II and noradrenaline caused dose-dependent
reductions in FBF (/K0.001) and, whilst responses to noradrenaline were similar
across the three groups, those to angiotensin II were less in both cirrhotic groups than
in controls (/?<0.01). Losartan caused a dose-dependent increase in FBF only in
refractory ascites patients (£><0.01). LBNP caused less reduction in FBF in patients
with refractory ascites than in both pre-ascitic patients and controls (p<0.01).
Conclusions: Despite hyporesponsiveness to exogenous angiotensin II in both early
and advanced cirrhosis, endogenous angiotensin II contributes to the maintenance of
basal vascular tone only in advanced cirrhosis. These findings suggest a role of
angiotensin II in the pathogenesis of ascites. The forearm vascular responses to
exogenous noradrenaline are unimpaired. However, attenuated LBNP responses
occurred only in advanced cirrhosis, without apparent interaction with endogenous
angiotensin II.
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2. Introduction and aims
Liver cirrhosis is characterised by hyperdynamic circulatory changes, including high
cardiac output and decreased systemic vascular resistance (Kowalski & Abelmann
1953; Murray et al 1958; Kontos et al 1964), that worsen with disease progression
(Braillon et al 1986; Bendtsen et al 1990; Meng et al 1994). Although compensatory
activation of vasopressin (Bichet et al 1982; Reznick et al 1983; Bichet et al 1983;
Epstein et al 1984), and the renin-angiotensin (Schroeder et al 1976; Arroyo 1981,
Bernardi et al 1982; Pariente et al 1985) and sympathetic nervous (Henriksen et al
1981; Bernardi et al 1982; Bichet et al 1982a; Ramond et al 1986; Flora et al 1991)
systems occurs, impaired vascular reactivity has been proposed to contribute to the
hyperdynamic circulation of cirrhosis and to the development of its complications,
such as portal hypertension, ascites and hepatorenal syndrome (Schrier et al 1988).
Present evidence of this hyporesponsiveness has been provided by systemic studies
and in vitro experiments. Although contributing to our understanding of the
pathophysiology of portal hypertension, systemic studies have the disadvantage of
invoking neurohumoral counter-regulatory mechanisms and having effects on a wide
range of organs, including the heart, brain and kidneys (Benjamin et al 1995; Webb
1995). Moreover, previous studies investigating the role of the renin-angiotensin
system in the maintenance of vascular tone in patients with cirrhosis (Schroeder et al
1976; Arroyo 1981) are weakened by the use of antagonists, such as saralasin, with
partial agonist activity (Case et al 1976; Anderson et al 1977; Anderson et al 1980),
or the use of angiotensin converting enzyme inhibitors (ACI; Pariente et al 1985),
such as captopril, which also inhibits the breakdown of bradykinins. However,
losartan, a selective angiotensin 11 type 1 (ATi) receptor antagonist that is devoid of
agonist activity, has recently become available for clinical use (Bauer et al 1995).
Furthermore, results of previous studies addressing this issue in patients with
advanced cirrhosis (MacGilchrist et al 1991; Newby et al 1998) have been
confounded by the use of diuretics, which produce hypovolaemia (Shah et al 1978)
with subsequent activation of the endogenous neurohumoral systems
(Dwarakanathan et al 1975; Schrier et al 1988) In addition, the combination of sub-
systemic and locally active intra-brachial artery infusions with bilateral forearm
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blood flow (FBF) measurements using venous occlusion plethysmography represents
a powerful and reproducible method of assessing in vivo vascular responses in an
isolated circulation without invoking systemic effects (Benjamin et al 1995; Webb
1995; Petrie et al 1998). Therefore, the aims of the studies included in this chapter -
in patients with pre-ascitic cirrhosis and those with diuretic-refractory ascites, and
age- and sex-matched healthy controls - were to:
1. measure the baseline forearm blood flow and its relation to disease severity.
2. evaluate the baseline plasma concentrations of angiotensin II (ANG II), plasma
renin activity (PRA), noradrenaline (Nad), and adrenaline, and their relation to
disease severity.
3. determine the role of endogenous ANG II in regulation of basal and
sympathetically-stimulated vascular tone in the forearm circulation;
4. assess the forearm vascular responses to exogenous ANG II and Nad, and
whether these responses are dose-related.
5. assess the forearm vascular responses to reflex sympathetic stimulation by low-
pressure baroreceptor unloading.
6. study the relation of vascular abnormalities, if any, and disease severity.
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3. Subjects and methods
3.1. Subjects:
Eighteen patients with biopsy-proven cirrhosis, 8 in the pre-ascitic stage and 10 in
the diuretic-refractory stage of the disease (Arroyo et al 1996) were recruited and
compared with eight age- and sex-matched healthy volunteers (49 ± 6 years; Female:
Male = 3: 5). After participation in the first study, one patient with refractory ascites
underwent liver transplantation and another underwent transjugular intrahepatic
portosystemic stent shunt (TIPSS) for variceal bleeding and the second study was
performed in another two patients and so the sixteen studies, eight in each protocol,
were completed in ten patients. All patients were ambulant and had normal serum
creatinine (<100 prnol/L), Paracentesis-induced haemodynamic disturbances were
shown to revert to the their basal levels within one week (Pozzi et al 1994). So,
patients with diuretic-refractory ascites were studied one week after their regular
therapeutic paracentesis, and were on a "no added salt diet" (100 mmol/day) and did
not receive any diuretic therapy for at least two weeks before the study. Patients with
alcoholic liver disease were abstinent from alcohol for at least one month (Howes &
Reid 1985), confirmed by history and random blood ethanol testing. None of the
subjects received vasoactive or non-steroidal anti-inflammatory drugs in the week
before each phase of the study. All subjects abstained from food, tobacco, and
caffeine containing drinks for at least 4 hours before each study.
To minimise between-subject variability, female control subjects who were pre¬
menopausal were studied between 7-12 days of their menstrual cycle (Hashimoto et
al 1995). All female cirrhotic patients had amenorrhoea. Studies were undertaken
with written informed consent from each subject, with the approval of the local
research ethics committee, and in accordance with the Declaration ofHelsinki (1989)
of the World Medical Association.
3.2. Intra-arterial administration:
Cannulation of the brachial artery of the non-dominant arm was performed using a
27-standard wire gauge steel needle (Cooper's Needle Works, Birmingham, UK)
under 1 % lidocaine (Xylocaine, Astra Pharmaceuticals Ltd, Kings Langley, UK)
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local anaesthesia. Patency was maintained by saline infusion at a constant rate of
infusion (1 ml/min) via an IVAC PI000 syringe pump (IVAC Ltd., Basingstoke,
UK).
3.3. Drugs:
Losartan (Dupont-Merck, Wilmington, USA) at doses of 30 and 90 pg/min;
angiotensin II (Clinalfa AG, Laufelfingen, Switzerland) at doses of 1, 3, 10 and 30
pmol/min; and Nad (Levophed, Sanofi-Winthrop Ltd., Guildford, UK) at doses of
20, 60, 180, 540 pmol/min (Newby et al 1997; Newby et al 1998a), were dissolved in
physiological saline (0.9% Baxter Healthcare Ltd., Thetford, UK) and administered
intra-arterially. To prevent its oxidation, Nad was dissolved in saline containing
0.1% ascorbic acid (Evans Medical, Langhurst, UK).
3.4. Measurements:
All studies were performed in a quiet, temperature controlled room maintained at 22-
24 °C. Blood pressure and pulse rate were measured in the control arm using a non¬
invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc,
Tokyo, Japan) at intervals throughout the study (Wiinberg et al 1988). FBF blood
flow was measured as previously described (Chapter 2).
3.5. Lower body negative pressure (LBNP):
Subjects rested supine in a plastic covered steel cage, which enclosed the lower body
from the waist and downwards as previously described (Brown et al 1966; Seidelin et
al 1991). A constant negative pressure of 15 mm Hg was achieved using an industrial
strength vacuum cleaner regulated by a pressure control unit (Medical Physics
Department, Edinburgh University, Edinburgh, UK). Alterations to and from
atmospheric pressure were attained within 1-2 seconds. This negative pressure
produces selective forearm vasoconstriction through low-pressure baroreceptor
unloading without altering arterial pressure or heart rate, thereby eliminating the
confounding effects of systemic hypotension (Seidelin et al 1991).
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3.6. Study design:
Two protocols (Figure 1-1) were applied on two separate occasions one week apart
and in random order. Subjects rested supine throughout each study. Strain gauges
and cuffs were applied and the brachial artery of the non-dominant arm cannulated.
FBF was measured in the last 3 minutes of each infusion period unless otherwise
stated. Before participating in each of the protocols, saline was infused for 30 min to
allow time for equilibration, with FBF measurements being made every 10 min and
the final measure taken as the baseline FBF. In protocol 2, the rationale for
combining LBNP with each of saline and losartan infusions was to assess the
contribution of endogenous ANGII to the forearm vascular responses to low-
pressure cardiopulmonary baroreceptors unloading.
3.7. Blood assays:
After 30 min of supine rest, and before any drugs were administered, venous blood
was withdrawn from the non-infused arm. Ten mL were admixed with each of the
following: 1 mL of 1% disodium EDTA/ 2% sodium metabisulphite for measuring
adrenaline and Nad concentrations; 0.5 mL of 0.45% (9-phenanthroline/ 4.65%
disodium EDTA for measuring ANG II concentration; and 1 mL of 1% disodium
EDTA and 1000 KIU aprotinin (Bayer AG, Leverkausen, Germany) for measuring
plasma renin activity (PRA). Blood samples were placed on ice and immediately
centrifuged at 1500 g for 20 min. Plasma was frozen and stored at -80°C until
assayed. Adrenaline and Nad concentrations were determined using an
electrochemical method following separation by reverse phase liquid
chromatography (Goldstein et al 1981). Plasma ANG II concentrations were
measured by radioimmunoassay (RIA) following extraction using Bond Elut®
columns (Varian, Harbor City, CA, USA) as previously described (Morton & Webb
1985). PRA was measured under standard conditions through the generation ofANG
I using RIA as previously described (Haber et al 1969).
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2.8. Data analysis and statistics:
Plethysmography data were extracted from the Chart1M (AD Instruments, Castle
Hill, Australia) data files and forearm blood flows were calculated for individual
venous occlusion cuff inflations using a template spreadsheet (Excel v5.0;
Microsoft). Recordings from the first 60 s following wrist cuff inflation were not
included in the analysis because of the variability in blood flow this produces
(Kerslake 1949). Usually, the last 5 flow recordings in each 3 min measurement
period were calculated and averaged for each arm. In order to reduce the variability
of blood flow data, the ratio of flows in the 2 arms was calculated for each time
point, thereby using the non-infused arm as a contemporaneous control (Benjamin et
al 1995; Webb 1995; Chin-Dusting et al 1999). The percentage change in FBF was
calculated as follows:
% change in FBF = 100 x [(It/ NIt) - (Ib / NIb)| / ( Ib / NIb);
where It andNIt are the bloodflows in the infused and non-infusedforearms
respectively at a given time point (t) and Ib andNib are the bloodflows in the infused
and non-infusedforearms respectively at baseline (b); time 0.
Unlike intra-arterial drug infusions, LBNP affects both arms, and therefore, the
changes in FBF during LBNP and either saline or losartan infusions were calculated
in the infused arm separately for every subject as % change from the flow during the
same infusion without LBNP as follows:
% change in FBF during LBNP = 100 x [(FBFlbnp - FBFSorL) / (FBFsoi-l)];
where FBFsorL is the blood in the infused arm during saline (S) or losartan (L)
infusion without LBNP, andFBFlbnp is the bloodflow in the infused arm during the
same infusion with LBNP, and then the results were averaged in each group.
FBF was expressed in mL. 100 mL"1 of tissue.min"1 (Whitney 1953). Data were
expressed as mean ± SEM and examined by two-factor ANOVA with repeated
measures, Pearson's correlation coefficient, and two-tailed paired and un-paired t-
tests as appropriate. Statistical significance was taken at the 5% level.
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4. Results
A summary of the patient characteristics is shown in Table 3-1. Patients with
diuretic-refractory ascites had significantly higher Child-Pugh score (Child &
Turcotte 1964; Pugh et al 1970) and prothrombin time, and significantly lower serum
albumin, than the pre-ascitic patients (p<0.01).
Table 3-1: Patient characteristics.
Variable Refractory ascites Pre-ascitic cirrhosis
Age: (yr) 56 + 4 48 ± 3
Sex: F:M 4:6 3:5
Child-Pugh score: ll.l±0.5# 6.3±0.4
Child grade: Grade A 0 6
Grade B o 2







Serum bilirubin: (pmol.L"1) 52 ± 17 35 ± 12
Serum albumin: (g.L"1) 27 + 2# 38 ± 2
Prothrombin time: (s) 18 + 1# 13 ± 1
Blood urea: (mmol.L"1) 4 ± 1 4 + 1
Serum creatinine: (pmol.L"1) 89 + 9 82 + 4
Results are expressed as mean ± standard error of the mean.
# p<0.01 v,y patients with pre-ascitic cirrhosis.
M, male. F, female. PBC, primary biliary cirrhosis. ALD, alcoholic liver disease.
HBV, hepatitis B virus, AICAH, autoimmune chronic active hepatitis.
4.1. Baseline systemic haemodynamics:
There were no changes in heart rate or mean arterial pressure throughout the studies.
Mean heart rate was significantly higher, and mean arterial pressure significantly
Chapter 3: Studies on the RAS & SNS. 90
lower, in patients with diuretic-refractory ascites than in pre-ascitic patients and
controls (/K0.01; Table 3-2). Heart rate correlated positively with PRA and basal
ANG II concentrations (r = 0.52; p<0.01 and r = 0.65; /?<0.01 respectively) and
mean arterial pressure correlated negatively with PRA and the basal ANG II
concentrations (r = -0.62;/?<0.01 and r = -0.61; /?<0.01 respectively).
4.2. Baseline forearm bloodflow:
There were no significant differences between the baseline FBF in the infused and
non-infused arms on each of the study days. The baseline FBF was significantly
lower in patients with refractory ascites than in both the pre-ascitic patients and the
control group (2.5 ± 0.2 v 4.8 ± 0.9 and 4.2 ± 0.8 mL. 100 mL"1 of tissue.min"1
respectively; p<0.05; Figure 3-2). No significant change in the blood flow in the non-



















Controls Pre-ascitic cirrhosis Refractory ascites
FIGURE 3-2: MEAN BASELINE BILATERAL FOREARM BLOOD FLOW.
*/?<0.05 vs pre-ascitic cirrhosis and controls.
Blood flow is expressed as ml. 100 mL tissue'1.min"1
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Angiotensin II: (pg mL"1)
PRA: (ng.mL Vh1)
88.0 ±3.4* 72.4 ±2.1



























Results are expressed as mean ± SEM. bpm, beat per min.
# p<0.01 vs controls,
* p<0.05 vs patients with pre-ascitic cirrhosis & controls,
**£><0.01 vs patients with pre-ascitic cirrhosis & controls,
4.3. Forearm bloodflow responses to angiotensin II and noradrenaline infusions:
Bilateral mean ± SEM absolute FBF (mL .100 mL"1 of tissue,min"1) at baseline, and
following ANG II and Nad infusions in all groups are shown in Tables 3-3 & 3-4.
Both ANG II and Nad infusions produced significant dose dependent reductions in
FBF in all subjects studied (£><0.001; Figure 3-3). The responses to ANG II were
significantly greater in the control group than in patients with diuretic-refractory
ascites (£><0.001) and patients with pre-ascitic cirrhosis (£><0.01). FBF responses to
Nad were similar in all groups.
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4.4. Forearm vascular responses to losartan infusions and LBNP:
Losartan caused dose-dependent increases in FBF in patients with refractory ascites
(/K0.001) but not in patients with pre-ascitic cirrhosis or controls, p<0.01 by
ANOVA (Figure 3-4). LBNP produced significantly less reduction in FBF in patients
with refractory ascites than in either patients with pre-ascitic cirrhosis or controls
0?<0.001 by ANOVA; Figure 3-5). In addition, responses to LBNP during saline
and losartan infusions were similar within each group. Although there was a trend
towards less reduction in FBF following LBNP during saline infusion compared with
that during losartan infusions in the refractory ascites group, it did not reach
statistical significance (p=0.13 &p=0A2 at doses of 30 & 90 pg/min respectively).
Bilateral mean ± SEM absolute FBF (mL. 100 mL"1 of tissue,min"1) at baseline, and
during saline, losartan and LBNP phases of the study in groups are shown in Figure
3-6.
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FIGURE3-6:ABSOLUTEOREARMBL ODWTASELINE,NDURINGSA IL SOWER BODYNEGATIVEPRESSUR(LBNP)H ESOFTHSTUD . Resultsareexp essedmean±SEM.**/?<0.01vpre-a citiccir ho sndontrols.FBFi expr sedL.10mL"1 ftis u .mi "1
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4.5. Assays:
As shown in Figure 3-7, basal plasma ANGII concentrations were significantly
higher in patients with diuretic-refractory ascites than in pre-ascitic cirrhotics
(p<0.05) and both were significantly higher than controls (/KO.O l ), Patients with
refractory ascites had significantly higher basal PRA (£><0.001; Figure 3-8) and
higher basal plasma Nad (£><0.01) and adrenaline concentrations (p<0.05) than the
patients with pre-ascitic cirrhosis and controls (Figure 3-9). Child-Pugh score
correlated positively with both PRA and plasma Nad concentrations (r = +0.71;


















FIGURE 3-7: BASELINE PLASMA CONCENTRATIONS OF ANGIOTENSIN II
#£><0.05 vs pre-ascitic cirrhosis and controls. *£><0.01 vs controls.











FIGURE 3-8: BASELINE PLASMA RENIN ACTIVITY.



















IGURE 3-9: BASELINE PLASMA CONCENTRATIONS OF ADRENALINE AND
NORADRENALINE.
* p<0.05 v.s' patients with refractory ascites.
** /K0.01 vs patients with refractory ascites.
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5. Discussion
In this study, we have shown that while patients with diuretic-refractory ascites and
those with pre-ascitic cirrhosis were hyporesponsive to exogenous ANGII,
endogenous ANG II contributed to the maintenance of basal vascular tone only in
patients with diuretic-refractory ascites, as demonstrated by the increase in forearm
blood flow with local intra-arterial losartan infusion. In addition, impaired peripheral
vasoconstrictor responses to low-pressure baroreceptor unloading occurred in
patients with refractory ascites although the vascular responses to exogenous Nad
were similar in all groups.
Previous studies in patients with cirrhosis have produced contradictory results
regarding the responsiveness to systemic administration of a-adrenergic agonists and
ANG II. While a number of studies have shown that responses to Nad were not
affected (Laragh et al 1963; Ames et al 1965; Lenz et al 1985; Hadoke et al 1998),
others have shown an attenuated response (Lunzar et al 1975; MacGilchrist et al
1991). Moreover, responses to ANG II were reported to be impaired in one study
(MacGilchrist et al 1991), whereas normal responses were reported in others (Laragh
et al 1963; Lunzar et al 1975; Lenz et al 1985). However, systemic drug
administration leads to concomitant effects on organs, such as the brain, kidney, and
heart, and influences neurohumoral reflexes by affecting systemic haemodynamics.
Consequently, vascular responses can't be wholly attributed to a direct effect of the
drug (Benjamin et al 1995; Webb 1995). In contrast, the use ofbilateral forearm
blood flow measurements, with unilateral brachial artery infusions of vasoactive
mediators at sub-systemic and locally active doses is a very powerful and
reproducible tool for directly assessing vascular responses in vivo (Benjamin et al
1995; Webb 1995). However, previous studies using the forearm model in patients
with liver cirrhosis are few and their results are also variable (Ryan et al 1993;
Calver et al 1994; Campillo et al 1995; Ryan et al 1996; Newby et al 1998a).
Because of the confounding influence of diuretic therapy and some methodological
concerns, such as use of unilateral blood flow measurements and non-standardised
infusion protocols, conflicting results have been reported, with the vasoconstrictor
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responses to Nad either reduced (Ryan et al 1993; Campillo et al 1995; Ryan et al
1995), or unaltered (Calver et al 1994; Newby et al 1998a).
Using the bilateral forearm model, our group has previously shown that patients with
cirrhosis and diuretic-responsive ascites have a significantly reduced vascular
reactivity to exogenous ANG II and cardio-pulmonary baroreceptor unloading
(Newby et al 1998a). However, maintenance of patients on regular diuretic therapy
may have influenced these results by producing relative intravascular hypovolemia
and associated neurohumoral activation (Dwarakanathan et al 1975). In the present
study, we recruited patients with early and advanced cirrhosis who were not
receiving maintenance diuretic therapy. Patients with refractory ascites were studied
one week after their regular therapeutic paracentesis and albumin therapy and were
haemodynamically stable.
In agreement with previous studies (Schroeder et al 1976; Arroyo et 1981; Bernardi
et al 1982; Pariente et al 1985; Bendtsen et al 1990; Newby et al 1998a), we have
shown that the renin angiotensin and sympathetic nervous systems are activated in
patients with cirrhosis and this neurohumoral activation becomes more marked with
disease progression. The observed reduction in baseline FBF in patients with
diuretic-refractory ascites may, in part, be explained by this neurohumoral activation
and supports the previously reported reduction in brachial, femoral and cerebral
arterial blood flow patients with cirrhosis and ascites, using duplex-Doppler
ultrasonography (Fernandez-Seara et al 1989; Maroto et al 1993; Dillon et al 1995).
Interestingly, we observed a trend towards increased baseline FBF in patients with
pre-ascitic cirrhosis. These observations support the hypothesis that the peripheral
circulation behaves differently from the splanchnic one, especially in the advanced
stages of the disease. This also indicates that the vasodilatation described in patients
with advanced cirrhosis is mainly splanchnic (Schrier et al 1988; Rahman et al
1992).
The present study demonstrates that the forearm circulation in cirrhotic patients is
hyporesponsive to ANG II even before the development of ascites, suggesting that
this abnormality may contribute to the pathogenesis of the hyperdynamic circulatory
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syndrome. The mechanism of this hyporesponsiveness is unclear but a previous
study in the animal model of cirrhosis has suggested that it may be mediated through
nitric oxide (Castro et al 1993). In addition, we have also demonstrated an increase in
the plasma ANG II concentrations of patients with pre-ascitic cirrhosis. The
mechanism underlying this increase is not clear, although the presence of an
activated renin-angiotensin system is consistent with a compensated vasodilated
state. Moreover, the activity of the renin-angiotensin system correlates with portal
pressure gradient (Bosch et al 1980). In the present study, all patients with pre-ascitic
cirrhosis had a high portal pressure as indicated by the presence of oesophageal
varices, and this explains the observed high ANG II concentrations in this group. A
reduction in the effective arterial blood volume contributes to the increased plasma
concentration of vasopressor agents especially in patients with advanced cirrhosis, as
evidenced by the acute suppression of their levels by both albumin and saline
infusion (Wong et al 1979). It is a possibility that the increased activity of the
endogenous vasopressor systems could have influenced the responses to the
exogenously administered ANG II and Nad resulting in a shift of the dose-response
curve. However, this is unlikely, at least regarding the responses to Nad, which were
similar in the three studied groups despite the presence of activated sympathetic
nervous system only in patients with diuretic-refractory ascites.
The finding that selective ATi receptor blockade with losartan increases FBF in
patients with diuretic-refractory ascites but produces no change in FBF in healthy
subjects or patients with pre-ascitic cirrhosis supports the concept that ANG II
contributes to the maintenance of peripheral vascular tone only in patients with
advanced liver disease but has no role in either healthy controls or early cirrhosis
(Baan et al 1996; Newby et al 1997; Newby et al 1998a). Oral losartan and irbesartan
have recently been shown to effectively reduce hepatic venous pressure gradient
(HVPG) in patients with cirrhosis and portal hypertension (Schneider et al 1999,
Klein et al 2000). The observed increase in plasma ANG II concentrations and the
vascular dependence on ANG II in patients with cirrhosis indicate that ANG II
contributes to the haemodynamic consequences of cirrhosis and, therefore, losartan
may potentially be helpful in the treatment of portal hypertension. In addition, the
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effects of the high plasma ANG II concentrations, observed in patients with pre-
ascific cirrhosis, on renal arteriolar blood flow may explain the subtle Na+ retention,
which is detected before the development of ascites (Wong et al 1995). Therefore,
the use ofATi receptor blockers may also improve Na+ excretion in patients with
pre-ascitic cirrhosis (Girgrah et al 2000), and consequently prevent or delay the
development of ascites.
LBNP has been used for many years to examine the neuro-circulatory reflex
response to reduced venous return to the heart (Greenfield et al 1963). In healthy
subjects, LBNP at intensities up to 20 mm Hg selectively unloads low-pressure
cardiopulmonary baroreceptors without causing changes in heart rate or blood
pressure. Such low intensity LBNP selectively reduces FBF (Zoller et al 1972;
Johnson et al 1974; Hirsch et al 1989; Seidelin et al 1991) and increases forearm Nad
spillover without affecting total peripheral vascular resistance or total body Nad
spillover. In contrast, LBNP at intensities greater than 20 mm Hg also unloads
arterial baroreceptors with concomitant increases in total body spillover ofNad,
increases in heart rate, and decreases in blood pressure (Jacobs et al 1996). Previous
studies in patients with decompensated cirrhosis have shown impaired
vasoconstrictor responses to both LBNP and body tilting (Lunzer et al 1975;
Bernardi et al 1982; Newby et al 1998a). In the present study, we document impaired
vasoconstrictor responses to LBNP in patients with diuretic-refractory ascites despite
normal responsiveness to exogenous Nad. This may be due to several mechanisms
including baroreceptor down-regulation or defective sympathetic neurotransmission
secondary to the autonomic dysfunction described with advanced cirrhosis (Oliver et
al 1997). In earlier studies by Wong et al, central venous pressure (CVP) has been
shown to be elevated in patients with pre-ascitic cirrhosis (Wong et al 1995; Wong et
al 1998). One may, therefore, anticipate that higher intensities ofLBNP are required
to achieve similar reflex responses in these patients. Nevertheless, these studies have
shown that, in response to LBNP of 15 mm Hg, patients with pre-ascitic cirrhosis
have similar reductions in CVP and FBF as healthy subjects (Wong et al 1995; Wong
et al 1998).
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The observation that the vasoconstrictor responses to LBNP of 15 mm Hg, in the
infused forearm, are unaffected by losartan infusions has been previously reported in
both cirrhotic patients (Newby et al 1998a) and controls (Newby et al 1997; Bishop
et al 1991; Duranteau et al 1995). This indicates that endogenous ANGII has little, if
any, role in mediating these regional responses to low levels ofLBNP in either
situation. In addition, these findings suggest that influences of endogenous ANG II
do not contribute to the impaired response to LBNP in patients with refractory
ascites.
In conclusion, despite hyporesponsiveness to exogenous ANG II in both early and
advanced cirrhosis, endogenous ANG II contributes to the maintenance of basal
vascular tone only in advanced cirrhosis. These findings suggest a role ofANG II in
the pathogenesis of ascites. The forearm vascular responses to exogenous Nad are
unimpaired. However, attenuated LBNP responses occurred only in advanced
cirrhosis, without apparent interaction with endogenous ANG II. Further studies are
required to elucidate the mechanism of the observed hyporesponsiveness to ANG II.
This will be shown in the Chapter 5.
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CHAPTER 4
STUDIES ON THE ENDOTHELIN SYSTEM
Helmy A, Jalan R, Newby DE, NR Johnston, Hayes PC, Webb DJ. Altered
peripheral vascular responses to exogenous and endogenous endothelin-1 in patients
with well-compensated cirrhosis. Hepatology 2001;33:826-831.
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1. Summary
Background/Aims: Plasma endothelin concentrations are elevated in cirrhosis and
correlate with disease severity. This study assessed forearm vascular responses to
exogenous endothelin-1 (ET-1), and evaluated the contribution of endogenous ET-1
to the maintenance of basal peripheral vascular tone in patients with well-
compensated cirrhosis (n=ll), and matched healthy controls (n=8).
Methods: Bilateral forearm blood flow (FBF) was measured at baseline, and
following unilateral sub-systemic, intra-brachial artery infusions ofET-1 (2 and 6
pmol/min); BQ-123, a selective ETA receptor antagonist (3 and 10 nmol/min), and
BQ-788, a selective ETb receptor antagonist (0.3 and 1 nmol/min), using venous
occlusion plethysmography. Baseline systemic haemodynamics, and plasma ET-1
and big ET-1 concentrations, were measured using electrical bioimpedance and
radioimmunoassay respectively.
Results: Patients and controls had similar baseline FBF, systemic haemodynamics,
and plasma ET-1 and big ET-1 concentrations. In both groups, ET-1 and BQ-788
caused significant vasoconstriction (p<0.001) and BQ-123 caused significant
vasodilatation (/K0.001). Compared with controls, cirrhotic patients had attenuated
ET-1 responses (/K0.001), augmented BQ-123 responses (p<0.001), and similar BQ-
788 responses (p=0.62).
Conclusions: Despite normal systemic haemodynamics and plasma ET-1
concentrations, forearm vascular responses to exogenous ET-1 are reduced in
cirrhotic patients. The augmented vasodilatation response to BQ-123 in cirrhotic
patients is consistent with a compensated vasodilated state, and a greater contribution
ofET-1 to the maintenance of basal vascular tone acting through the ETA receptor.
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2. Introduction and aims
A hyperdynamic circulation characterized by low arterial pressure, high cardiac
output, and low systemic vascular resistance is a feature of patients with advanced
cirrhosis and portal hypertension (Kowalski & Abelmann 1953; Murray et al 1958;
Kontos et al 1964). These circulatory disturbances worsen with disease progression
(Braillon et al 1986; Bendtsen et al 1990; Meng et al 1994), and are accompanied by
a reduced reactivity to vasopressor agents, including responses mediated by the
renin-angiotensin and sympathetic nervous systems. These haemodynamic changes
play a crucial role in the pathogenesis of portal hypertension and its complications,
including variceal haemorrhage, ascites, and the hepatorenal syndrome (Schrier et al
1988; Groszmann et al 1994).
Endothelin-1 (ET-1) is the most potent vasoconstrictor known, belonging to a 21-
amino acid peptide family with a range of biological effects (Yanagisawa et al 1988;
Spokes et al 1989; Masaki et al 1992). ET-1 was originally identified in the culture
medium of porcine aortic endothelial cells (Yanagisawa et al 1988; Masaki et al
1992), and is derived from a larger pre-pro-endothelin-1 (212 amino acids) which is
cleaved by endopeptidases to produce big endothelin-1 (38 amino acids), which is
then converted by specific endothelin converting enzymes (ECEs) to ET-1
(Yanagisawa et al 1988; Masaki et al 1992).
Molecular studies have, so far, identified two endothelin receptor subtypes in
mammalian species: endothelin-A (ETA) and endothelin-B (ETB). In vascular smooth
muscle cells, both receptors are expressed (Spokes et al 1989; Davenport et al 1995),
and these mediate vasoconstriction (Spokes et al 1989; Tschudi & Luscher 1994;
Davenport et al 1995; Haynes et al 1995). Only the ETB receptors are found on
endothelial cells, where these cause vasodilatation through the release of
endothelium-derived vasodilators, such as nitric oxide (NO) (Takayanagi et al 1991).
ET-1 induced vasoconstriction is predominantly mediated by the ETA receptor but
ETb receptors may contribute under some circumstances (Davenport & Maguire
1994).
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Since 1991, many studies have reported increased plasma concentrations ofET-1 in
patients with decompensated liver cirrhosis (Moore et al 1992; Uchihara et al 1992;
Asbert et al 1993; Isobe et al 1993; Moller et al 1993; Hartleb et al 1994; Matsumuto
et al 1994; Gerbes et al 1995; Moller et al 1995; Salo et al 1995a; Tsai et al 1995;
Kitano et al 1996; Newby et al 1998a), while normal levels were shown in two
earlier studies (Lerman et al 1991; Textor et al 1992). The mechanisms underlying
the elevated ET-1 concentrations are unclear, and do not appear to be related to
hypovolemia or endotoxemia (Salo et al 1995a; Salo et al 1995b). However, there
have been no studies to address the vascular responsiveness to ET-1 in vivo, or its
role in the maintenance of basal peripheral vascular tone, in patients with cirrhosis.
Because of the complications in decompensated cirrhosis associated with
concomitant medications, and effects on baseline forearm and systemic
haemodynamics, this study was conducted in patients with well-compensated
cirrhosis and portal hypertension and in matched healthy controls.
The aims of these studies were to:
1. evaluate the plasma concentrations ofET-1 and its biological precursor big
ET-1 in patients and its relation to disease severity.
2. determine the forearm vascular responsiveness to exogenous ET-1, and
3. assess the role of endogenous ET-1 in the maintenance of basal forearm
vascular tone using the selective ETA and ETB receptor antagonists, BQ-123
and BQ-788 respectively.
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3. Subjects and methods
3.1.~Suhjects:
Eleven patients with biopsy-proven and well-compensated cirrhosis (Child grade A;
Table 4-1) and eight healthy control subjects were recruited. All patients were
ambulant, and had endoscopically proven oesophageal varices, normal serum
creatinine (<100 p,mol/L), and no clinical evidence of systemic circulatory
disturbance. Patients with alcoholic liver disease were abstinent from alcohol for at
least one month, confirmed by history and random blood ethanol testing, to prevent
the depression of vascular responses this causes (Howes & Reid 1985). To avoid the
possibility of altering the endogenous vasopressor systems, all subjects in both
groups were maintained on their normal sodium intake. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in the week before, and all
subjects abstained from food, tobacco and caffeine-containing drinks for at least 4
hours before, each study. All female subjects were post-menopausal, both for safety
and to avoid the variability in vascular responses that may be associated with cyclic
hormonal changes (Hashimoto et al 1995). Exclusion criteria included the presence
ofmalignancy, encephalopathy, portosystemic shunt, previous gastrointestinal
bleeding, or any significant cardiovascular disease such as diabetes mellitus and
hypertension. Studies were undertaken in accordance with the Declaration of
Helsinki (1989) of the World Medical Association, the approval of the local research
ethics committee, and the written informed consent of each subject.
3.2. Drugs, intra-arterial administration and measurement ofFBF:
All studies were performed in a quiet, temperature-controlled room maintained at 22
-24 °C. Cannulation of the brachial artery of the non-dominant arm was performed
using a 27-standard wire gauge steel needle (Cooper's Needle Works, Birmingham,
England) under 1% lidocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings Langley,
England) local anaesthesia. Patency was maintained by saline infusion at a constant
rate (1 mL/min) via an 1VAC PI000 syringe pump (IVAC Ltd., Basingstoke,
England). FBF was measured as previously described (Newby et al 1998a; Helmy et
al 2000, Chapter 2).
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ET-1 (Clinalfa AG, Laufelfingen, Switzerland) at doses of 2 and 6 pmol/mL, BQ-123
(a selective ETA receptor antagonist; Clinalfa) at doses of 3 and 10 nmol/mL, and
BQ-788 (a selective ETB receptor antagonist; Clinalfa) at doses of 0.3 and 1
nmol/mL, were dissolved in physiological saline (0.9% Baxter Healthcare Ltd.,
Thetford, England) and administered intra-arterially.
On the basis of previous studies, we used doses that are sub-systemic and act locally
to produce ~ 40 % reduction, ~ 30 % increase, and ~ 20 % reduction in FBF in
healthy subjects after a 60 min infusion ofET-1 (5 pmol/min), BQ-123 (10
nmol/min), and BQ-788 (1 nmol/min) respectively (Haynes & Webb 1994; Newby et
al 1998; Verhaar et al 1998). In such studies, by 60 min, these doses produce
maximal and sustained responses (Haynes & Webb 1994; Newby et al 1998; Verhaar
et al 1998). Pilot studies have suggested that higher doses may evoke systemic
haemodynamic effects. Moreover, such studies have only used a single dose ofET-1,
which has a maximal effect by 60 min because of the slow onset and offset of its
action (Clarke et al 1989).
3.3. Study design:
Schematic diagrams of the three protocols applied in this study are shown in Figure
4-1. ET-1, BQ-123, and BQ-788 were administered on three separate occasions, in
random order, at least one week apart. Subjects rested supine throughout each study.
Strain gauges and cuffs were applied, and the brachial artery of the non-dominant
arm cannulated. In all protocols, saline was infused for 30 min to allow time for
equilibration, with FBF measurements being made every 10 min and the final
measurement taken as the baseline FBF. Thereafter, ET-1, BQ-123, or BQ-788 was
infused for 60 min at each of two incremental doses, and FBF measured every 10
min.
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3.4. Measurement ofsystemic haemodynamics:
Arterial blood pressure and heart rate (HR) were measured in the non-infused arm
using a non-invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda
Medical Inc, Tokyo, Japan) at 20 min intervals throughout each study (Wiinberg et al
1988). The mean arterial pressure (MAP) was calculated according to the formula;
MAP (mm Hg) = diastolic arterial pressure + 1/3 pulse pressure (systolic arterial
pressure - diastolic arterial pressure).
Baseline cardiac functions, including HR, stroke volume and cardiac output, were
measured using a non-invasive thoracic electrical bioimpedance method (BoMed
NC-COM3, BoMed Medical Manufacturer Ltd, Irvine, CA, USA) as previously
described (Apple et al 1986). Bioimpedance is a non-invasive and reproducible
method for assessing systemic haemodynamic parameters, such as cardiac output and
systemic vascular resistance (Apple et al 1986; Salandin et al 1988; Northridge et al
1990; Thomas et al 1992). Cardiac index (CI), stroke index (SI), and total peripheral
vascular resistive index (TPVRI) were calculated according to the formulae: CI
(L.min"1 m"2) = cardiac output (L.min"1) / body surface area (m2); SI (mL.nf2) =
stroke volume (mL) / body surface area (m2); and TPVRI (mm Hg.L'Vmin.m2) =
MAP (mm Hg) / CI (L.min"1.m"2).
3.5. Blood assays:
Before drug administration and after 30 min of supine rest, 20 mL of venous blood
was withdrawn and 10 mL were admixed with each of the following: 0.5 mL of
0.45% O-phenanthroline/ 4.65% disodium EDTA for plasma ANG II assay; and 1
mL of 1% disodium EDTA and 1000 KIU aprotinin (Bayer AG, Leverkusen,
Germany) for plasma ET-1, Big ET-1 and plasma renin activity (PRA) assays. Blood
samples were placed on ice and immediately centrifuged at 1500 g for 20 min.
Plasma was frozen and stored at -80 °C until assayed. Plasma ANG II concentrations
were measured by radioimmunoassay (RIA) following extraction using Bond Elut®
columns (Varian, Harbor City, CA, USA) as previously described (Morton & Webb
1985). PRA was determined under standard conditions through the measurement of
the generation of ANG I using RIA as previously described (Haber et al 1969).
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Following extraction using Bond Elut® columns (Varian, Harbor City, CA, USA),
the plasma concentrations ofET-1 (Peninsula Laboratories Europe Ltd., St. Helens,
England) and big ET-1 (Peninsula Laboratories Europe Ltd.) were determined by
RIA as previously described (Rolinski et al 1994).
3.6. Data analysis and statistics:
Plethysmographic data were extracted from the ChartIM (AD Instruments, Castle
Hill, Australia) data files and forearm blood flows were calculated for individual
venous occlusion cuff inflations using a template spreadsheet (Excel v5.0;
Microsoft). Recordings from the first 60 s following inflation of the wrist cuffwere
not included in the analysis because of the variability in blood flow this produces
(Kerslake 1949). Usually, the last 5 flow recordings in each 3 min period were
calculated and averaged for each arm. To reduce the variability of blood flow data,
the ratio of flows in both arms was calculated for each time point, thereby using the
non-infused arm as a contemporaneous control (Benjamin et al 1995; Webb 1995).
The percentage change in FBF was calculated as follows:
% change in FBF = 100 x [(It / NIt) - (Ib / NI„)] / (Ih / NIb);
where /, andNIt are the bloodflows in the infused and non-infusedforearms
respectively at a given time point (t) andh andNh are the bloodflows in the infused
and non-infusedforearms respectively at baseline (b); time 0.
FBF was expressed in mL. 100 mL tissue"1.min"1 (Whitney 1953). Data were
expressed as mean ± standard error of the mean (SEM) and examined by two-factor
analysis of variance (ANOVA) with repeated measures, regression analysis and two-
tailed paired and un-paired Student's t-tests as appropriate. Statistical significance
was taken at the 5% level.
Chapter 4: Studies on the endothelin system 115
4. Results
A summary of baseline characteristics of the subjects is shown in Table 4-1. Patients
with cirrhosis were well matched to the control subjects for age, sex and body mass
index (BMI). Six patients (5 males and 1 female) completed all 3 protocols; one
female patient completed two protocols, and the remaining 4 studies were performed
in 4 female patients. Therefore, the 24 studies were completed in 11 patients. No
adverse effects were observed in either patients or controls during or after the
studies. The 24 h urinary Na+ excretion was similar in both groups (Table 4-2).






























Results are expressed as mean ± SEM. ALD, alcoholic liver disease. BMI, body
mass index. BSA, body surface area. HCV, hepatitis C virus. PBC, primary biliary
cirrhosis.
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4.1. Baseline systemic haemodynamics:
As s"hown in Table 4-2, both cirrhotic patients and healthy controls had similar
baseline systemic haemodynamics including HR, MAP, SI, CI and TPVRI. There
was no significant difference in baseline FBF (mL. 100 mL tissue"1, min"1) in the
infused arm between patients with cirrhosis and controls subjects (2.8 ± 0.3 and 2.5 ±
0.3 respectively; Table 4-2). Throughout all protocols, there were no significant
changes in MAP, HR, or FBF in the non-infused arm.
Table 4-2: Baseline systemic haemodynamics and hormonal assays.
Variable Cirrhotics Controls
Heart rate (beat.min"1) 72.3+2.7 65.8 + 2.8
Mean arterial pressure (mm Hg) 93.9 + 3.2 95.2 + 4.2
Cardiac index (L.min'.m2) 3.7 + 0.2 3.7 + 0.4
Stroke index (mL.m"2) 54.3+4.8 56.8+4.7
TPVRI (mm Hg.L"1.min.m2) 25.8 + 1.2 28.3+4.3
FBF infused arm ** 2.8 + 0.3 2.5+0.3
FBF non-infused arm ** 2.9 + 0.3 2.3 ±0.3
Plasma ANGII concentrations (pg.mL1) 31.8 + 7.2* 10.9 + 2.0
Plasma renin activity (ng.mL '.h"1) 1.7 + 0.3# 1.1 ±0.1
Plasma ET-1 (fmol.mL"1) 1.2 + 0.1 1.2 + 0.2
Plasma big ET-1 (fmol.mL"1) 7.6 + 0.8 6.8 ± 1.8
Results expressed as mean ± SEM. * p<0.05. #p = 0.08. ** expressed in mL. 100 mL
tissue"1.min"1
4.2. Forearm bloodflow responses to ET-1 infusions:
ET-1 infusion caused a significant dose-dependent reduction in FBF both in cirrhotic
patients and in controls (^<0.001, ANOVA for each group). However, the
vasoconstriction was significantly less in the patients than in the controls (/K0.001,
two-way ANOVA with repeated measures; Figure 4-2). The maximum reduction in
FBF following infusion of the first dose ofET-1 (2 pmol/mL) was 11.5 + 5.3% and
25.4 ± 3.6% in the cirrhotic patients and controls respectively, and reached 25.0 ±
3.6% and 36.3 ± 5.2% respectively following infusion of the second dose (6
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pmol/mL; Figure 4-2). Absolute FBF in both arms before and during infusion ofET-
1 is shown in Table 4-3.
4.3. Forearm bloodflow responses to BQ-123 infusions:
ETa receptor antagonism, using BQ-123 infusion, produced a dose-dependent
increase in FBF in both cirrhotic patients and controls (p<0.001, ANOVA for each
group). This vasodilator response was significantly greater in the patients than the
controls (p<0.001, two-way ANOVA with repeated measures). The maximum
increase in FBF following infusion of the first dose ofBQ-123 (3 nmol/min) was
30.0 ± 5.2% and 10.0 + 2.2% in cirrhotic patients and controls respectively, and
reached 47 7 ± 6.1% and 37.1 ± 12.5% respectively following infusion of the second
dose (10 nmol/min; Figure 4-3). Absolute FBF in both arms before and during
infusion ofBQ-123 is shown in Table 4-4.
4.4. Forearm bloodflow responses to BQ-788 infusions:
ETb receptor antagonism, using BQ-788 infusion, produced a significant dose-
dependent reduction in FBF in both the cirrhotic patients and controls (p<0.001,
ANOVA for each group). This vasoconstrictor response was similar in the two
groups (p=0.62). The maximum reduction in FBF following infusion of the first dose
ofBQ-788 (0.3 nmol/mL) was 11.4 ± 5.8% and 14.2 ± 6.2% in cirrhotic patients and
controls respectively, and reached 22.2 ± 7.5% and 26.4 ± 9.2% respectively
following infusion of the second dose (1 nmol/mL; Figure 4-4). Absolute FBF in
both arms before and during infusion ofBQ-788 is shown in Table 4-5.
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Table 4-3: Absolute forearm blood flow during endothelin-1 infusion.
-
Controls Cirrhotics
Time Infused arm Non-infused arm Infused arm Non-infused arm
Baseline 0 2.5 ±0.3 2.3 ±0.3 2.8 ±0.3 2.9 ±0.3
10 min 2.2 ±0.3 2.4 ±0.3 2.8 ±0.3 2.9 ±0.2
20 min 2.1 ±0.2 2.4 ±0.3 2.6 ±0.3 2.9 ±0.3
30 min 2.3 ±0.2 2.6 ±0.3 2.5 ±0.3 2.8 ±0.2
40 min 2.1 ±0.3 2.4 ±0.3 2.6 ±0.3 2.9 ±0.3
50 min 2.2 ±0.3 2.8 ±0.3 2.5 ±0.3 3.0 ± 0.3
60 min 2.2 ±0.3 2.5 ±0.3 2.6 ±0.3 3.0 ±0.3
70 min 1.9 ±0.2 2.4 ±0.3 2.5 ±0.2 3.0 ±0.3
80 min 1.9 ± 0.3 2.6 ±0.4 2.4 ±0.3 2.8 ±0.2
90 min 2.1 ±0.3 3.1 ±0.6 2.4 ±0.4 3.0 ±0.3
100 min 2.0 ±0.3 2.8 ±0.4 2.3 ±0.4 2.8 ±0.3
110 min 2.0 ±0.3 2.9 ±0.5 2.4 ±0.5 3.1 ±0.4
120 min 1.9 ± 0.3 2.8 ±0.4 2.4 ±0.5 3.1 ±0.4
Results are expressed as mean ± SEM.
Blood flow is expressed in mL.100 mL"1 of tissue,min"1.
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Table 4-4: Absolute forearm blood flow during BQ-123 infusion.
Controls Cirrhotics
Time Infused arm Non-infused arm Infused arm Non-infused arm
Baseline 0 2.7 ±0.3 2.3 ±0.3 3.8 ±0.4 2.6 ±0.2
10 min 2.7 ±0.4 2.5 ±0.3 3.8 ±0.4 2.7 ±0.2
20 min 2.7 ±0.2 2.3 ±0.2 3.9 ±0.5 2.5 ±0.2
30 min 2.6 ±0.3 2.2 ±0.3 4.2 ±0.6 2.4 ±0.2
40 min 2.8 ±0.3 2.3 ±0.2 4.6 ±0.6 2.6 ± 0.1
50 min 2.9 ±0.3 2.2 ±0.2 4.6 ±0.8 2.4 ±0.2
60 min 2.8 ±0.3 2.3 ±0.2 4.6 ±0.8 2.5 ±0.4
70 min 3.0 ±0.2 2.2 ±0.2 4.6 ±0.7 2.3 ±0.2
80 min 3.0 ±0.4 2.2 ±0.2 4.2 ±0.7 2.2 ±0.2
90 min 3.2 ±0.4 2.1 ±0.3 5.1 ±0.7 2.4 ±0.2
100 min 2.8 ±0.3 2.1 ±0.2 5.0 ±0.8 2.3 ±0.2
110 min 3.3 ±0.3 2.3 ±0.2 4.9 ±0.8 2.4 ±0.2
120 min 3.2 ±0.3 2.4 ±0.2 5.0 ±0.7 2.4 ±0.2
Results are expressed as mean ± SEM.
Blood flow is expressed in mL. 100 mL"1 of tissue,min"1.
Chapter 4: Studies on the endothelin system 123
Table 4-5: Absolute forearm blood flow during BO-788 infusion.
Controls Cirrhotics
Time Infused arm Non-infused arm Infused arm Non-infused arm
Baseline 0 3.7 ± 0.5 3.4 ±0.9 4.4 ±0.7 3.3 ±0.5
10 min 3.8 ±0.6 3.9 ±1.2 4.5 ±0.8 3.3 ±0.4
20 min 3.6 ±0.5 3.5 ± 1.1 4.4 ±0.8 3.4 ± 0.5
30 min 3.4 ±0.6 3.7 ± 1.4 4.1 ±0.6 3.3 ±0.5
40 min 3.1 ±0.5 3.8 ± 1.5 4.2 ±0.6 3.6 ±0.6
50 min 3.4 ± 0.6 3.4 ± 1.0 3.9 ±0.6 3.5 ±0.5
60 min 3.0 ±0.4 3.4 ± 1.0 4.5 ±0.7 3.7 ±0.5
70 min 3.2 ±0.6 3.4 ± 1.2 4.3 ±0.7 3.5 ±0.4
80 min 2.9 ±0.5 4.3 ±2.1 4.4 ±0.7 3.8 ±0.6
90 min 3.0 ± 0.5 3.9 ± 1.6 3.7 ±0.5 3.9 ±0.6
100 min 3.3 ±0.5 4.1 ± 1.6 4.1 ±0.6 4.1 ±0.5
110 min 3.6 ± 1.1 4.5 ±2.3 4.2 ±0.7 4.4 ±0.6
120 min 3.8 ±1.3 4.4 ±0.9 3.9 ±0.5 4.1 ±0.4
Results are expressed as mean ± SEM.
Blood flow is expressed in mL. 100 mL"1 of tissue,min"1.
Chapter 4: Studies on the endothelin system 124
4.5. Blood assays:
Basal plasma ANG II concentrations were higher (/K0.05) and PRA tended to be
higher (p= 0.08) in patients with cirrhosis. However, basal plasma concentrations of
ET-1 and big ET-1 were similar in pre-ascitic cirrhotic patients and controls (Table
4-2) and correlated positively with each other (r= 0.82; /K0.001). In addition, plasma
concentrations ofET-1 and Big ET-1 were significantly higher in patients with
advanced cirrhosis compared with patients with pre-ascitic cirrhosis and controls
(p<0.01 for each; Figure 4-5)
□ ET-1
Big ET-1
Advanced cirrhosis Pre-ascitic cirrhosis Controls
FIGURE 4-5: BASELINE PLASMA CONCENTRATIONS OF ENDOTHELIN-1
AND BIG ENDOTHELIN-1.
* /K0.001 vs pre-ascitic cirrhotic patients and controls for both.
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5. Discussion
In patients with well-compensated cirrhosis, portal hypertension and normal plasma
ET-1 concentrations, we have shown peripheral vascular hyporesponsiveness to
exogenous ET-1 before the development of any systemic haemodynamic
abnormality. Moreover, these patients have an augmented response to ETA receptor
antagonism, whilst retaining a normal response to ETb receptor antagonism. These
findings are consistent with an activated endothelin system in cirrhosis leading to
downregulation of the responses to exogenous ET-1, and a greater contribution of
endogenous ET-1 to basal forearm vascular tone acting through the ETA receptor. It
also suggests a potential counter-regulatory role for ET-1 in the pathogenesis of the
circulatory disturbances of cirrhosis.
Patients with advanced cirrhosis and fluid retention have elevated plasma ET-1
concentrations (Moore et al; 1992; Uchihara et al 1992; Isobe et al 1993; Asbert et al
1993; Moller et al 1993; Matsumuto et al 1994; Gerbes et al 1995; Moller et al 1995;
Salo et al 1995a), which are particularly high in those patients with hepatorenal
syndrome (Moore et al 1992). Moreover, plasma ET-1 concentrations correlate
positively with the severity of liver disease as measured by Child-Pugh score (Isobe
et al 1993; Moller et al 1995; Gerbes et al 1995), the hepatic blood flow (measured
by D-sorbitol infusion) and the hepatic venous pressure gradient (Moller et al 1995),
and inversely with the liver cell mass as measured by galactose elimination capacity
(Gerbes et al 1995) and creatinine clearance (Uchihara et al 1992; Moller et al 1993;
Moller et al 1995). However, due to its paracrine mode of action, the majority ofET-
1 is released abluminally to act on adjacent vascular smooth muscle and endothelial
cells and, as a consequence, plasma ET-1 concentrations may not truly reflect the
underlying activity of the endothelin system (Frelin & Guedin 1994). In the present
study, we have confirmed the previous findings of normal plasma ET-1 and big ET-1
concentrations in patients with well-compensated cirrhosis (Lerman et al 1991;
Textor et al 1992; Uchihara et al 1992) but have additionally demonstrated evidence
of functional abnormalities in the tonic activity of the endothelin system. This is
consistent with evidence suggesting that modest activation of the endothelin system
can occur without a change in plasma ET-1 concentrations.
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For the first time, we report an impaired in vivo vasoconstrictor response to
exogenous ET-1 in patients with well-compensated cirrhosis in the absence of a
measurable abnormality in baseline FBF, cardiac function or systemic
haemodynamics. This reduced responsiveness to ET-1 may, in part, reflect a greater
basal ET-1 activity as suggested by the enhanced vasodilator response to BQ-123
infusion. Using the same forearm model we have also shown impaired
vasoconstrictor response to ANG II in patients with early (Helmy et al 2000) and
advanced cirrhosis (Newby et al 1998a; Helmy et al 2000). This observation is in
keeping with the impaired vasopressor responses to both ET-1 (Hartleb et al 1994a)
and ANG II (Castro et al 1993) in the rat model of secondary biliary cirrhosis and
portal hypertension. The mechanisms underlying the reduced responsiveness to ET-1
remain unclear, but downregulation of the ETa receptor secondary to activation of
the endothelin system may be implicated. In addition, NO, and possibly other
mediators, may be involved (Castro et al 1993; Sieber 1995; Sogni et al 1995; Martin
et al 1998). This is supported by the observations of increased NO production, and
nitric oxide synthase (NOS) activity, in portal hypertension49 and by the reversal of
the ET-1 (Hartleb et al 1994a) and ANG II (Castroe et al 1993) hyporesponsiveness
observed in the rat model of cirrhosis following NOS inhibition.
Several studies have suggested that alterations in post-receptor signal transduction
pathways may be involved in the hyporesponsiveness to vasopressor agents in
cirrhosis (Murray & Paller 1985; Lee et al 1986; Mahl & Groszmann 1991; Lee &
Severson 1994; Moreau & Lebrec 1995; Huang et al 1996; Levy 1997; Hadoke
1999). Protein kinase C (PKC) is one of the main intracellular messengers involved
in the signal transduction of protein-G coupled receptors, including ET-1 and ANG II
receptors (Lee & Severson 1994), and through phosphorylation, has additional
actions to reduce the catalytic activity ofNOS in vascular endothelial cells (Hirata et
al 1995). Thus, altered PKC activity may contribute to the observed reduction in the
ET-1 vasoconstrictor response. This is supported by the observed abnormalities in
PKC activity in the lymphocytes of patients with cirrhosis (Spinozzi et al 1991), in
the intestinal microcirculation of portal hypertensive rats (Wu & Benoit 1994), in
cultured aortic vascular smooth muscle cells obtained from cirrhotic rats (Tazi et al
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1997), and in cirrhotic rat aortae (Trombino et al 1998). Another possible
explanation for the reduced vasoconstrictor response to ET-1 is down-regulation of
endothelin receptors by the increase in transforming growth factor beta-1 (TGF(31),
which has been reported to decrease ET-1 receptor density in cirrhosis (Gabriel et al
1999). Further studies directly assessing the role of these mechanisms in the impaired
vasoconstrictor responses of patients with cirrhosis are needed.
This study has also demonstrated, for the first time, that patients with well-
compensated cirrhosis exhibit an enhanced forearm vasodilatation response to the
infusion of the ETA receptor antagonist, BQ-123. This observation is consistent with
an activated endothelin system, and a greater contribution ofET-1 to the
maintenance of basal forearm vascular tone acting through the ETA receptor in these
patients. Interestingly, this forearm vasodilator response to BQ-123 infusion has been
shown to be largely reversed by inhibiting endogenous NO production, but not by
cyclo-oxygenase inhibition, in healthy subjects (Verhaar et al 1998). Whether the
enhanced forearm vasodilatation observed in the present study, in patients with well-
compensated cirrhosis, is mediated through a higher endogenous NO production is
currently unknown.
In the present study, we have shown that patients with well-compensated cirrhosis
and healthy controls have similar forearm vasoconstrictor responses to the infusion
of the ETb receptor antagonist BQ-788. The interpretation of this observation is
complex for several reasons. First, the relative predominance ofETb receptor-
mediated vasoconstriction or vasodilatation (Takayanagi et al 1991; Davenport &
Maguire 1994; Tschudi & Luscher 1994; Davenport et al 1995; Haynes et al 1995)
will depend largely on the proportionate expression of these receptors in the vascular
smooth muscle and endothelial cells. Selective cell-specific blockade of the ETb
receptors would be valuable to dissect out these relative contributions but the tools
needed to address this issue do not currently exist (Gray & Webb 1996). Second,
since the ETb receptor appears to function as a clearance receptor (Gray & Webb
1996; Strachan et al 1999), the responses to BQ-788 could possibly represent the
effect ofET-1 displacement on to the ETA receptor. Thus, the vasoconstriction
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following ETb receptor antagonism, by BQ-788, is the sum of the unopposed
vasoconstrictor action of endogenous ET-1 at the ETA receptors, and the absence of
its vasodilator action at the endothelial ETB receptors. Third, it is unlikely that
stimulation ofETB receptors is the sole mechanism for the increased NO production
in cirrhosis, in which case one would have anticipated greater vasoconstriction in
such patients following selective ETB receptor antagonism. Further studies are now
needed to address the relationship between NO production and ETB receptor
stimulation, in patients with cirrhosis.
The findings of the present study apply directly to the forearm circulation, but add to
our understanding of the role ofET-1 in regulation of peripheral vascular tone in
cirrhosis, and are probably representative of the systemic resistance vascular beds
(Webb 1995). As yet, there are no reports of systemic studies assessing the actions of
either exogenous or endogenous ET-1 in the systemic and splanchnic circulations in
patients with cirrhosis, apart from a preliminary report of infusing the ETA receptor
antagonist, BQ-123, in 3 patients with advanced cirrhosis and hepatorenal syndrome.
Interestingly, this study showed an improvement in renal blood flow and creatinine
clearance (Soper et al 1996). However, on the basis of our study, and the peripheral
vasodilatation hypothesis (Schrier et al 1988), if selective ETA receptor antagonists
were to exert their major effect on the splanchnic circulation, then they might further
exacerbate portal hypertension and systemic hypotension. Therefore, we believe that
systemic studies are clearly needed to assess the clinical role ofET-1 antagonists in
patients with cirrhosis and portal hypertension.
Patients with pre-ascitic cirrhosis often appear, at some stage, to have normal
systemic haemodynamics (Wong et al 1994, Wong et al 1996; Henriksen et al 1999)
due to a compensated vasodilated state. Our findings are in agreement with this
since, in these patients, we have demonstrated a normal cardiac output and peripheral
vascular resistance with an evidence of activation of the renin-angiotensin system. In
addition, the observed forearm vascular hyporesponsiveness to ET-1 and enhanced
dilatation following BQ-123 infusion indicates that these altered vascular responses
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precede the appearance of systemic haemodynamic derangements, or ascites
formation, and may, therefore, have a role in their pathogenesis.
Experimental studies in the rat model of cirrhosis and portal hypertension have
shown reductions in splanchnic blood flow and portal venous pressure by the non¬
selective endothelin receptor antagonists TAK-044 (Gandhi et al 1998), bosentan
(Reichen et al 1998; Sogni et al 1998), and SP206970 (Kojima et al 2000), and by
the selective ETr receptor antagonist, IRL1038, while selective ETa receptor
antagonism produced no clear effects (Cahill et al 1998): a response which has
recently been shown in a preliminary report in patients with cirrhosis (Siegerstetter et
al 2000). Also, ETB receptor overexpressin in the splanchnic vasculature was
demonstrated in the same rat model (Cahill et al 1998) suggesting a role ofET-1 in
the pathogenesis of splanchnic vasodilatation, mediated through the ETB receptor,
which is central in the pathogenesis of portal hypertension and its complications.
When these experimental data are viewed in concert with the findings of the present
study, we may speculate that the use of selective ETB receptor antagonists or non¬
selective ET antagonists may have a therapeutic role in patients with portal
hypertension through reducing splanchnic blood flow without producing
derangement in systemic haemodynamic.
One of the potential limitations of the present study is that four out of the eleven
patients had alcoholic liver disease. Indeed, excessive and regular alcohol intake may
alter the vascular responses to exogenous vasopressor agents such as noradrenaline
(Howes & Reid 1985). In each phase of the present study, only two or three out of
eight patients had alcoholic cirrhosis. All subjects were abstinent from alcohol for a
minimum of one month as determined by both clinical history and repeated random
blood ethanol testing. In our previous studies (Newby et al 1998a; Helmy et al 2000)
incorporating similar patients, we have shown normal vascular responses to
noradrenaline infusion. In addition, we have re-evaluated the present results
following exclusion of patients with alcoholic cirrhosis and have found consistent
results without alteration in the statistical significance or in the magnitude of the
effects of the study findings
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In conclusion, the forearm circulation in patients with well-compensated cirrhosis is
hyporesponsive to exogenous ET-1 despite the absence of any significant differences
in basal systemic haemodynamic characteristics and normal circulating ET-1
concentrations in these patients. The enhanced vasodilatation in response to BQ-123
infusion in cirrhotic patients suggests a compensated vasodilated state, an activated
endothelin system, and a greater contribution ofET-1 to the maintenance of forearm
basal vascular tone acting through the ETA receptor. The mechanism underlying this
hyporesponsiveness to ET-1 warrants further investigation. The role ofNO in
mediating the enhanced forearm vasodilatation in response to ETA receptor blockade
will be addressed with in Chapter 6.
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CHAPTER 5
NITRIC OXIDE AND THE IMPAIRED
VASCULAR RESPONSES TO ANGIOTENSIN II
Helmy A, Newby DE, Jalan R, NR Johnston, Hayes PC, Webb DJ. Reduced
Vasoconstrictor response to angiotensin II in patients with pre-Ascitic cirrhosis is
mediated by nitric oxide. Submitted to Hepatology
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1. Summary
Background/Aims: Altered vascular responses to vasopressor agents contribute to
the pathogenesis of the circulatory dysfunction in cirrhosis. The aim of this study
was to assess the role of endogenous nitric oxide (NO) in the reduced vascular
responsiveness to angiotensin II (ANG II) in 8 patients with pre-ascitic cirrhosis
compared with 8 age- and sex-matched healthy controls.
Methods: Forearm blood flow (FBF) responses to sub-systemic, locally-active intra-
brachial infusions ofANG II were measured using venous occlusion
plethysmography before and during the application of an 'NO-clamp': a balanced co-
infusion of L-A^monomethyl arginine (a selective NO synthase inhibitor) and
sodium nitroprusside (an exogenous NO donor) to block endogenous NO production
and restore normal NO-mediated basal blood flow respectively.
Results: Before applying the 'NO-clamp', ANG II caused dose-dependent reductions
ofFBF in both groups (p<0.001) that were significantly attenuated in the cirrhotic
patients (p= 0.012). In the presence of the 'NO-clamp', the ANG II mediated
vasoconstriction was enhanced in cirrhotic patients (p<0.01), unchanged in controls,
and was now similar in both groups.
Conclusions: This study confirms that vasoconstriction to ANG II is reduced in
patients with pre-ascitic cirrhosis, and suggests that this is principally due to
enhanced NO generation mediated by ANG II.
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2. Introduction
Patients with cirrhosis commonly exhibit a hyperdynamic circulation, characterized
by a high cardiac output, hypervolemia, a low systemic vascular resistance and an
increased portal pressure (Kowalski & Ablemann 1953; Murray et al 1958; Kontos
1964), that worsens with disease severity (Braillon et al 1986; Bendtsen et al 1990;
Meng et al 1994). This hyperdynamic circulation is associated with impaired
responses to vasopressor and neurohumoral systems, and is believed to be
responsible for the development of the complications of cirrhosis such as ascites,
oesophageal varices and the hepatorenal syndrome (Schrier et al 1988; Groszmann
1994).
We have previously demonstrated impaired peripheral vasoconstriction to exogenous
angiotensin II (ANG II) in patients with pre-ascitic cirrhosis (Helmy et al 2000 &
Chapter 3), diuretic-responsive ascites (Newby et al 1998a), and diuretic-refractory
ascites (Helmy et al 2000 & Chapter 3). The potential mechanisms underlying these
impaired responses include receptor down-regulation (Hadoke 1999), post-receptor
signal transduction defects (Murray & Paller 1985; Huang et al 1996), and increased
circulating levels of vasodilators (Genecin & Groszmann 1994). Animal models of
cirrhosis and portal hypertension have shown that the vascular hyporesponsiveness to
ANG II and endothelin-1 (ET-1) can be corrected by endothelial denudation or
inhibition of nitric oxide (NO) synthesis (Castro et al 1993; Hartleb et al 1994a;
Sieber 1995). Indeed, many workers have demonstrated an increase in endothelium-
derived NO synthesis in patients with cirrhosis (Sogni et al 1995; Martin et al 1998),
as suggested by increased plasma concentrations ofNO and its metabolites (Guarner
et al 1993; Albillos et al 1995; Matsumuto et al 1995; Battista et al 1997), enhanced
responses to NO-dependent vasodilators (Albillos et al 1995), increased NO in
exhaled air (Matsumuto et al 1995; Sogni et al 1995a), and increased nitric oxide
synthase (NOS) activity in both monocytes (Laffr et al 1995) and polymorphonuclear
cells (Criado-Jimenez et al 1995) However, at present, there have been no clinical
studies to assess the contribution of endogenous NO production to the impaired
vasoconstriction to ANG II in patients with cirrhosis.
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L-A^'monomethyl arginine (L-NMMA) is a selective and competitive NOS inhibitor
thafcan block NO synthesis (Vallance et al 1989a). Because NO is continuously
released by the endothelium, and tonically relaxes the underlying vascular smooth
muscle, brachial artery administration ofL-NMMA causes forearm vasoconstriction
and a reduction in basal blood flow (Vallance et al 1989a). When assessing the
contribution of NO to the actions of a given vasoactive agent, these L-NMMA-
induced changes in vessel geometry and blood flow may confound the interpretation
of subsequent responses (Benjamin et al 1995; Webb 1995). However, co-infusion of
sodium nitroprusside (SNP, an exogenous NO donor) with L-NMMA can be used to
restore the baseline blood flow and vessel geometry by replacing endogenous NO
with exogenous NO - the 'NO-clamp' (Stroes et al 1997). This technique establishes
a stable baseline forearm blood flow (FBF) that can be maintained for at least 120
min (Verhaar et al 1998) and permits the assessment of vascular responses in the
absence of endogenous NO synthesis (Stroes et al 1997; Verhaar et al 1998).
The aims of the study presented in this chapter - in patients with pre-ascitic cirrhosis
and healthy control subjects - were to:
1. assess the relationship between the vascular reactivity to ANG II and endogenous
NO release using the 'NO-clamp' technique.
2. evaluate the contribution of endogenous NO release to the maintenance of basal
peripheral vascular tone.
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3. Subjects and methods
3.1. Subjects:
Eight patients with biopsy-proven cirrhosis in the pre-ascitic stage were recruited and
compared with eight age- and sex-matched healthy volunteers. All patients were
ambulant and had normal serum creatinine (<100 pmol/L), endoscopically proven
oesophageal varices and no clinical evidence of systemic circulatory disturbance.
Patients with alcoholic liver disease were abstinent from alcohol for at least one
month, confirmed by history and random blood ethanol testing, to prevent the
depression of vascular responses this causes (Howes & Reid 1985). To avoid the
possibility of altering the activity of endogenous vasopressor systems, all subjects in
both groups were maintained on their normal sodium intake Rankin et al 1981; Stein
et al 1995). None of the subjects received vasoactive or non-steroidal anti¬
inflammatory drugs in the week before, and all subjects abstained from food, tobacco
and caffeine-containing drinks for at least 4 hours prior to, each study. All female
subjects were post-menopausal, both for safety and to avoid the variability in
vascular responses that may be associated with cyclic hormonal changes (Hashimoto
et al 1995). Exclusion criteria included the presence ofmalignancy, encephalopathy,
portosystemic shunt, previous gastrointestinal bleeding, or any significant
cardiovascular disease such as diabetes mellitus and hypertension. Studies were
undertaken with the approval of the local research ethics committee, written
informed consent of each subject, and in accordance with the Declaration ofHelsinki
(1989) of the World Medical Association.
3.2. Intra-arterial administration and drugs:
The brachial artery of the non-dominant arm was cannulated using a 27-standard
wire gauge steel needle (Cooper's Needle Works, Birmingham, England) under local
anaesthesia by 1% lidocaine (Xylocaine, Astra Pharmaceuticals Ltd, Kings Langley,
England). Needle patency was maintained by saline infusion via an IVAC PI000
syringe pump (IVAC Ltd., Basingstoke, England) at a constant rate of infusion (1
mL/min).
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Pharmaceutical grade synthetic ANG II peptide (Clinalfa AG, Laufelfingen,
Switzerland) was infused at locally active and sub-systemic incremental doses of 3,
10 and 30 pmol/min (Benjamin et al 1989; Newby et al 1997; Newby et al 1998a;
Helmy et al 2000). L-NMMA (Clinalfa) was given at a dose of 4 pmol/min. This
dose has previously been shown to produce a maximal vasoconstrictor response in
the forearm circulation (Vallance et al 1989a; Calver et al 1994). SNP (David Bull
Laboratories, Victoria, Australia), was administered at titrated doses (80-600
ng/min), see below. The drugs were dissolved in physiological saline (0.9%, Baxter
Healthcare Ltd., Thetford, England). Due to its light sensitivity, SNP was prepared
and infused in syringes covered by opaque foil.
3.3. Measurement ofsystemic haemodynamics:
Blood pressure and pulse rate were measured in the control arm using a non-invasive
oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc, Tokyo,
Japan) at intervals throughout the study (Wiinberg et al 1988). The mean arterial
pressure (MAP) was calculated according to the formula; MAP (mm Hg) = diastolic
arterial pressure + 1/3 pulse pressure (systolic arterial pressure - diastolic arterial
pressure). Baseline cardiac functions, including heart rate, stroke volume and cardiac
output, were measured using a non-invasive thoracic electrical bioimpedance method
(BoMed NC-COM3, BoMed Medical Manufacturer Ltd) as described previously
(Apple et al 1986; Northridge et al 1990). Arterial compliance (AC) was calculated
according to the formula: AC (mL. mm Hg"1) = stroke volume (mL) / pulse pressure
(mmHg). Cardiac index (CI), stroke index (SI), and total peripheral vascular resistive
index (TPVRI) were calculated according to the formulae: CI (mL. min"1. m"2) =
cardiac output (mL. min"1) / body surface area (m2); SI (mL.m"2) = stroke volume
(mL) / body surface area (m2); and TPVRI (mm Hg. mL"1. min. m2) = MAP (mm Hg)
/ CI (mL. min"1. m"2).
3.4. Measurement offorearm bloodflow:
All studies were performed in a quiet, temperature controlled room maintained at 22-
24 °C. FBF was measured as previously described (Newby et al 1997; Newby et al
1988a, Helmy et al 2000; and Chapter 2).
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3.5. Study design:
A schematic diagram of the study protocol is shown in Figure 5-1. Following
baseline infusion of saline for 30 min (phase 1), ANG II was infused at incremental
doses of 3, 10 and 30 pmol/min, each for 6 min (phase 2). After a saline washout
period of 20 min (phase 3), endogenous NO synthesis in the infused forearm was
inhibited by the 'NO-clamp' as described previously (Stroes 1997; Verhaar et al
1998; Dijkhorst-Oei et al 1999). Briefly, L-NMMA was continuously infused at a
rate of 4 pmol/min for 20 min to achieve maximal inhibition of local NOS activity
(phase 4). Thereafter, SNP was co-infused at titrated doses until FBF had been
restored to within 10% of baseline flow and was sustained for at least 2 consecutive
FBF measurements (phase 5; variable duration). The same doses ofANG II were re-
infused, each for 6 min, during the 'NO-clamp' (phase 6). ANG II does not undergo
tachyphylaxis on repeated infusion in the human forearm (Benjamin et al 1989;
Dijkhorst-Oei et al 1999).
3.6. Blood assays:
After 30 min of supine rest, and before any drugs were administered, venous blood
was withdrawn from the non-infused arm. Ten mL were admixed with each of the
following: 1 mL of 1% disodium EDTA and 1000 KIU aprotinin (Bayer AG,
Leverkusen, Germany) for measuring plasma renin activity (PRA); and 0.5 mL of
0.45% O-phenanthrolene/ 4.65% disodium EDTA for measuring ANG II
concentration. The samples were placed on ice and immediately centrifuged at 1500
g for 20 min. Plasma was frozen and stored at -80°C until assayed. Plasma ANG II
concentrations were measured by radioimmunoassay (RIA) following extraction
using Bond Elut® columns (Varian, Harbor City, CA, USA) as described previously
(Morton & Webb 1985). PRA was measured under standard conditions through the
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3.7. Statistical analysis:
FBF was expressed in mL. 100 mL tissue"1. Min"1 (Whitney 1953) Recordings from
the first 60 s following wrist cuff inflation were not included in the analysis because
of the variability in blood flow this produces (Kerslake 1949). Usually, the final 5
flow recordings in each 3 min measurement period were calculated and averaged for
each arm. In order to reduce the variability of blood flow data, the ratio of flows in
the 2 arms was calculated for each time point, thus using the non-infused arm as a
contemporaneous control (Benjamin et al 1995; Webb 1995). The percentage change
in FBF was calculated according to the formula:
% change in FBF = 100 x [(It/ NIt) - (Ib / NIb)] / ( Ib / NIb);
where /, andNIt are the bloodflows in the infused and non-infusedforearms
respectively at a given time point (t) andh andNh are the bloodflows in the infused
and non-infusedforearms respectively at baseline (b); time 0.
Data were expressed as mean ± standard error of the mean (SEM) and examined by
2-way analysis of variance (ANOVA) for repeated measures, the Pearson's
correlation coefficient or two-tailed paired and un-paired Student's Mests as
appropriate. A probability value ofp<0.05 was taken to represent a statistically
significant difference.
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4. Results
A summary of baseline characteristics of the subjects is shown in Table 5-1. Patients
with cirrhosis were well matched to the control subjects for age, sex and body mass
index (BMI). As shown in Table 5-2, cirrhotic patients and healthy controls also had
similar HR and MAP. However, patients with pre-ascitic cirrhosis had higher SI
(p<0.05), higher CI (£><0.01) and lower TPVRI (£><0.05). Throughout the study there
were no significant changes in MAP, HR, or FBF in the non-infused arm.
Table 5-1: Subjects characteristics.
Controls Cirrhotics
Variable (n=8) (n=8)
Age (years) 51.1 ±4.3 52.9 + 3.5
Sex (male:female) 4:4 4:4
Weight (kg) 75.4 + 4.7 69.3 +6.8
Height (cm) 167 ±4 170 ±4
BSA (m2) 1.8 ± 0.1 1.8 + 0.1
BMI (kg.m2) 26.9 + 1.1 23.5 + 1.1
Liver disease aetiology
Primary biliary cirrhosis 5
Hepatitis C virus 2
Alcoholic liver disease 1
Child-Pugh Score 6.4
Child Grade A 6 -
B 2
Oesophageal varices 8
Results are expressed as mean + SEM.
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4.1. Baseline forearm bloodflow:
As shown in Table 5-3, there were no significant differences between the baseline
FBF in the infused and non-infused arms in each of the study groups. In addition,
FBF after the application of the 'NO-clamp' was unchanged from baseline, and was
similar in both groups (Figure 5-2). No significant change in the FBF in the non-
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FIGURE 5-2: BASELINE BILATERAL FOREARM BLOOD FLOW.
White bars, the infused arm. Hatched bars, the non-infused arms.
Baseline 1, baseline at the end of phase 1 of the study protocol (saline infusion).
Baseline 2, baseline after adjustment of the 'NO-clamp' and before re-infusion of
ANG II (end of phase 5 of the study protocol).
/?>0.05 infused to non-infused, by un-paired /-tests.
/;>0.05 baseline 1 to baseline 2 in each forearm, by paired /-tests.
4.2. Responses to L-NMMA infusion:
As shown in Table 5-3, L-NMMA infusion significantly reduced FBF in both
patients with pre-ascitic cirrhosis and healthy controls (p<0.001, one-way ANOVA
vs baseline 1). This response reached a plateau after 10 min of infusion, and was
similar in both groups at 10 and 20 min infusion ofL-NMMA. Blood flow in the
infused arm was reduced by 34.7 ± 2.4 % and 31.0 ± 5.4 % in the cirrhotic patients,
and by 26.6 ± 8.3 % and 25.6 ± 7.6 % in the control group respectively (Figure 5-3).
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In addition, the dose of SNP required to restore baseline FBF was similar in patients















FIGURE 5-3: PERCENTAGE CHANGE IN FOREARM BLOOD FLOW IN
RESPONSE TO L-NMMA INFUSION
L-NMMA dose is 4 p,mol/min. Cirrhotic patients, (□). Controls (■).
/K0.001 from baseline 1 in both groups.
p>0.05 cirrhotic patients vs controls, two-way ANOVA with replication.
4.3. Responses to ANG IIinfusion before the 'NO-clamp':
Before applying the 'NO-clamp', ANG II infusion dose-dependently reduced FBF
(/K0.001, one-way ANOVA) in both groups. However, responses were significantly
greater in the control group than in patients with pre-ascitic cirrhosis (p = 0.012,
two-way ANOVA with repeated measures; Figure 5-4 and 5-5).
4.4. Responses to ANG II infusion during the 'NO-clamp
ANG II infusion also dose-dependently reduced FBF during the 'NO-clamp'
(/?<0.001, one-way ANOVA). Now, responses were similar in both groups (p= 0.75,
2-way ANOVA with repeated measures; Figure 5-4). Compared with the responses
to ANG II infusion before the application of the 'NO-clamp', patients with pre-
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ascitic cirrhosis had greater reductions in FBF with ANG II infusion (p<0.001, 2-way
ANOVA with repeated measures), while controls showed similar responses (p= 0.57,
2-way ANOVA with repeated measures; Figure 5-5).
4.5. Blood assays:
As shown in Table 5-2, basal plasma ANG II concentrations were higher in patients
with pre-ascitic cirrhotics than in controls (p= 0.04) and there was a trend towards
higher basal PRA in the cirrhotic group (p= 0.08). Basal plasma ANG II
concentrations correlated positively with basal PRA (/K0.0001; r = 0.87).
Table 5-2: Basal systemic haemodynamics and hormonal assays.
Variable Controls (n=8) Cirrhotics (n=8) Unit
Cardiac index 3.6 + 0.2 5.3+0.5# L.min'.m"2
Stroke index 57.6 + 3.9 76.6 + 7.0* mL.tn"2
Heart rate 64.3+3.2 69.7 + 3.8 beat/min
MAP 90.0 + 2.4 87.4 + 4.6 mm Hg
TPVRI 25.3 ± 1.7 17.7 + 2.1* mm Hg.L~'.min.m
ANG II 10.6+1.6 25.1 ±6.0* pg/mL
PRA 1.1 ±0.1 1.6 + 0.3** ng.ml/'.h"1
Results are expressed as mean ± SEM. #p<0.01. * p<0.05. ** p= 0.08.
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5. Discussion
Consistent with our previous work (Chapter 3; Helmy et al 2000), we have
demonstrated impaired forearm vasoconstrictor responses to exogenous ANG II in
patients with pre-ascitic cirrhosis, despite normal vasoconstriction to L-NMMA.
These attenuated responses to ANG II were augmented and normalized by the
application of'NO-clamp'. These findings suggest that the impairment ofANG II
responses in patients with pre-ascitic cirrhosis is principally due to an enhanced
ANG II-mediated NO release.
At least two main ANG II receptor subtypes have been identified: the AT] and AT2
receptors. The majority of the physiological actions of ANG II, including
vasoconstriction and aldosterone release, are mediated through the AT-1 receptor,
whereas the role of the AT2 receptor remains unclear (Matsubara et al 1998;
Matsubara 1998). ANG II stimulates both endothelial NOS messenger RNA
expression (Hennington et al 1998) and endothelial NOS activity (Olson et al 1997).
Moreover, ANG II has been shown to increase NO bioavailability in isolated rings
from rat carotid artery under static conditions, an effect that is abolished by losartan,
a selective AT-1 receptor antagonist, or L-NMMA (Boulanger et al 1995). Thus,
ANG II- mediated NO release may be enhanced or mediated by the AT-1 receptor
but this does not preclude an interaction with the AT2 receptor. Indeed, although low
in large vessels such as the aorta, surface AT2 receptor expression is high in the
microvasculature (Nora et al 1998). Genetic murine AT2 receptor knockout models
are associated with an increase in both systemic blood pressure and vasoconstrictor
responses to ANG II (Hein et al 1995), whereas targeted overexpression of AT2
receptor leads to an increased ANG II mediated cGMP production and reduced ANG
II mediated vasoconstriction (Tsutsumi et al 1999). The vascular effects of the AT2
receptor have been shown to be mediated, at least in part, by NO release in rat
endothelial cells (Wiemer et al 1993), isolated rat carotid arteries (Boulanger et al
1995), and canine coronary arteries (Seyedi et al 1995). Our findings of an impaired
vasoconstrictor response to ANG II, mediated by enhanced release ofNO, may
indicate relative overexpression and activity of the AT2 receptor in patients with
cirrhosis. However, this needs to be tested using a selective AT2 receptor antagonist.
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Finally, It has also been suggested that ANG II infusion can induce NO synthesis and
activity through its vasoconstriction-induced increase in vessel wall shear stress
(Dijkhorst-Oei et al 1999) as shear stress is a major stimulus for NO synthesis
(Nishida et al 1992; Hecker et al 1993), but this needs to be confirmed.
We (Newby et al 1998a; Helmy et al 2000), and others (Schroeder et al 1976; Arroyo
et al 1981; Bernardi et al 1982; Pariente et al 1985) have previously shown an
increased activity of the RAS in patients with cirrhosis that correlates with both
disease severity (Helmy et al 2000) and portal pressure (Bosch et al 1980). The
elevated basal plasma ANG II concentrations of patients in the present study are
consistent with our previous findings in a similar group of patients (Helmy et al
2000), and may be related to the high portal pressure in these patients (Bosch et al
1980), as indicated by the presence of oesophageal varices. Activation of the RAS,
together with the altered systemic haemodynamic parameters in patients with pre-
ascitic cirrhosis, is consistent with a compensated vasodilated state. In addition,
higher basal plasma ANG II concentrations may contribute to the subtle sodium
retention reported in these patients (Wong et al 1995), and consequently to the
pathogenesis of ascites (Schrier et al 1988). Moreover, down-regulation of the ATi
receptor and/or over-expression of the AT2 receptor may result from the increased
activity of the RAS in cirrhotic patients, and lead to the impaired vasoconstriction in
response to exogenous ANG II.
The 'NO-clamp' technique has been successfully used in previous studies in healthy
volunteers (Stroes et al 1997; Verhaar et al 1998; Dijkhorst-Oei et al 1999). Using
this in vivo technique, we have demonstrated, for the first time, normalisation of
ANG II-mediated vasoconstriction in patients with pre-ascitic cirrhosis. This finding
is consistent with the previously demonstrated improvement in the vascular
responses to ANG II in the rat model of cirrhosis following endothelial denudation or
NOS inhibition (Castro et al 1993). These data suggest a direct ANG II-mediated
release of endothelial NO, which may account for the attenuated vasoconstrictor
response to ANG II infusion in these patients. It remains to be investigated whether
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the effects of ANG II on NO synthesis are agonist-specific or can be elicited by other
vasopressor agents such as ET-1.
ANG II-induced vasoconstriction was unaltered in the healthy controls during 'NO-
clamp', a finding at variance with a previous study (Dijkhorst-Oei et al 1999). This
apparent disparity may be explained by differences in the study populations and
study design. Unlike the study ofDijkhorst-Oei et al 1999, our study was performed
on a single occasion and FBF responses are known to be much less variable when
comparisons are made within rather than between days (Newby et al 1997a).
The significant vasoconstriction produced by L-NMMA, a specific inhibitor ofNOS,
infusion in the studied groups confirms the role of endogenous NO production in the
maintenance of basal peripheral vascular tone in both healthy humans (Vallance et al
1989a; Calver et al 1994; Campillo et al 1995; Ryan et al 1996; Newby et al 1998a)
and patients with early (Calver et al 1994; Campillo et al 1995; Ryan et al 1996) and
advanced cirrhosis (Campillo et al 1995; Newby et al 1998a). The similarity of the L-
NMMA-mediated vasoconstrictor response in both groups is in keeping with the
results of previous studies in a similar group of patients (Calver et al 1994; Campillo
et al 1995; Ryan et al 1996), and argues against a greater basal NOS activation in the
peripheral arterioles of patients with well-compensated cirrhosis.
The 'NO-clamp' has been shown to be able to maintain a stable FBF for at least 120
min (Verhaar et al 1998) and it is, therefore, unlikely that the augmented
vasoconstriction to ANG II was the result of tachyphylaxis to SNP. Moreover, the
mean SNP dose required to restore baseline FBF was similar in both groups and
there was no change ofANG II-mediated vasoconstriction in control subjects. From
the present study, we are unable to determine whether the ANG II-mediated NO
release is due to stimulation of constitutive NOS (cNOS) and/or inducible NOS
(iNOS) because L-NMMA inhibits both cNOS and iNOS unselectively. NOS
inhibitors that can selectively inhibit each of these enzymes would be required to
address this issue, but are currently not available for clinical studies.
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Impaired responses to vasopressor systems, including the RAS, in addition to
increased NO release may be responsible for the development of splanchnic
vasodilatation, and consequently the pathogenesis of portal hypertension and its
complications (Schrier et al 1988, Groszmann 1994, Hadoke 1999). Given that 'NO-
clamp' can not be applied in the splanchnic circulation, the potential therapeutic role
ofNOS inhibition have been studied both in the rat model (Pizcueta et al 1992;
Niederberger et al 1995; Pilette et al 1996), and patients with cirrhosis through the
systemic infusion of the NOS inhibitor, L-NM.MA (Forrest et al 1995). Interestingly,
these studies showed a significant improvement in systemic haemodynamics, but no
change in the portal venous pressure or portal collateral shunting (Pizcueta et al
1992; Niederberger et al 1995; Pilette et al 1996). The reason for this improvement in
systemic, but not portal haemodynamics is unclear. However, the study ofForrest et
al 1995, on patients with cirrhosis, did not measure the hepatic blood flow, the
activity of the vasopressor systems, or the renal function. As shown by the animal
studies (Pizcueta et al 1992; Niederberger et al 1995), the absence of changes in
portal venous pressure may be explained by a concomitant reduction in splanchnic
arterial blood flow and an increase in the intrahepatic vascular resistance. Factors
related to the severity of cirrhosis and portal hypertension, the dose ofL-NMMA,
duration and type of the NOS inhibitor used, and the concomitant use of vasoactive
medications, such as diuretics, should also be considered.
In conclusion, this study confirms that patients with pre-ascitic cirrhosis have
impaired forearm vasoconstrictor responses to exogenous ANG II and normal
vasoconstrictor responses to L-NMMA. The restoration of normal vasoconstrictor
responses to ANG II during the 'NO-clamp' suggests a greater ANG Il-induced NO
release in these patients, and that NO mediates the peripheral hyporesponsiveness to
ANG II seen in the cirrhotic patients.
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CHAPTER 6
NITRIC OXIDE AND THE ENHANCED
VASODILATATION IN RESPONSE TO
ENDOTHELIN TYPE-A RECEPTOR
BLOCKADE
Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced forearm vasodilation
after endothelin-A receptor antagonism in patients with pre-ascitic cirrhosis: role of
nitric oxide. Underpreparation.
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1. Summary
Background/Aims: Patients with cirrhosis have systemic vasodilatation and
increased nitric oxide (NO) production despite activated vasopressor systems,
including the endothelin system. The aims of this study were to assess the
contribution of endogenous ET-1 and NO to the maintenance of basal forearm
vascular tone in patients with pre-ascitic cirrhosis (n=7) and age- and sex-matched
healthy controls (n=7).
Methods: Using venous occlusion plethysmography, forearm blood flow (FBF)
responses to sub-systemic, locally-active intra-arterial infusion ofBQ-123 (a
selective ETA receptor antagonist; 10 nmol/min) were measured before, and during
the application of an 'NO-clamp': a balanced co-infusion ofL-A^-monomethyl
arginine (a selective NO synthase inhibitor) and sodium nitroprusside (an exogenous
NO donor) to block endogenous NO production and restore normal NO-mediated
basal FBF respectively.
Results: L-NMMA infusion produced a reduction in FBF (p<0.001), which was
similar in both groups. Before applying the 'NO-clamp', BQ-123 caused an increase
in FBF in both groups (p<0.001) that was greater in patients with cirrhosis (p<0.01).
During the 'NO-clamp', the BQ-123-induced vasodilatation was abolished in
controls and attenuated in patients (p<0.001), but remained significantly greater in
patients with cirrhosis (p<0.01).
Conclusions: These findings indicate a greater contribution of endogenous ET-1 to
the maintenance of basal forearm vascular tone in patients with pre-ascitic cirrhosis.
In addition, the enhanced vasodilatation to BQ-123 in these patients can 't be entirely
attributed to NO release, but is likely to be related to direct ET-1 mediated tone.
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2. Introduction
Patients with cirrhosis exhibit a hyperdynamic circulation characterized by a high
cardiac output, hypervolemia, a low systemic vascular resistance and an increased
portal pressure (Kowalski & Abelmann 1953; Murray et al 1958; Kontos et al 1964)
that worsen with disease severity (Schrier et al 1988; Bendtsen et al 1990). This
hyperdynamic circulation is due to systemic arteriolar dilatation, which occurs
despite the presence of activated vasopressor systems including the endothelin
system, and is believed to be responsible for the development of the complications of
cirrhosis such as ascites, oesophageal varices, and hepatorenal syndrome (Schrier et
al 1988; Groszmann 1994). Therefore, a better understanding of the mechanism(s)
underlying the systemic vasodilatation associated with cirrhosis is essential for the
development of therapeutic, and possibly preventive, interventions.
Endothelin-1 (ET-1) is one of the most potent vasoconstrictor known, belonging to a
21-amino acid peptide family with a range ofbiological effects (Yanagisawa et al
1988; Arai et al 1990; Masaki and Yanagisawa 1992). Molecular studies have
identified, so far, two endothelin receptor subtypes in mammalian species:
endothelin-A (ETa; Arai et al 1990) and endothelin-B (ETb; Sakurai et al 1990). In
vascular smooth muscle cells, both receptors are expressed (Arai et al 1990; Sakurai
et al 1990) and mediate vasoconstriction (Spokes et al 1989; Tschudi et al 1994;
Davenport et al 1995; Haynes et al 1995). The vasoconstriction induced by ET-1 is
predominantly mediated by the ETA receptor, but the ETB receptors may contribute
under some circumstances (Davenport & Maguire 1994). The ETB receptors are also
found on endothelial cells where they cause vasodilatation through the release of
endothelium-derived vasodilators, such as NO (Takayanagi et al 1991). Therefore,
the ET-1 mediated vascular tone is a result of a balance between the constrictive and
relaxive effects on these two receptors.
We have demonstrated that selective ETA receptor antagonism, using BQ-123, causes
forearm vasodilatation in healthy humans (Verhaar et al 1998; Helmy et al 2001),
and this vasodilatation response is principally mediated through NO generation
(Verhaar et al 1998). We have also shown that BQ-123 infusion produces an
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enhanced forearm vasodilatation in patients with pre-ascitic cirrhosis (Helmy et al
2001). The exact mechanism underlying this enhanced vasodilatation is unknown.
However, evidence of increased nitric oxide (NO) production in patients with
cirrhosis is accumulating (Sogni et al 1995; Martin et al 1998). These were in the
form of increased plasma concentrations ofNO and its metabolites (Guarner et al
1993; Albillos et al 1995; Matsumuto et al 1995; Battista et al 1997; Barak et al
1999), enhanced responses to NO-dependent vasodilators (Albillos et al 1995),
increased NO in exhaled air (Matsumuto et al 1995; Sogni et al 1995a), and
increased nitric oxide synthase (NOS) activity in both monocytes (Laffi et al 1995)
and polymorphonuclear cells (Criado-Jimenez et al 1995). However, at present, there
have been no clinical studies to assess the contribution of endogenous NO production
to the enhanced vasodilatation response to ETa receptor blockade in patients with
cirrhosis.
Therefore, the aims of the present study, in patients with pre-ascitic cirrhosis and
healthy controls, were to:
1. assess the contribution of endogenous ET-1 and NO to the maintenance of basal
peripheral vascular tone, and
2. determine the relationship between ATa receptor antagonism and endogenous
NO release.
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3. Subjects and methods
3.1 Subjects:
Seven patients with biopsy-proven cirrhosis in the pre-ascitic stage and eight age-
and sex-matched healthy volunteers were recruited. All patients were ambulant, had
normal serum creatinine (<100 pmol/L), and endoscopically proven oesophageal
varices. To avoid the depressive effect of ethanol on vascular responses (Howes &
Reid 1985), patients with alcoholic liver disease were abstinent from alcohol for at
least one month as confirmed by history and random blood ethanol testing. In
addition, all subjects in both groups were maintained on their normal sodium diet to
avoid the possibility of altering the activity of endogenous vasopressor systems
(Rankin et al 1981; Stein et al 1995). None of the subjects received vasoactive or
non-steroidal anti-inflammatory drugs in the week before, and all subjects abstained
from food, tobacco and caffeine-containing drinks for at least 4 hours prior to each
study. All female subjects were post-menopausal, both for safety and to avoid the
variability in vascular responses that may be associated with cyclic hormonal
changes (Hashimoto et al 1995). Exclusion criteria included the presence of
malignancy, encephalopathy, surgical or interventional radiological portosystemic
shunt, or any significant cardiovascular disease such as diabetes mellitus and
hypertension. Studies were undertaken with the approval of the local research ethics
committee, written informed consent of each subject, and in accordance with the
Declaration ofHelsinki (1989) of the World Medical Association.
3.2. Intra-arterial administration and drugs:
The brachial artery of the non-dominant arm was cannulated using a 27-standard
wire gauge steel needle (Cooper's Needle Works, Birmingham, England) under local
anaesthesia using 1% lidocaine (Xylocaine, Astra Pharmaceuticals Ltd, Kings
Langley, England). Needle patency was maintained by saline infusion via an IVAC
PI000 syringe pump (IVAC Ltd., Basingstoke, England) at a constant rate of
infusion (1 mL/min).
All drugs were dissolved in physiological saline (0.9%, Baxter Healthcare Ltd.,
Thetford, England). Pharmaceutical grade BQ-123 (Clinalfa AG, Laufelfingen,
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Switzerland), a selective ETA receptor antagonist (Ihara et al 1992); was infused at
the locally active and sub-systemic dose of 10 nmol/mL. With this dose, FBF has
been shown to plateau after 60 min of infusion (Verhaar et al 1998). For the 'NO-
clamp' (see below), the selective nitric oxide synthase (NOS) inhibitor L-N°~
monomethyl arginine (L-NMMA, Clinalfa) at a dose of 4 pmol/min, and the
exogenous NO donor sodium nitroprusside (SNP, David Bull Laboratories, Victoria,
Australia) at titrated doses (80-600 ng/min) were used. This dose of L-NMMA has
previously been shown to produce a maximal vasoconstrictor response in the forearm
circulation (Vallance et al 1989a; Calver et al 1994). Due to the light sensitivity of
SNP, it was prepared and infused in syringes covered by opaque foil.
3.3. Measurement ofsystemic haemodynamics:
Baseline cardiac function, including heart rate, stroke volume and cardiac output,
was measured using a non-invasive thoracic electrical bioimpedance method (BoMed
NC-COM3, BoMed Medical Manufacturer Ltd) as previously described (Appel et al
1986; Northridge et al 1990). Cardiac index (CI), stroke index (SI), and total
peripheral vascular resistive index (TPVRI) were calculated according to the
formulae: CI (mL. min"1. m"2) = cardiac output (mL. min"1) / body surface area (m2);
SI (mL. m"2) = stroke volume (mL) / body surface area (m2); and TPVRI (mm Hg.
mL"1. min. m2) = MAP (mm Hg) / CI (mL. min"1. m"2).
Blood pressure and pulse rate were measured in the control arm using a non-invasive
oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc, Tokyo,
Japan) at intervals throughout the study (Wiinberg et al 1988). The mean arterial
pressure (MAP) was calculated according to the formula; MAP (mm Hg) = diastolic
arterial pressure + 1/3 pulse pressure.
3.4. Measurement offorearm bloodflow (FBF):
All studies were performed in a quiet, temperature controlled room maintained at 22-
24 °C. FBF was measured as previously described (Verhaar et al 1998; Newby et al
1998a; Helmy et al 2000). Briefly, FBF measurements were made in both the infused
and non-infused arms by venous occlusion plethysmography using mercury-in-
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Silastic strain gauges applied to the widest part of the forearm. Hands were excluded
by rapid inflation ofwrist cuffs to a pressure of 220 mm Hg using E20 Rapid Cuff
Inflators (D.E. Hokanson Inc, Washington DC, USA). Upper arm cuffs were inflated
to 40 mm Hg for 10 seconds in every 15 seconds to achieve venous occlusion and
obtain blood flow measurements.
3.5. Study design:
Two protocols (Figure 6-1) were applied on two separate occasions one week apart
and in random order. Before participating in each of the protocols, saline was infused
for 30 min to allow time for equilibration, with FBF measurements being made every
10 min and the final measure taken as the baseline FBF. In protocol 1, BQ-123 was
infused at a dose of 10 nmol/min for 60 min during which FBF was measured every
10 min. In protocol 2, to assess the contribution of endogenous NO production to the
forearm vascular responses to ETA receptor blockade, endogenous NO synthesis was
inhibited by the 'NO-clamp' as previously described (Stroes et al 1997, Verhaar et al
1998; Dijkhorst-oei et al 1999). Briefly, L-NMMA was continuously infused at a rate
of 4 pmol/min for 20 min to achieve maximal inhibition of local NOS activity.
Thereafter, SNP was co-infused at titrated doses until FBF had been restored to
within 10% ofbaseline flow and was sustained for at least 2 consecutive FBF
measurements. Once a stable baseline FBF was obtained, the same dose of BQ-123
was co-infused with the 'NO-clamp' for 60 min.
3.6. Blood assays:
After 30 min of supine rest, and before any drugs were administered, venous blood
was withdrawn from the non-infused arm. Ten mL were admixed with each of the
following: 1 mL of 1% disodium EDTA and 1000 KIU aprotinin (Bayer AG,
Leverkusen, Germany) for measuring plasma ET-1, big-ET-I, and plasma renin
activity (PRA); and 0.5 mL of 0.45% O-phenanthrolene/ 4.65% disodium EDTA for
measuring plasma ANG II concentration. The samples were placed on ice and
immediately centrifuged at 1500 g for 20 min. Plasma was frozen and stored at -80°C
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CA^USA), the plasma concentrations ofET-1 (Peninsula Laboratories Europe Ltd.,
St. Helens, England) and big ET-1 (Peninsula Laboratories Europe Ltd.) were
determined by radioimmunoassay as described previously (Rolinski et al 1994). PRA
was measured under standard conditions through the generation ofANG I using R1A
as described previously (Haber et al 1969). Plasma ANG II concentrations were
measured by RIA following extraction using Bond Elut® columns (Varian) as
described previously (Morton & Webb 1985).
3. 7. Statistical analysis:
FBF was expressed in mL. 100 mL tissue"1, min"1 (Whitney et al 1953) Recordings
from the first 60 s following wrist cuff inflation were not included in the analysis
because of the variability in blood flow this produces (Kerslake 1949). Usually, the
final 5 flow recordings in each 3 min measurement period were calculated and
averaged for each arm. In order to reduce the variability of blood flow data, the ratio
of flows in the 2 arms was calculated for each time point, thus using the non-infused
arm as a contemporaneous control (Benjamin et al 1995; Webb 1995). The
percentage change in FBF was calculated according to the formula:
% change in FBF = 100 x [(I,/ NIt) - (Ib / NIb)] / (I„ / NIb);
where I, andNIt are the bloodflows in the infused and non-infusedforearms
respectively at a given time point (t) andh andNf, are the bloodflows at baseline
(b); time 0.
The % attenuation in area under the curve was calculated according to the formula:
% change in AUC = 100 x (%changepc - %changeAc) / (%changeAc);
where PC andAC are the presence and absence of the 'NO-clamp' respectively.
Data were expressed as mean ± standard error of the mean (SEM) and examined by
2-way analysis of variance (ANOVA) for repeated measures, the Pearson's
correlation coefficient or two-tailed paired and un-paired Student's /-tests as
appropriate. A probability value ofp<0.05 was taken to represent a statistically
significant difference.
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4. Results
A summary of baseline subject's characteristics is shown in Table 6-1. Patients with
cirrhosis were well matched to the control subjects for age, sex and body surface area
(BSA) although weight and, consequently, body mass index (BMI) were
significantly less in the cirrhotic group (p<0.05). In comparison to healthy controls,
patients with cirrhosis had similar HR and MAP, but higher SI (p<0.05), higher CI
(£><0.01) and lower TPVR1 (p<0.01, Table 6-2). Throughout each study there were
no significant changes in MAP, HR, or FBF in the non-infused arm.
Table 6-1: Subjects characteristics.
Cirrhotics Controls
Variable (n=7) (n=7)
Age (years) 53 + 5 52 + 5
Sex (male: female) 3:4 3:4
Weight (kg) 61+4* 75+4
Height (cm) 167 + 4 167 + 4
BSA (m2) 1.7 + 0.1 1.8 ±0.1
BMI (kg.nf2) 22.0 + 0.9* 26.9 + 1.1
Liver disease aetiology
Primary biliary cirrhosis 3 -
Hepatitis C virus 1 -
Alcoholic liver disease 2 -
Autoimmune CAH 1 -
Child-Pugh Score 6.3+0.5 -
Child Grade A 4 -
B 3 -
Oesophageal varices 7 -
Results are expressed as mean ± SEM. * p < 0.05 vs controls.
BMA, body mass index. BSA, body surface area. CAH, chronic active hepatitis.
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Table 6-2: Baseline systemic haemodynamics and hormonal assays.
cirrhotics Controls
Variable (n= 7) (n= 7) Unit
HR 67 + 2 61+2 beat.min"1
MAP 85 ± 5 90 + 2 mm Hg
CI 5.2 ± 0.4# 3.6 + 0.2 L.min'.m"2
SI 77 + 6* 58 +4 mL.m"2
SV 128 + 11 105 + 8 mL
TPVRI 17 ± 2# 25 + 2 mm Hg.L^.min.m2
FBF (infused) 2.9 + 0.4 3.1+0.2 mL. 100 mL tissue"1, min"1
FBF (non-infused) 2.7 ± 0.4 3.0 ± 0.3 mL.100 mL tisue"1. min"1
ET-1 3.3+0.2 4.0 + 0.6 pg.mL"1
Big ET-1 78 + 26 67 + 21 pg.mL"1
ANGII 33+8* 11+2 pg.mL"1
PRA 1.4 + 0.3 1.1+0.1 ng.mL'.h"1
Results are expressed as mean ± SEM. * /?<0.05. #/?<0.01.
CI, cardiac index. FBF, forearm blood flow. HR, heart rate. MAP, mean arterial
pressure. SI, stroke index. TPVRI, total peripheral vascular resistive index.
4.1. Baselineforearm bloodflow:
There was no significant difference between the baseline FBF in the infused and non-
infused arms in each of the study groups (Table 6-2 and Figure 6-2). In addition, FBF
after the application of the 'NO-clamp' was unchanged from baseline, and similar in
both groups.
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FIGURE 6-2: BASELINE FOREARM BLOOD FLOW.
Baseline 1 = baseline at the end of phase 1 of the study protocol (saline infusion).
Baseline 2 = baseline after adjustment of the 'NO-clamp' and before the re-infusion
of ANGII (end of phase 5 of the study protocol).
/?>0.05 infused vs non-infused, by the un-paired t-tests.
p>0.05 baseline 1 vs Baseline 2 in each forearm, by the paired t-tests.
4.2. Responses to L-NMMA infusion:
L-NMMA infusion significantly reduced FBF in both patients with pre-ascitic
cirrhosis and healthy controls (p<0.001, one-way ANOVA vs baseline). This
response reached a plateau after 10 min of infusion, and was similar in both groups at
both 10 and 20 min. Blood flow in the infused arm was reduced by 33.5 ± 5 % and
35.2 ± 4 % in the cirrhotic patients, and by 30.1 ± 2 % and 28.5 ± 4 % in the healthy
controls respectively (Figure 6-3). The dose of SNP required to restore baseline FBF
was similar in the cirrhotic patients and controls (806 ± 140 ng/min and 811 ± 109
ng/min respectively, p = NS).
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Time (min)
10 min 20 min
FIGURE 6-3: PERCENTAGE CHANGE IN FOREARM BLOOD FLOW AFTER
L-NMMA INFUSION.
L-NMMa dose is 4 p,mol/min.
p= 0.75, two-way ANOVA with repeated measures;
/;<0.001 from baseline in each group, one-way ANOVA.
4.3. Responses to BQ-123 infusion without the 'NO-clamp':
ETa receptor antagonism, with BQ-123 infusion, increased FBF in both patients with
cirrhosis and controls (p<0.001, one-way ANOVA for each group). This
vasodilatation was significantly greater in the patients than the controls (p<0.001,
two-way ANOVA with repeated measures). The maximum increase in FBF was 52.1
± 6.4% and 37.1 + 5.6% in cirrhotic patients and controls respectively (Figure 6-4).
The Mean absolute FBF in both arms during this protocol is shown in Table 6-3.
4.4. Responses to BQ-123 infusion during the 'NO-clamp':
Application of the 'NO-clamp' significantly attenuated the BQ-123-induced
vasodilatation in both groups (p<0.001, 2-way ANOVA for both groups). However,
FBF remained greater in the patients with cirrhosis than controls (/?<0.01, 2-way
ANOVA). Whilst significant vasodilatation persisted during 'NO-clamp' application
in patients with cirrhosis (p<0.01, one-way ANOVA), BQ-123-induced
vasodilatation was nearly abolished, and FBF did not change from baseline in the
control group (p>0.05, one-way ANOVA). The maximum increase in FBF was 21.6
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± 6.2% and 8.6 ± 5.2% in the cirrhotic patients and controls respectively (Figure 6-
4). The Mean absolute FBF in both arms during this protocol is shown in Table 6-4.
The mean ± SEM area under the curve in both groups before and during the
application of the 'NO-clamp' are shown in Figure 6-5. The percentage attenuation
in the area under the curve for BQ-123-induced vasodilatation due to application of
the 'NO-clamp' was 66 ± 9% and 82 ± 24% for patients and controls respectively
(/?>0.05, two-way ANOVA with repeated measures). Also, the absolute change in the
calculated area under the curve following application of the 'NO-clamp' was 152 +






















FIGURE 6-5: CALCULATED AREA UNDER THE BQ-123 INFUSION CURVE
WITHOUT AND WITH THE APPLICATION OF THE 'NO-CLAMP'.
* /?<0.001 with clamp vs without clamp in each groups.
4.5. Blood assays:
As shown in Table 2, basal plasma ANG II concentrations were higher in patients
than controls (p<0.05) but basal PRA was similar in both groups (p>0.05). In




















FIGURE6-4:PERCENTAGECHA GIOR ARMBLOODWR SPONSTQ-123INFUSION. BQ-123dosei10nmol/min.Left,PatientswithcirrhosRig t,ontrol•,'NO-clamp'.o, it utthapplicationt' - clamp'./?<0.001forbaselineineachrespo sexcepto s swit'NO-clamp' on rols,one-wayANOVA.*p<0.001with ut 'NO-clamp'vswith'NO-clainatientscirrhosiando rols,tw -wayANOVArepeatedmeasur s.**/?<0.01p ti n vscontrolswi hithout'NO-clamp',tw -wayANOVArepeatedmeasures.
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Saline (Baseline 0) 2.9 + 0.4 3.0 + 0.4 3.8 + 0.5 4.1 ±0.5
BQ-123 (10 min) 2.6 + 0.3 3.4 + 0.4 3.5 + 0.4 4.1 ±0.4
BQ-123 (20 min) 2.6 + 0.3 3.5 + 0.5 3.3+0.4 4.4 + 0.4
BQ-123 (30 min) 2.7 + 0.3 3.8 + 0.5 3.7 + 0.4 4.7 + 0.5
BQ-123 (40 min) 2.7 + 0.4 3.8 + 0.6 3.4 + 0.3 4.6 + 0.4
BQ-123 (50 min) 2.7 + 0.4 4.1 ±0.7 3.4 + 0.4 4.8 + 0.5
BQ-123 (60 min) 2.8 + 0.4 4.3+0.7 3.3+0.4 4.9 + 0.4
Results are expressed as mean ± SEM. Blood flow is expressed as mL. 100 mL
tissue"1, min"1.











Saline (Baseline 1) 2.7 + 0.4 2.9 + 0.4 3.0 + 0.3 3.1 ±0.2
L-NMMA (10 min) 2.8 + 0.4 2.0 + 0.3 3.1 ±0.3 2.2 + 0.1
L-NMMA (20 min) 3.2 + 0.6 2.1 ±0.3 3.2 + 0.2 2.4 + 0.1
Adjusted 'NO-clamp
(Baseline 2) 3.1 ±0.5 3.7 + 0.5 3.3+0.3 3.7 + 0.4
BQ-123 (10 min) 3.4 + 0.5 4.3 ±0.6 3.3 ±0.4 3.9 + 0.5
BQ-123 (20 min) 3.1 ±0.4 4.2 + 0.5 3.0 + 0.3 3.6 + 0.5
BQ-123 (30 min) 3.2 + 0.4 4.3+0.5 3.2 + 0.3 3.8 + 0.6
BQ-123 (40 min) 3.0 + 0.3 4.0 + 0.4 3.4 + 0.3 4.0 + 0.7
BQ-123 (50 min) 3.1 ±0.4 4.4 + 0.5 3.5 + 0.4 4.4 + 0.7
BQ-123 (60 min) 3.1 ±0.4 4.5+0.4 3.4 + 0.5 4.2 + 0.7
Results are expressed as mean ± SEM. Blood flow is expressed as mL. 100 mL
tissue"1, min"1. * 'NO-clamp' is a balanced co-infusion of L-jV°"monomethyl arginine
(a selective NO synthase inhibitor) and sodium nitroprusside (an exogenous NO
donor) to block endogenous NO production without affecting basal blood flow.
Chapter 6: NO & ETA receptor blockade. 167
5. Discussion
Consistent with our previous findings in Chapter 4, we have demonstrated an
enhanced forearm vasodilatation response to exogenous BQ-123 in patients with pre-
ascitic cirrhosis. Application of the 'NO-clamp' attenuated this vasodilatation in both
groups, but the vasodilatation persisted in the patient group. These findings suggest
that although NO substantially contributes to the BQ-123-induced vasodilatation, it is
unlikely to be the mediator of the enhanced vasodilatation in patients with cirrhosis.
The use ofBQ-123 selective inhibits the actions of endogenously produced ET-1 on
the ETa receptor while allowing it to act unopposed on the non-isopeptide-selective
ETb receptor. Stimulation of the endothelial ETB receptor produces dilatation and the
vascular smooth muscle ETb receptor causes constriction. Therefore, the overall
response to ETB receptor stimulation will depend on the balance between these two
actions. Pharmacological agents that can distinguish between the endothelial and
smooth muscle ETB receptors are, so far, not available for clinical use. Nevertheless,
previous studies in healthy controls using ETB receptor subtype-specific antagonist,
BQ-788, have shown that the balance ofET-1 effects on the ETB receptor favors
vasodilatation, probably through endothelial production ofNO (Haynes et al 1995;
Verhaar et al 1998). Indeed, we have previously shown that infusion ofBQ-788, a
selective ETB receptor antagonist, constricts the forearm arteries (Elaynes et al 1995;
Verhaar et al 1998; Helmy et al 2001), and increases systemic vascular resistance
(Strachan et al 1999).
In ageement with a previous study in healthy controls (Verhaar et al 1998), we have
shown that selective ETA receptor antagonism causes dilatation of the forearm
resistance vessels. This response appears, to a large extent, to be due to NO
production as demonstrated by the marked reduction ofBQ-123-induced
vasodilatation with the concomitant use of the 'NO-clamp' (Verhaar et al 1998). We
have also shown, in this study and previously (Helmy et al 2001), an enhanced
forearm vasodilatation following selective ETA receptor antagonism in patients with
pre-ascitic cirrhosis. Together with the observed systemic haemodynamic
derangements, this enhanced vasodilatory responses to BQ-123 infusion suggests an
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actiyated endothelin system, a compensated vasodilated state, and greater
dependence of basal vascular tone on ET-1 in these patients, mediated through the
ETa receptor.
The exact mechanism underlying this enhanced vasodilatation in the cirrhotic
patients is not clear. It could be either due to an increased ETb receptor expression
with subsequent greater NO release, or increased production ofNO-unrelated
vasodilators or both. The detection ofETb receptor overexpression in an animal
model of cirrhosis (Cahill et al 1998) favours the first possibility. However, the
absence of enhanced forearm vasoconstriction during selective ETb receptor
antagonism (Helmy et al 2001) or NOS inhibition (Calver et al 1994; Ryan et al
1996) in a similar group of patients argues against this possibility. In addition, the
concomitant application of the 'NO-clamp' with BQ-123 infusion did not reduce
FBF in the cirrhotic patients to baseline as in the healthy controls. This indicates that
the enhanced dilatation observed in these patients is largely, but not exclusively,
mediated through endothelial NO release. Further studies to address the relative
expression of the ETB receptor in various vascular beds and its relationship to NO
production, in patients with cirrhosis, are now needed.
Endothelins have been shown to interact with the endothelial cells, in autocrine and
paracrine manners, to produce not only NO but also prostacyclin (Suzuki et al 1991),
and atrial natriuretic peptide (ANP) (Fukuda et al 1989; Stasch et al 1989), probably
mediated through its endothelial ETb receptor. In addition, cyclo-oxygenase
inhibitors potentiated the ET-1 induced vasoconstriction (De Nucci et al 1988).
Moreover, pretreatment of rats with antiserum to ANP potentiated the vasopressor
responses to ET-1 (Valentin et al 1991). High plasma concentrations ofANP and
cyclic guanosine monophosphate (cGMP) have recently been confirmed in patients
with pre-ascitic cirrhosis (Iwao et al 1997; Iwao et al 2000) and inversely correlate
with peripheral vascular resistance (Iwao et al 1997). Also, prostacyclin production
increases in patients with cirrhosis (Arroyo et al 1983; Guarner et al 1992), and its
inhibition reduced COP and increase systemic vascular resistance (Bruix et al 1985).
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Indeed, patients included in the present study had significantly lower systemic
vascular resistance. Because we did not measure the concentration of these
vasodilators, we can't answer from the present study whether the enhanced FBF in
following BQ-123 infusion is due to greater ETB receptor-mediated production of
these vasodilators in patients with pre-ascitic cirrhosis. However, we postulate that
selective inhibition of the ETA receptor allows the unopposed action of endogenous
ET-1 on the ETB receptor with subsequent generation of endothelium-derived
vasodilators.
It has also been suggested that endothelin may produce vasodilatation by activating
the K+ channels causing membrane hyperpolarization (Lippton et al 1991). The
relationship between this effect and the production of the endothelial derived
hyperpolarizing factor (EDHP) is unknown (Hadoke 1999). In addition, whether
endothelin produces these actions through the ETB receptor, as the case with NO, or
through another yet un-identified receptor, that can't be blocked by BQ-123, needs to
be investigated. In addition to the role of the ETB receptor in mediating the
vasodilatory responses, it appears to function as a clearance receptor (Fukuroda et al
1994). Whether an increase in ETB receptor-mediated clearance of endothelin
contributes to the enhanced vasodilatation following ETA receptor antagonism is
currently unknown.
IfNO is the sole mediator of vasodilation in cirrhosis, one might expect that systemic
infusion of a selective NOS inhibiton, such as L-NMMA, would reduce the
splanchnic vasodilatation in cirrhosis, and consequently reduce portal pressure.
However, this was not the case in either the rat model of portal hypetension (Pizcueta
et al 1992; Niederberger et al 1995; Pilette et al 1996), or in patients with portal
hypertension (Forrest et al 1995). Interestingly, L-NMMA infusion in all these
studies improved the systemic haemodynamics without affecting portal pressure.
The significant vasoconstriction produced by L-NMMA, a specific inhibitor ofNOS,
infusion in the studied groups confirms the role of endogenous NO production in the
maintenance of basal peripheral vascular tone in both healthy humans (Vallance et al
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1989a; Calver et al 1994; Ryan et al 1996) and patients with early (Calver et al 1994;
Ryan et al 1996) and advanced cirrhosis (Newby et al 1998a). The similarity of the
L-NMMA-mediated vasoconstrictor response in both groups is in keeping with the
results of previous studies in a similar group of patients (Calver et al 1994; Ryan et al
1996), and argues against a greater basal NOS activation in the peripheral arterioles
of patients with well-compensated cirrhosis.
In conclusion, this study confirms that patients with pre-ascitic cirrhosis have
enhanced forearm vasodilator responses to selective ETA receptor antagonism and
normal vasoconstrictor responses to L-NMMA. The persistance of greater FBF in
these patients during the concomittant application of the 'NO-clamp' and BQ-123
infusion, despite being attenuated in both groups, indicates that although NO
substantially contributes to the enhanced vasodilatation induced by BQ-123 in these
patients, other vasodilators are likely to have a role.
CHAPTER 7




1.1. Overview of the Main results:
The main findings of the series of studies included in this thesis indicate that the
forearm resistance vessels in patients with cirrhosis and portal hypertension are
hyporesponsive to both exogenous ANGII and ET-1, but not Nad. These
abnormalities start from the pre-ascitic stage of the disease, suggesting a role for
ANG II and ET-1 in ascites pathogenesis. However, hyporesponsiveness to reflex
sympathetic stimulation using LBNP occurs only in the advanced stages of the
disease, suggesting a role of cardiopulmonary baroreceptors in ascites perpetuation.
In addition, the observation of forearm vasodilatation in response to losartan infusion
only in patients with advanced liver disease suggests that endogenous ANG II does
not contribute to the maintenance of basal peripheral vascular tone except under
conditions ofmarked RAS activation. In contrast, NO and ET-1 contribute to basal
vascular tone in both the healthy state and early cirrhosis, although ET-1 contributes
more in patients with pre-ascitic cirrhosis than healthy controls. Moreover, there is
an important interaction between the endogenous tonic vasopressor and
vasodepressor systems since NO generation largely mediates the vasodilatation
response to ETa receptor antagonism, and, in patients with cirrhosis, the impairment
of ANG II vasoconstriction. However, the abnormalities in endothelin mediated
vascular tone cannot be entirely attributed to an increase in NO release, and is likely
to reflect the direct vascular effects ofET-1.
We have demonstrated an increase in plasma ANG II concentrations of patients with
pre-ascitic cirrhosis. The mechanism underlying this increase is not clear, although
the presence of an activated RAS is consistent with a compensated vasodilated state,
and correlated with portal pressure gradient (Bosch et al 1980). In addition, we have
demonstrated that the responses to LBNP are not affected by losartan infusion,
indicating that endogenous ANG II has little, if any, role in mediating the forearm
vascular responses to low levels of LBNP, and that endogenous ANG II does not
contribute to the impaired response to LBNP in patients with advanced cirrhosis.
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Basal NO release does not appear to be enhanced in patients with pre-ascitic
cirrhosis. This is demonstrated by their normal forearm vasoconstriction in response
to L-NMMA infusion. However, the ANG II-stimulated NO release is greater in
these patients as shown by normalisation of their impaired responses to exogenous
ANG II during the application of the 'NO-clamp'.
The enhanced vasodilatation in response to BQ-123 in patients with pre-ascitic
cirrhosis is consistent with a compensated vasodilated state, an activated endothelin
system, a greater contribution ofET-1 to basal peripheral vascular tone. Although
NO largely mediates the forearm vasodilatation in response to ETA receptor
antagonism in both patients with cirrhosis and healthy controls, the enhanced
vasodilatation to BQ-123 infusion in the cirrhotic group cannot be attributed to NO
release alone, but is also related to a direct ET-1 mediated tone.
1.2. Selection ofpatients:
Variations in the characteristics of the patients involved in previous studies make the
interpretation of their results very difficult (Hadoke 1999). These criteria include the
severity of liver disease, the concomitant use of diuretics, alcohol intake, the
presence or absence of portal hypertension, the amount of dietary salt, and to a lesser
extent the aetiology of cirrhosis. All these variables may affect the endogenous
neurohumoral systems as well as the vascular reactivity to exogenous vasoactive
mediators. Therefore, most of the studies included in this thesis were performed in
patients with biopsy-proven cirrhosis, endoscopically proven portal hypertension,
who were abstinent from alcohol for a minimum of one month, on the same salt
intake (150 mmol/day) as the controls, and were not receiving diuretics or any
vasoactive medications. In addition, patients in the pre-ascitic stage of cirrhosis have
mild, or negligible activation of endogenous vasopressor systems and consequently
less effect of these systems was seen on the responses to exogenous mediators. In
addition, we concentrated on the pre-ascitic stage of cirrhosis because we believe that
better understanding of the neurohumoral abnormalities occurring in this early stage
is crucial for the development of better therapeutic and/or preventive options.
However, it should be noted that the pre-ascitic stage of cirrhosis is the longest in the
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natural history of the disease, during which subtle abnormalities occur either
progressively or intermittently. For example, urinary sodium excretion has been
shown to be normal or impaired, systemic haemodynamics are temporarily altered by
postural changes, and PRA can be low, normal or high.
All patients with pre-ascitic cirrhosis included in this thesis had portal hypertension
as indicated by the presence of endoscopically proven oesophageal varices. This may
explain the demonstrated increase in the activity of the RAS and the endothelin
system in patients with pre-ascitic cirrhosis. Indeed, the activity of the RAS
correlates with portal pressure gradient (Bosch et al 1980). This factor needs to be
considered when comparing our results with those in patients with early cirrhosis
without any evidence of portal hypertension. Patients with diuretic-refractory ascites
were not on diuretic therapy and were studies 7 days after their regular paracentesis.
By this time, all the circulatory and humoral effects of paracentesis return to the pre-
procedure levels (Pozzi et al 1994).
1.3. Effects ofbile acids and vascular responses:
Bile acids have vasodilator properties and circulate in increased levels in patients
with primary biliary cirrhosis. Therefore, one may assume that the observed vascular
hyporesponsiveness to ANG II or ET-1 may be related to high circulating bile acids
in these patients. Indeed, plasma concentrations of bile acids correlate with disease
severity and with the blood levels of liver function tests (Ohkubo et al 1984).
However, most patients with pre-ascitic cirrhosis included in this thesis were not
jaundiced, their plasma bilirubin levels were < 30 pmol/L, and were Child grade A.
In addition, patients with pre-ascitic cirrhosis had normal vasoconstrictor responses
to exogenous Nad. Also, the effects of reducing the circulating levels of bile acids on
the hyperdynamic circulation in experimental cirrhosis are contradictory (Genecin et
al 1990; Thomas et al 1991). Furthermore, we have observed that patients with pre-
ascitic primary biliary cirrhosis have a statistically similar systemic vascular resistive
index to those with cirrhosis of other aetiologies.
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1.4. Effects ofalcohol intake:
Excessive and regular alcohol intake can affect vascular responses to exogenous
vasopressor agents as previously shown with Nad (Howes & Reid 1985). Therefore,
all patients with alcoholic liver disease included in this thesis were abstinent from
alcohol for a minimum of one month as determined by both clinical history and
repeated random blood ethanol estimations. In our previous studies (Newby et al
1998a; Helmy et al 2000), we have shown normal vascular responses to Nad
infusion. In addition, we have re-evaluated the results following exclusion of patients
with alcoholic cirrhosis. In this post-hoc analysis, exclusion of patients with
alcoholic cirrhosis did not affect the statistical significance or the magnitude of the
study findings. Therefore, it is very unlikely that inclusion of such patients had an
effect on the validity of the results of the whole groups.
1.6. Effects ofsalt intake:
Sodium status may alter the peripheral vascular responses to vasoactive substances.
For example, vasopressor responses to exogenous Nad are affected only by extremes
of sodium intake: differing from 10 to 80 fold in both healthy subjects (Rankin et al
1981; Stein et al 1995) and patients with cirrhosis (Wong et al 1995; Wong et al
1996). One of the potential limitations of the studies presented in Chapter 3 in
patients with pre-ascitic cirrhosis and diuretic-refractory ascites is that patients in the
diuretic-refractory group were on a "no added-salt diet" (100 mmol/day), while
patients with pre-ascitic cirrhosis and controls were allowed normal sodium intake
(150 mmol/day). The variation in sodium intake is modest (1.5 fold) and such small
differences, around the usual western diet, have not previously been shown to
influence subsequent vascular responses. Indeed, we found similar reductions in FBF
to Nad infusion in patients and controls.
1. 7. Selection of theforearm circulation:
It is generally accepted that the systemic vasodilatation in patients with cirrhosis
mainly affects the splanchnic circulation. In this thesis, we have concentrated on the
reactivity of local forearm resistance vessels. The changes in FBF mainly reflect the
changes in arteriolar resistance tone, although effects on pre-capillary sphincters or
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smaller arteries, may also contribute (Folkow et al 1971). Responses to vasoactive
agents in the forearm circulation tend to parallel those in the major resistance beds
(Collier et al 1978; Webb & Hand 1995), and are therefore applicable to most of the
vessels that contribute to systemic vascular resistance. Also, the changes in hepatic
venous pressure gradient in response to propranolol treatment have been shown to
correlate with FBF in patients with cirrhosis (Albillos et al 1997). We have shown
that FBF becomes less with disease severity, a finding, which is consistent with what
have previously been shown in renal, brachial and cerebral blood flows (Fernandez-
Seara et al 1989; Maroto et al 1993; Dillon et al 1995). Therefore, the forearm
represents an accessible model to study the systemic vascular responses to different
vasoactive drugs and mediators. The ideal drug treatment of portal hypertension
should not adversely affect the systemic haemodynamics, and hence, knowledge of
the effects of vasopressor systems on the peripheral circulation is essential before
testing their effects on the whole body. In addition, some of the studies, which are
designed to examine a pathophysiologic mechanism, such as those using the 'NO-
clamp' technique, are difficult to apply in the splanchnic circulation.
1. 8. Selection of theplethysmography methodology:
The combination of unilateral brachial artery infusion of locally active doses of
vasoactive agents and bilateral FBF measurements using mercury-in-silastic strain-
gauge venous occlusion plethysmography is a commonly used, powerful, and
reproducible, method of assessing vascular responses in vivo without invoking
systemic effects (Benjamin et al 1995; Webb 1995). We have used this method
putting into considerations, while designing and performing the studies included in
this thesis, all the strengths, weaknesses, pitfalls, and precautions of this technique,
which are mentioned in Chapter 2. We have also used selective receptor antagonists,
which are devoid of agonist activity when assessing the role of endogenous
mediators.
1.9. Data analysis:
The correct statistical method to analyse data, which represent serial measurements
of a variable, such as blood flow, is still debatable. However, it is generally accepted
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that the use of ANOVA with replication followed by post-hoc-tests is the most
suitable and correct way for this type of experiments (Chin-Dusting et al 1999). The
second best method is to obtain a single-point summary of the data set from both
groups i.e., patients vs controls or during 'NO-clamp' vs without 'NO-clamp' as area
under the curve (Matthews et al 1990). The third method of analysing serial
measures is the use of the maximal response point only. This method is the least
sensitive, as it does not take into account the full data set available (Chin-Dusting et
al 1999). In this thesis we have mainly used ANOVA with replication and AUC in
some situations. It can also be noticed that we did not use the calculated FVR
(perfusion pressure divided by FBF). This is because this formula is driven through a
distensible system by a pulsatile pressure rather than a fixed resistance under a steady
driving pressure (Benjamin et al 1995; Chin-Dusting et al 1999).
1.10. The renin-angiotensin and sympathetic nervous systems:
We have confirmed the presence of increased activity of the RAS and SNS in
patients with cirrhosis and its correlation with disease severity. Despite the forearm
vascular hyporesponsiveness to exogenous ANG II in both early and advanced
cirrhosis, endogenous ANG II contributes to the maintenance of basal forearm
vascular tone only in advanced cirrhosis. These findings suggest a role for ANG II in
the pathogenesis of ascites and the subtitle sodium retention in patients with pre-
ascitic cirrhosis (Wong et al 1995; Wong et al 1998). The impaired vasoconstriction
in response to ANG II was augmented and normalized by the application of'NO-
clamp'. These findings indicate that the attenuated ANG II responses in patients with
pre-ascitic cirrhosis are principally due to an enhanced ANG II-mediated NO release.
The possible overexpression of the AT2 receptors in these patients needs to be
examined.
The forearm vascular responses to exogenous Nad are unimpaired. However,
attenuated LBNP responses occurred only in advanced cirrhosis, without apparent
interaction with endogenous ANG II, suggesting low-pressure baroreceptor down-
regulation or defective neuronal transmission. With advancing liver disease, further
activation of the neurohumoral systems occurs, and the peripheral circulation is
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progressively constricts. ATi receptor blockade may provide a useful strategy for
preventing the development of ascites in pre-ascitic patients but must be used with
caution in patients with advanced liver disease (Binder 1999).
1.11. The endothelin system:
We have shown, for the first time in patients with cirrhosis, that the forearm
resistance vessels exhibit an impaired vasoconstriction in responses to exogenous
ET-1, a normal response to ETB receptor blockade, and an enhanced vasodilatation
in response to ETA receptor blockade. These findings suggest an activated endothelin
system, and a greater contribution of endogenous ET-1 to the maintenance of basal
peripheral vascular tone in patients with pre-ascitic cirrhosis. In addition, these
findings may suggest a role for the endothelin system in ascites pathogenesis and the
subtle sodium retention observed in this stage if the disease (Wong et al 1995).
The mechanism of the observed hyporesponsiveness to ET-1 is still unclear.
However, ETA receptor down-regulation and/or a post-receptor defect may have a
role. This needs to be evaluated in future studies. Also, a possible role for
endogenous vasodilators, such as NO, cannot be excluded. The role of the ETB
receptor is complex because of: 1) its existence in both the vascular smooth muscle
and vascular endothelial cells mediating both vasoconstriction and vasodilatation
respectively; 2) the unavailability of antagonists, which can selectively block the
ETb receptor on each of these cells; 3) its possible involvement in the clearance of
ET-1. In the presence of the 'NO-clamp', the BQ-123-induced vasodilatation was
abolished in controls and attenuated in patients with cirrhosis, with FBF remaining
significantly greater in the patients' group. Therefore, the enhanced vasodilatation
abnormalities in endothelin mediated vascular tone cannot be entirely attributed to an
increase in NO release, and is likely to reflect the direct vascular effects ofET-1.
A recent preliminary report has shown forearm vasodilatation in response to ET-1
infusion in patients with decompensated cirrhosis (Vaughan et al 2000). However,
the results of this report are questionable due to major methodological problems,
such as the inclusion of 5 patients only who had advanced cirrhosis, the
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measurement ofFBF in one arm only, and it did not show what medications these
patients were on.
2. Future directions
Although the work included in this thesis has broadened our understanding of the
peripheral vascular reactivity in patients with cirrhosis and portal hypertension, it has
generated many questions, which need to be addressed in the future.
New and powerful vasopressor mediators, such as urotensin II, continue to be
recognized, and their role in homeostasis and in the pathogenesis of the
haemodynamic abnormalities will need to be addressed. Moreover, the vascular
reactivity to exogenous vasopressin, and its contribution to the maintenance of basal
vascular tone have, to date, not been studied in humans in vivo, despite the
characterisation of its receptors and the availability of their selective antagonists.
The effects of systemic doses of losartan and the endothelin receptor antagonists on
systemic, renal, hepatic haemodynamics need to be evaluated. Also, clinical studies
on the potential therapeutic role of these antagonists in reducing portal pressure in
patients with cirrhosis are needed, which may hopefully pave the way towards their
use in future clinical trials.
Extension of the current studies to examine the relative expression ofANG II
receptors (ATi & AT2) and the ET-1 receptors (ETA & ETb) in different vascular
bed in patients with cirrhosis needs to be examined. Doing so will improve the
current understanding of the altered vascular responses to exogenous and
endogenous ANG II and ET-1 respectively. In addition, when selective AT2 receptor
antagonists become available for clinical use, their contribution to the impaired
responses to ANG II, and to the release ofNO can be determined. Moreover, the
ETb receptor exists on both the vascular smooth muscle and vascular endothelial
cells, and mediates both vasoconstriction and vasodilatation respectively. The lack of
availability of antagonists, which can selectively block this receptor on either cell
limits the definition of the exact ETB receptor-mediated actions ofET-1. Also, the
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'NO-clamp' technique can be used to assess the contribution of endogenously
produced NO to the observed forearm vascular responses to ET-1 and BQ-788.
Several studies have suggested that alterations in post-receptor signal
transduction pathways may be involved in the hyporesponsiveness to
vasoconstrictors in cirrhosis (Murray et al 1985; Lee & Severson 1994; Haung et
al 1996), but this has not yet been confirmed. For example, defective PKC, which
is one of the main transducers of the vasoconstrictor effects (Lee & Severson
1994), has been shown in both human and experimental cirrhosis (Spinozzi et al
1991; Wu & Benoit 1994; Tazi et al 1997; Trombino et al 1998; Lahaye et al
1998). Therefore, studies, which compare PKC activity, expression and
subcellular distributions ofPKC isoforms in VSMC obtained from the hepatic
arteries of healthy controls and cirrhotic patients (liver transplant donor and
recipient respectively) are required. Also, the involvement ofPKC isoforms in
agonist-induced vasoconstriction can be determined using phorbol ester, which
down-regulates PKC. Moreover, whether PKC isoforms are differentially
activated by different vasoconstrictors in control and cirrhotic human VSMC
needs to be identified.
The responses of the splanchnic and renal vessels to low-pressure baroreceptor
unloading and the role of these receptors in the pathogenesis of splanchnic
vasodilatation can be examined using LBNP in patients with cirrhosis who have
TIPSS in situ during their follow up portogram. In addition, the hepatic arterial
blood flow responses to low-pressure baroreceptor unloading can be measured in
both patients with cirrhosis and healthy controls before and after LBNP using
colour Doppler ultrasonography. When combining these experiments with
simultaneous FBF measurements, one can clearly demonstrate the interactions
between the blood flow changes in the renal, hepatic or splanchnic territories and
those in the forearm circulation.
In patients with advanced cirrhosis, we have shown that losartan infusion
produces vasodilatation in the forearm circulation. This effect may, at least in
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part, be due to a decrease in the ANG II-mediated activation of the SNS. To
obtain a direct evidence of such an effect, muscle sympathetic nerve activity can
be measured using microneurography before and after losartan administration.
The same needs to be done to assess the activity of the SNS before and after BQ-
123 infusion.
In patients with cirrhosis and portal hypertension, the potential therapeutic role of
NOS inhibitors, such as L-NMMA, in reducing portal pressure has only been
examined in one clinical study (Forrest et al 1995). Interestingly, this study
showed a significant improvement in systemic haemodynamics but not the
wedged hepatic pressure. The reason for this improvement in systemic but not
portal haemodynamics is unclear. Therefore, the study ofForrest et al 1995 needs
to be reproduced with measurement of the hepatic blood flow, the activity of the
vasopressor systems and the renal function (Martin et al 1998). As shown in the
experimental animal studies (Pizcueta et al 1992; Niederberger et al 1995), the
absence of changes in portal venous pressure may be explained by a concomitant
reduction in splanchnic arterial blood flow and an increase in the intrahepatic
vascular resistance. Factors related to the severity of cirrhosis and portal
hypertension, the dose ofL-NMMA, duration and type of the NOS inhibitor
used, and the concomitant use of vasoactive medications such as diuretics should
also be considered when designing this study.
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Role of Angiotensin II in Regulation of Basal and
Sympathetically Stimulated Vascular Tone in Early
and Advanced Cirrhosis
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and DAVID JOHN WEBB§
*Liver Unit, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh; tDepartment of Cardiology, Royal Infirmary of Edinburgh,
Edinburgh; and ^Clinical Pharmacology Unit and Research Centre, Department of Medical Sciences, Western General Hospital,
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Background & Aims: The renin-angiotensin and sympa¬
thetic nervous systems are activated in cirrhosis. This
study aimed to establish the role of angiotensin II (ANG
II) in the regulation of basal and sympathetically
stimulated vascular tone in preascitic cirrhotic patients
and patients with diuretic-refractory ascites compared
with age- and sex-matched healthy controls. Methods:
Forearm blood flow (FBF) responses to lower body
negative pressure (LBNP) and to subsystemic, intrabra-
chial infusions of losartan, an angiotensin II type 1 (AT,)
receptor antagonist, norepinephrine, and ANG II were
measured using venous occlusion plethysmography.
Results: In all groups, ANG II and norepinephrine caused
dose-dependent reductions in FBF (P < 0.001); re¬
sponses to norepinephrine were similar across the 3
groups but those to ANG II were less in both cirrhotic
groups than in controls (P < 0.01). Losartan caused a
dose-dependent increase in FBF only in patients with
refractory ascites (P < 0.01). LBNP caused less reduction
in FBF in refractory ascites patients than in both preascitic
patients and controls (P < 0.01). Conclusions: Despite
hyporesponsiveness to exogenous ANG II in both early
and advanced cirrhosis, endogenous ANG II contrib¬
utes to the maintenance of basal vascular tone only in
advanced cirrhosis. These findings suggest a role of
ANG II in the pathogenesis of ascites. Attenuated LBNP
responses occurred only in advanced cirrhosis, without
apparent interaction with endogenous ANG II.
Cirrhosis is characterized by hyperdynamic circulatorychanges, including high cardiac output and de¬
creased systemic vascular resistance,1-3 that worsen with
disease progression.4 Although compensatory activation
of vasopressin5 8 and the renin-angiotensin 9 and
sympathetic nervous9,13-16 systems occurs, impaired vas¬
cular reactivity has been proposed to contribute to the
hyperdynamic circulation of cirrhosis and to the develop¬
ment of its complications, such as portal hypertension,
ascites, and hepatorenal syndrome.17
Present evidence of this hyporesponsiveness has been
provided by systemic studies and in vitro experiments.
Although contributing to our understanding of the
pathophysiology of portal hypertension, systemic studies
have the disadvantage of invoking neurohumoral, counter-
regulatory mechanisms and having effects on a wide
range of organs, including the heart, brain, and kid¬
neys.18,ly Also, previous studies investigating the role of
the renin-angiotensin system6,8 in the maintenance of
vascular tone in patients with cirrhosis were weakened by
the use of antagonists, such as saralasin, with partial
agonist activity.20-22 However, losartan, a selective angio¬
tensin II type 1 (AT,) receptor antagonist that is devoid of
agonist activity, has recently become available for clinical
use.23 In addition, the combination of subsystemic and
locally active intrabrachial artery infusions with bilateral
forearm blood flow (FBF) measurements using venous
occlusion plethysmography represents a powerful and
reproducible method of assessing in vivo vascular re¬
sponses in a single circulation without invoking systemic
effects.18,19
Therefore, the aims of this study were to evaluate, in
patients with preascitic cirrhosis and those with diuretic-
refractory ascites, the role of endogenous angiotensin II
(ANG II) in the maintenance of basal and sympatheti¬
cally stimulated vascular tone in the forearm circulation;
to assess the forearm vascular responses to exogenous
norepinephrine (NE) and ANG II; and to determine
whether changes in reactivity, if any, are related to disease
severity.
Abbreviations used in this paper: ANG II, angiotensin II; ATi,
angiotensin II type 1; EP, epinephrine; FBF, forearm blood flow;
LBNP, lower body negative pressure; MAP, mean arterial pressure;
NE, norepinephrine; PRA, plasma renin activity.
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Patients and Methods
Subjects
Eighteen patients with biopsy-proven cirrhosis, 8 in
the preascitic stage and 10 in the diuretic-refractory stage of
the disease,24 were recruited and compared with 8 age- and
sex-matched healthy volunteers (age, 49 ± 6 years; 3 women
and 5 men). All patients were ambulant and had normal serum
creatinine levels (<100 pmol/L). Patients with diuretic-
refractory ascites were studied during a no-added-salt diet (100
mmol/day) 1 week after their regular therapeutic paracentesis
and did not receive diuretic therapy for at least 2 weeks before
the study. Patients with alcoholic liver disease were abstinent
from alcohol for at least 1 month,25 confirmed by history and
random blood ethanol testing. None of the subjects received
vasoactive or nonsteroidal anti-inflammatory drugs in the week
before each phase of the study. All subjects abstained from food,
tobacco, and caffeine-containing drinks for at least 4 hours
before each study. To minimize between-subject variability,
female control subjects who were premenopausal were studied
between day 7 and day 12 of their menstrual cycle.26 All female
cirrhotic patients were amenorrheic. Studies were undertaken
with written informed consent from each subject, with the
approval of the local research ethics committee, and in
accordance with the Declaration of Helsinki (1989) of the
World Medical Association.
Drugs and Intra-arterial Administration
Cannulation of the brachial artery of the nondominant
arm was performed using a 27-standard wire gauge steel needle
(Cooper's Needle Works, Birmingham, England) under 1%
lidocaine (Xylocaine; Astra Pharmaceuticals Ltd., Kings Lang-
ley, England) local anesthesia. Patency was maintained by
saline infusion at a constant rate of infusion (1 mL/min) via an
IVAC P1000 syringe pump (IVAC Ltd., Basingstoke, England).
Losartan (Dupont-Merck, Wilmington, DE) at doses of 30
and 90 pg/min; ANG II (Clinalfa, AG Liiufelfingen, Switzer¬
land) at doses of 1, 3, 10, and 30 pmol/min; and NE (Levophed;
Sanofi-Winthrop Ltd., Guildford, England) at doses of 20, 60,
180, and 540 pmol/min were dissolved in physiological saline
(0.9% Baxter Healthcare Ltd., Thetford, England) and admin¬
istered intra-arterially at these locally active doses.27,28 To
prevent its oxidation, NE was dissolved in saline containing
0.1% ascorbic acid (Evans Medical, Langhurst, England).
Measurements
All studies were performed in a quiet, temperature-
controlled room maintained at 22°C—24°C. Blood pressure and
pulse rate were measured in the control arm using a noninva¬
sive oscillometry sphygmomanometer (Takeda UA 751; Tak-
eda Medical Inc., Tokyo, Japan) at intervals throughout the
study.29 FBF was measured as described previously.28,29 Briefly,
FBF measurements were made in both arms (i.e., the infused
and the noninfused arms) by venous occlusion plethysmogra¬
phy using mercury-in-Silastic strain gauges applied to the
widest part of the forearm. The hands were excluded from
measurements by rapid inflation of wrist cuffs to a pressure of
220 mm Hg using E20 Rapid Cuff Inflators (D. E. Hokanson
Inc., Washington, DC). Upper-arm cuffs were inflated to 40
mm Hg for 10 seconds at every 15 seconds to achieve venous
occlusion and obtain blood flow measurements.
Lower Body Negative Pressure
Subjects were rested supine in a plastic-covered steel
cage that enclosed the lower body from the waist downward, as
described previously.30,31 A constant negative pressure of 15
mm Hg was achieved using an industrial-strength vacuum cleaner
regulated by a pressure control unit (Medical Physics Department,
Edinburgh University, Edinburgh, Scotland). Alterations to and
from -atmospheric pressure were attained within 1-2 seconds. This
negative pressure produces selective forearm vasoconstriction through
low-pressure baroreceptor unloading without altering arterial
pressure or heart rate, thereby eliminating the confounding
effects of systemic hypotension.31
Study Design
Two protocols (Figure 1) were applied on 2 separate
occasions 1 week apart and in random order. Subjects rested
supine throughout each study. Strain gauges and cuffs were
applied, and the brachial artery of the nondominant arm was
cannulated. FBF was measured in the last 3 minutes of each
infusion period unless otherwise stated. Before participating in
each of the protocols, saline was infused for 30 minutes to allow
time for equilibration, with FBF measurements made every 10
minutes, and the final measure taken as the baseline FBF. In
protocol 2, the rationale for combining lower body negative
pressure (LBNP) with each of the saline and losartan infusions
was to assess the contribution of endogenous ANG II to the
Protocol 1: (duration: 54 min)
(30 min) (each dose for 6min)
Saline for equilibration Angiotensin II
1 3 10 30
LfJ |_Fj |_F 1x1 LfJ LfJ lil
Protocol 2: (duration: 121 min)
(30 min) (13 min) (each dosefor 13 min) (13 min) (15 min) (each dose for 6 min)
1 Saline for equilibration
1
Saline Losartan Saline Saline wash Norepinephrine
30 90 20 1 60 j 180 1 540
LLl LU IfJ 4a 4il 4fl 4a LlJ LfJ LlJ LfJ ill
Figure 1. Schematic diagram of
the 2 study protocols 1 week
apart. F, Bilateral FBF measure¬
ments each for 3 minutes; L,
LBNP application each for 3 min¬
utes. NE doses are in picomoles
per minute, ANG II doses in
picomoles perminute, and losar¬
tan doses in micrograms per
minute.
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forearm vascular responses during low-pressure cardiopulmo¬
nary baroreceptor unloading.
Blood Assays
After 30 minutes of supine rest, and before any drugs
were administered, venous blood was withdrawn from the
noninfused arm. Ten milliliters was admixed with each of the
following: 1 mL of 1% disodium EDTA/2% sodium metabisul-
fite for measuring epinephrine (EP) and NE concentrations; 0.5
mL of 0.45% O-phenanthroline/4.65% disodium EDTA for
measuring ANG II concentration; and 1 mL of 1% disodium
EDTA and 1000 KIU aprotinin (Bayer AG, Leverkusen,
Germany) for measuring plasma renin activity (PRA). The
samples were placed on ice and immediately centrifuged at
1500g for 20 minutes. Plasma was frozen and stored at — 80°C
until assayed. EP and NE concentrations were determined using an
electrochemical method following separation by reverse-phase liq¬
uid chromatography.32 Plasma ANG II concentrations were mea¬
sured by radioimmunoassay following extraction using Bond Elut
columns (Varian, Harber City, CA) as previously described.33 PRA
was measured under standard conditions through the generation
ofANG I using radioimmunoassay as previously described.34
Data Analysis and Statistics
Plethysmography data were extracted from the Chart
(AD Instruments, Castle Hill, Australia) data files, and FBFs
were calculated for individual venous occlusion cuff inflations
using a template spreadsheet (Excel v. 5.0; Microsoft). Recordings
from the first 60 seconds after wrist-cuff inflation were not included
in the analysis because of the variability in blood flow this
produces.35 Usually, the last 5 flow recordings in each 3-minute
measurement period were calculated and averaged for each arm.
To reduce the variability of blood flow data, the ratio of flows
in the 2 arms was calculated for each time point, thereby using
the noninfused arm as a contemporaneous control.18'19 The
percentage change in FBF was calculated as follows:
% Change in FBF = 100 X - (lkINlh)]l(lhINlh),
where I, and NI, are the blood flows in the infused and
noninfused forearms, respectively, at a given time point (t), and
h and Nlk are the blood flows in the infused and noninfused
forearms, respectively, at baseline (b)\ time 0.
The changes in FBF during LBNP were calculated in each
forearm as % change from the flow immediately before the
application of LBNP as follows:
% Change in FBF During LBNP = 100
X [(/WW " FBFm)KFBFr/trXh
where FBFfkil is the forearm blood flow immediately before
LBNP, and FBFLBtlp is the forearm blood flow during LBNP.
Mean arterial pressure (MAP) was calculated according to
the formula: MAP = Diastolic Arterial Pressure + 1/3 Pulse
Pressure (Systolic Arterial Pressure — Diastolic Arterial Pres¬
sure). FBF was expressed in mL ■ 100 mL tissue-1 • min-1.36
Data are expressed as mean ± SEM and examined by analysis of
variance (ANOVA) with multiple comparisons, the Pearson's corre¬
lation coefficient, and 2-tailed paired and unpaired Student t tests as
appropriate. Statistical significance was taken at the 5% level.
Results
A summary of the patient characteristics is shown
in Table 1. Patients with diuretic-refractory ascites had a
significantly higher Child—Pugh score and prothrombin
time and significantly lower serum albumin level than
preascitic patients (P < 0.01). After participation in the
first study, 1 patient with refractory ascites underwent
liver transplantation and another underwent transjugular
intrahepatic portosystemic stent shunt for variceal bleed¬
ing, and the second study was performed in another 2
patients. Therefore, the 16 studies, 8 in each protocol,
were completed in 10 patients.
Baseline Hemodynamics
There were no changes in heart rate or MAP
throughout the studies. Mean heart rate was significantly
higher and MAP significantly lower in patients with
diuretic-refractory ascites than in preascitic patients and
controls (P < 0.01; Table 2). Heart rate correlated
positively with PRA and basal ANG II concentrations (r =
+0.52, P < 0.01; and r = +0.65, P < 0.01, respec¬
tively), and MAP correlated negatively with PRA and the
basal ANG II concentrations (r = —0.62, P < 0.01; and
r = —0.61, P < 0.01, respectively).
Baseline FBF
There were no significant differences between the
baseline FBF in the infused and noninfused arms on each
Table 1. Patient Characteristics
Refractory Preascitic
Variable ascites cirrhosis
Age (yr) 56 + 4 48 ± 3
Sex (F:M) 4:6 3:5








ALD + HBV 1 —
Cryptogenic 1 —
AICAH — 1
Serum bilirubin (p.mo//L) 52 ± 17 35 ± 12
Serum albumin (g/L) 27 ± 2a 38 ± 2
Prothrombin time (s) 18 ± Is 13 ± 1
Blood urea (mmol/L) 4 ± 1 4 ± 1
Serum creatinine (gmo//L) 89 ± 9 82 + 4
NOTE. Results are expressed as mean ± SEM.
PBC, primary biliary cirrhosis; ALD, alcoholic liver disease; HBV,
hepatitis B virus; AICAH, autoimmune chronic active hepatitis.
3P < 0.01 vs. preascitic cirrhotic patients.
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Before LBNP 88.0 ± 3.4" 72.4 + 2.1 67.4 + 2.6
After LBNP 89.0 4.5" 74.7 ± 2.6 62.0 + 2.3
MAP (mm Hg)
Before LBNP 80.7 + 1.2° 91.8 ± 3.2 93.7 + 3.9




Infused arm 2.5 ± 0.2« 4.8 ± 0.9 4.2 ± 0.8
Noninfused arm 2.2 -t- 0.4" 4.2 -i- 0.6 3.5 0.7
Basal plasma
EP (nmol/mL) 1.2 ± 0.3s 0.7 ± 0.2 0.4 ± 0.2
NE (nmol/mL) 2.9 ± 0.3C 1.1 ± 0.1 1.4 -t- 0.4
ANG II (pg/mL) 237.7 30.8" 57.3 ± 17.3 a 3.2 ± 0.3
PRA
(ng • mL'1 ■ h'1) 15.4 2.4b 3.5 -f- 1.0 1.7 ± COo
NOTE. Results are expressed as mean ± SEM.
bpm, beats per minute.
aP < 0.01 vs. controls.
6P < 0.05 vs. preascitic cirrhotics and controls.
CP < 0.01 vs. preascitic cirrhotics and controls.
dP < 0.05 vs. preascitic cirrhotics and controls.
study day. The baseline FBF was significantly lower in
patients with refractory ascites than in both preascitic
patients and the control group (2.5 ± 0.2 vs. 4.8 ± 0.9
and 4.2 ± 0.8 mL - 100 mL tissue"1 • min"1, respec¬
tively; P < 0.05). No significant change in blood flow in
the noninfused arm was observed during the protocols,
except during LBNP.
Forearm Vascular Responses to ANG II
and NE Infusions
Both ANG II and NE infusions produced signifi¬
cant dose-dependent reductions in FBF (P < 0.001) in all
subjects studied (Figure 2). The responses to ANG II
were significantly greater in the control group than in
patients with diuretic-refractory ascites (P < 0.001) and
patients with preascitic cirrhosis (P < 0.01). FBF
responses to NE were similar in all groups.
Forearm Vascular Responses to Losartan
Infusions and LBNP
Absolute values of FBF (mL ■ 100 mL tissue"1 •
min"1) for each arm at baseline and during saline,
losartan, and LBNP phases of the study in all groups are
shown in Table 3. Losartan caused dose-dependent in¬
creases in FBF in patients with refractory ascites (P <
0.001) but not in patients with preascitic cirrhosis or
controls (P < 0.01 by 3-way ANOVA between groups;
Figure 3). LBNP produced significantly less reduction in
FBF in patients with refractory ascites than in either
patients with preascitic cirrhosis or controls (P < 0.01 by
2-way ANOVA; Figure 4). In addition, responses to
LBNP were similar during saline and losartan infusions
within each group. Although LBNP responses appeared
to be less during saline than during losartan infusions in
the refractory ascites group, this did not reach statistical
significance (P = 0.13 and P = 0.42 at doses of 30 and
90 pg/min, respectively).
Assays
Basal plasma ANG II concentrations were signifi¬
cantly higher in patients with diuretic-refractory ascites
than in preascitic cirrhotics (P < 0.05), and both were
significantly higher than in controls (P < 0.01). Patients
with refractory ascites had significantly higher basal PRA
(P < 0.001) and higher basal plasma NE (P < 0.01) and
EP concentrations (P < 0.05) than patients with preascitic
cirrhosis and controls. Child—Pugh score correlated positively






























Figure 2. Responses in FBF to
incremental doses of ANG II
(pmol/min) and NE (pmol/min).
NS, not significant. Results are
mean ±SEM.
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Table 3. Absolute FBF During Baseline, Saline, Losartan, and LBNP Phases of the Study
Refractory ascites Preascitic cirrhosis Controls
Noninfused Infused Noninfused Infused Noninfused Infused
arm8 arm8 arm arm arm arm
Baseline 2.2 ± 0.4 2.5 ± 0.2 4.2 ± 0.6 4.8 ± 0.9 3.5 ± 0.7 4.2 ± 0.8
Saline (1) 2.3 ± 0.4 2.6 ± 0.3 4.2 ± 0.6 5.1 ± 1.0 3.6 ± 0.7 4.3 ± 0.8
Saline (1) + LBNP 2.4 ± 0.4 2.5 ± 0.3 3.2 ± 0.5 3.8 ± 0.7 2.8 ± 0.6 3.3 ±0.7
Losartan 30 2.3 ± 0.5 3.1 ± 0.4 5.1 ± 0.8 6.0 ± 1.1 3.7 ± 1.0 4.7 ± 1.2
Losartan 30 + LBNP 2.4 ± 0.4 2.6 ± 0.3 3.7 ± 0.5 4.1 ± 0.5 3.0 ± 0.7 3.6 ± 0.6
Losartan 90 2.2 ± 0.4 3.0 ± 0.3 5.1 ± 0.8 6.2 ± 1.1 4.1 ± 0.9 5.2 ± 1.1
Losartan 90 + LBNP 2.2 ± 0.3 2.4 ± 0.3 3.7 ± 0.6 4.4 ± 0.6 3.5 ± 0.8 4.1 + 0.9
Saline (2) 2.1 + 0.5 2.7 + 0.3 5.3 ± 0.9 6.2 ± 1.2 4.1 ± 0.9 5.2 ± 1.1
Saline (2) + LBNP 2.4 ± 0.5 2.6 ± 0.3 3.8 ± 0.5 4.5 ± 0.6 3.3 ± 0.9 4.4 + 1.2
NOTE. Results are expressed as mean ± SEM. Data are reported in mL ■ 100 mL tissue"1 • min~
aP < 0.001 by 3-way ANOVA; refractory ascites vs. preascitic cirrhotics and controls.
+0.71, P <
respectively).
0.001; and r = +0.60, P < 0.01,
Discussion
In this study we show that although patients with
diuretic-refractory ascites and those with preascitic cirrho¬
sis are hyporesponsive to exogenous ANG II, endogenous
ANG II contributes to the maintenance of basal vascular
tone, as demonstrated by the response to losartan, only in
patients with diuretic-rciractory ascites. In addition,
impaired peripheral vasoconstrictor responses to low-
pressure baroreceptor unloading occurs in patients with
refractory ascites, although the vascular responses to
exogenous NE are similar in all groups.
Previous studies in patients with cirrhosis have pro¬
duced contradictory results regarding the responsiveness
to systemic administration of ct-adrenergic agonists and
ANG II. Many studies showed that responses to NE were
not affected,37~,t; but others showed an attenuated re¬
sponse.4<)'41 Responses to ANG II were reported to be
impaired in one study,41 whereas normal responses were
reported in others.38-40 However, systemic drug adminis¬
tration leads to concomitant effects on organs, such as the
brain, kidney, and heart, and influences neurohumoral
reflexes by affecting systemic hemodynamics. Conse¬
quently, vascular responses cannot be wholly attributed
to a direct effect of the drug.18,19 In contrast, the use of
bilateral FBF measurements, with unilateral brachial
artery infusions of vasoactive mediators at subsystemic
and locally active doses, is a very powerful and reproduc¬
ible tool for directly assessing vascular responses in
vivo.18'19 However, previous studies using the forearm
model in patients with cirrhosis are few and their results
are also variable.28,42^15 Because of the confounding
influence of diuretic therapy and some methodological
concerns, such as use of unilateral blood flow measure¬
ments and nonstandardized infusion protocols, conflict¬
ing results have been reported, e.g., either reduced42^14 or
unaltered28,45 vasoconstrictor responses to NE.
Using the bilateral forearm model, we have previously
shown that patients with a combination of cirrhosis and
diuretic-responsive ascites have a significantly reduced
vascular reactivity to exogenous ANG II and cardiopulmo¬
nary baroreceptor unloading.28 However, maintenance of
patients on regular diuretic therapy may have influenced




Pre-ascitic cirrhosis Refractory ascites
Losartan (30 mg/miu) Losartan (90 mg/min)
Figure 3. Responses in FBF to losartan infusions in the 3 studied
groups. Results are mean ±SEM. *P < 0.01 by 3-way ANOVA;






Figure 4. Responses in FBF to LBNP application in the 3 studied
groups during saline (□), 30 pg/min losartan (■), and 90 pg/min
losartan (■) infusions. Results are mean ±SEM. *P < 0.01 by 3-way
ANOVA; refractory ascites vs. preascitic cirrhosis and controls.
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lemia and associated neurohumoral activation. In the
present study, we recruited patients with early and
advanced cirrhosis who were not receiving maintenance
diuretic therapy. Patients with refractory ascites were
studied 1 week after their regular therapeutic paracentesis
and albumin therapy and were hemodynamically stable.
In agreement with previous studies,4,9~12,28 we have
shown that the renin-angiotensin and sympathetic ner¬
vous systems are activated in patients with cirrhosis and
this neurohumoral activation becomes more marked with
disease progression. The observed reduction in baseline
FBF in patients with diuretic-refractory ascites may, in
part, be explained by this neurohumoral activation -and
supports the previously reported reduction in brachial, femo¬
ral, and cerebral arterial blood flow patients with cirrhosis and
ascites, using duplex-Doppler ultrasonography.46,47
The present study demonstrates that the forearm
circulation is hyporesponsive to ANG II in cirrhotic
patients even before the development of ascites, suggest¬
ing that this abnormality may contribute to the pathogen¬
esis of the hyperdynamic circulatory syndrome. The
mechanism of this hyporesponsiveness is unclear, but a
recent study has suggested that it may be mediated
through nitric oxide.48 In addition, we have shown an
increase in plasma ANG II concentrations in patients
with preascitic cirrhosis. The mechanism underlying this
increase is not clear, although the presence of an activated
renin-angiotensin system is consistent with a compen¬
sated vasodilated state. Moreover, the activity of the
renin-angiotensin system correlates with portal pressure
gradient49; in the present study, all patients with preas¬
citic cirrhosis had a high portal pressure as indicated by
the presence of esophageal varices. Increased activity of
the endogenous vasopressor systems could influence
responses to exogenously administered ANG II and NE,
resulting in a right shift of the dose-response curve.
However, this is unlikely, at least for responses to NE,
which were similar in all groups despite the presence of
an activated sympathetic nervous system only in patients
with diuretic-refractory ascites.
The finding that selective AT[-receptor blockade with
losartan increases FBF in patients with diuretic-refractory
ascites but produces no change in FBF in healthy subjects
or patients with preascitic cirrhosis supports the concept
that ANG II contributes to the maintenance of basal
vascular tone only in patients with advanced liver disease,
having no role in either healthy controls or early cirrho¬
sis.27,28,50 A recent finding that oral losartan effectively
reduced hepatic venous pressure gradient in patients with
cirrhosis and portal hypertension,51 together with the
observed increase in plasma ANG II concentrations and
vascular dependence on ANG II in severe cirrhosis,
indicates that ANG II contributes to the hemodynamic
consequences of cirrhosis and, therefore, that losartan
may potentially be helpful in the treatment of portal
hypertension. Additionally, the effects of the high plasma
ANG II concentrations observed in patients with preas¬
citic cirrhosis on renal arteriolar blood flow and distribu¬
tion help to explain the subtle Na+ retention detected
before the development of ascites52 and suggest that use
of ATi -receptor blockers may improve Na+ excretion in
patients with preascitic cirrhosis, and thus prevent or
delay the development of ascites.
LBNP has been used for many years to examine the
neurocirculatory reflex response to reduced venous return
to the heart.55 In healthy subjects, LBNP at intensities up
to 20 mm Hg selectively unloads low-pressure cardiopul¬
monary baroreceptors without causing changes in heart
rate or blood pressure. Such low-intensity LBNP selec¬
tively reduces FBF51,54-57 and increases forearm NE
spillover without affecting total peripheral vascular resis¬
tance or total body NE spillover. In contrast, LBNP at
intensities greater than 20 mm Hg also unloads arterial
baroreceptors with concomitant increases in total body
spillover of NE, increases in heart rate, and decreases in
blood pressure.57 Previous studies in patients with decom¬
pensated cirrhosis have shown impaired vasoconstrictor
responses to both LBNP and body tilting.9,28,40 In the
present study, we document impaired vasoconstrictor
responses to LBNP in patients with diuretic-refractory
ascites despite normal responsiveness to exogenous NE.
This may be the result of several mechanisms including
baroreceptor down-regulation or defective sympathetic
neurotransmission secondary to the autonomic dysfunc¬
tion described with advanced cirrhosis.58 In earlier stud¬
ies by Wong et al.,52,59 central venous pressure was
elevated in patients with preascitic cirrhosis. One may
therefore anticipate that higher intensities of LBNP are
required to achieve similar reflex responses in these
patients. Nevertheless, these studies have shown that, in
response to LBNP of 15 mm Hg, patients with preascitic
cirrhosis have reductions in central venous pressure and
FBF similar to healthy subjects.52,59
The observation that the vasoconstrictor responses to
LBNP of 15 mm Hg in the infused forearm are unaffected
by losartan infusions has been reported in both cirrhotic
patients28 and controls,27,60,61 and indicates that endog¬
enous ANG II has little, if any, role in mediating these
regional responses to low levels of LBNP in either
situation. These findings also suggest that influences of
endogenous ANG II does not contribute to the impaired
response to LBNP in patients with refractory ascites.
One of the potential limitations of the present study is
that patients in the diuretic-refractory group were on a
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no-added-salt diet (100 mmol/day), whereas patients
with preascitic cirrhosis and controls were allowed nor¬
mal sodium intake (150 mmol/day). Sodium status may
alter the peripheral vascular responses to vasoactive
substances. However, pressor responses to exogenous NE,
for example, in healthy subjects are affected only by
extremes of sodium intake, differing from 10—80-
fold.52,62^3 In our study, the variation in sodium intake is
modest (1.5-fold) and such small differences around the
usual Western diet have not been shown to influence subse¬
quent vascular responses. Indeed, we found similar reductions
in FBF to NE infusion in patient and control groups.
In conclusion, despite hyporesponsiveness to exog¬
enous ANG II in both early and advanced cirrhosis,
endogenous ANG II contributes to the maintenance of
basal forearm vascular tone only in advanced cirrhosis.
These findings suggest a role for ANG II in the
pathogenesis of ascites. The forearm vascular responses to
exogenous NE are unimpaired. However, attenuated
LBNP responses occur only in advanced cirrhosis, with¬
out apparent interaction with endogenous ANG II,
suggesting low-pressure baroreceptor down-regulation or
defective neuronal transmission. With advancing liver
disease, further activation of the neurohumoral systems
occurs, and the peripheral circulation is progressively
vasoconstricted. ATi-receptor blockade may provide a
useful strategy for preventing the development of ascites
in preascitic patients but must be used with caution in
patients with advanced liver disease.64 Further studies are
required to elucidate the mechanism of the observed
hyporesponsiveness to ANG II.
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Altered Peripheral Vascular Responses to Exogenous and
Endogenous Endothelin-1 in Patients With
Well-Compensated Cirrhosis
Ahmed I-Ielmy,1 Rajiv Jalan,1 David Ernest Newby,2 Neil Russell Johnston,2 Peter Clive Hayes,1 and David John Webb2
Plasma endothelin concentrations are elevated in cirrho¬
sis and correlate with disease severity. This study assessed
forearm vascular responses to exogenous endothelin-1 (ET-
1), and evaluated the contribution of endogenous ET-1 to
the maintenance of basal peripheral vascular tone in pa¬
tients with well-compensated cirrhosis (n = 11) and
matched healthy controls (n = 8). Bilateral forearm blood
flow (FBF) was measured at baseline and following unilat¬
eral, subsystemic, intrabrachial artery infusions of ET-1 (2
and 6 pmol/min); BQ-123, a selective ETA receptor antago¬
nist (3 and 10 nmol/min); and BQ-788, a selective ETB re¬
ceptor antagonist (0.3 and 1 nmol/min) using venous occlu¬
sion plethysmography. Baseline systemic hemodynamics
and plasma ET-1 and big ET-1 concentrations were mea¬
sured using electrical bioimpedance and radioimmunoas¬
say, respectively. Patients and controls had similar baseline
EBF, systemic hemodynamics, and plasma ET-1 and big
ET-1 concentrations. In both groups, ET-1 and BQ-788
caused significant vasoconstriction (P < .001) and BQ-123
caused significant vasodilatation (P < .001). Compared
with controls, cirrhotic patients had attenuated ET-1 re¬
sponses (P < .001), augmented BQ-123 responses (P <
.001), and similar BQ-788 responses (P = .62). Despite nor¬
mal systemic hemodynamics and plasma ET-1 concentra¬
tions, forearm vascular responses to exogenous ET-1 are
reduced in cirrhotic patients. The augmented vasodilatation
to BQ-123 in cirrhotic patients is consistent with a compen¬
sated vasodilated state, and a greater contribution ofET-1 to
the maintenance of basal vascular tone acting through the
ETa receptor. (Hepatology 2001;33:826-831.)
Abbreviations: ET-1, endothelin-1; ETA, endothelin type A receptor; ETD, endothelin
type B receptor; NO, nitric oxide; FBF, forearm blood flow; I1R, heart rate; MAP, mean
arterial pressure.
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A hyperdynamic circulation characterized by low arterial
pressure, high cardiac output, and low systemic vascular re¬
sistance is a feature of patients with advanced cirrhosis and
portal hypertension.1'2 This hyperdynamic circulation wors¬
ens with disease progression4'6 and is accompanied by a re¬
duced reactivity to vasopressor systems including the renin-
angiotensin and sympathetic nervous systems. These
hemodynamic changes play a crucial role in the pathogenesis
of portal hypertension and its complications, including
variceal hemorrhage, ascites, and the hepatorenal syn¬
drome.712
Endothelin-1 (ET-1) is the most potent vasoconstrictor
known, belonging to a 21-amino acid peptide family with a
range of biological effects.9"11 ET-1 was originally identified in
the culture medium of porcine aortic endothelial cells910 and
is derived from a larger pre-pro-endothelin-1 (212 amino ac¬
ids), which is cleaved by endopeptidases to produce big ET-1
(38 amino acids), which is then converted to ET-1 by specific
endothelin-converting enzymes.9'10
Molecular studies have, so far, identified 2 endothelin re¬
ceptor subtypes in mammalian species: endothelin-A (ETA)
and endothelin-B (ETB). In vascular smooth muscle cells, both
receptors are expressed1112 and mediate vasoconstriction.1114
Only the ETB receptors are found on endothelial cells, where
these cause vasodilatation through the release of endotheli-
um-derived vasodilators, such as nitric oxide (NO).15 ET-1-
induced vasoconstriction is predominantly mediated by the
ETa receptor, but ETB receptors may contribute under some
circumstances.16
Since 1991, many studies have reported increased plasma
concentrations of ET-1 in patients with cirrhosis.17"26 The
mechanisms underlying the elevated ET-1 concentrations are
unclear and do not appear to be related to hypovolemia or
endotoxemia.2227 However, there have been no studies to ad¬
dress the vascular responsiveness to ET-1 in vivo, or its role in
the maintenance of basal peripheral vascular tone in patients
with cirrhosis. Therefore, the aims of the present study—in
patients with well-compensated cirrhosis and portal hyper¬
tension—were to determine the forearm vascular responsive¬
ness to exogenous ET-1 and to assess the role of endogenous
ET-1 in the maintenance of basal forearm vascular tone using
the selective ETA and ETB receptor antagonists, BQ-123 and
BQ-788, respectively.
PATIENTS AND METHODS
Patients. Eleven patients with biopsy-proven and well-compen¬
sated cirrhosis and 8 healthy control subjects were recruited. All
patients were ambulant and had endoscopically proven esophageal
varices, normal serum creatinine (<100 mol/L), and no clinical ev-
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idence of syslemic circulatory disturbance. Patients with alcohol-
induced liver disease were abstinent from alcohol for at least 1
month, confirmed by history and repeated random blood elhanol
testing, to prevent the depression of vascular responses that this
causes.2" To avoid the possibility of altering the endogenous vaso¬
pressor systems, all subjects in both groups were maintained on their
normal sodium intake. None of the subjects received vasoactive or
nonsteroidal anti-inflammatory drugs in the week before, and all
subjects abstained from food, tobacco, and caffeine-containing
drinks for at least 4 hours before each study. All female subjects were
postmenopausal, both for safety and to avoid the variability in
vascular responses that may be associated with cyclic hormonal
changes.21' Studies were undertaken in accordance with the Declara¬
tion of Helsinki (1989) of the World Medical Association, the ap¬
proval of the local research ethics committee, and the written in¬
formed consent of each subject.
Drugs and lnlra-arterial Administration. Cannulation of the brachial
artery of the nondominant arm was performed using a 27-standard
wire gauge steel needle (Cooper's Needle Works, Birmingham, UK)
under 1% lidocaine (Xylocaine; Astra Pharmaceuticals Ltd., Kings
Langley, UK) local anesthesia. Patency was maintained by saline
infusion at a constant rale (1 mL/min) via an 1VAC P1000 syringe
pump (1VAC Ltd., Basingstoke, UK).
ET-1 (Clinalfa AG, Laufelftngen, Switzerland) at doses of 2 and 6
pmol/mL, BQ-123 (Clinalfa AG) at doses of 3 and 10 nmol/mL, and
BQ-788 (Clinalfa AG) at doses of 0.3 and 1 nmol/mL, were dissolved
in physiologic saline (0.9% Baxter Healthcare Ltd., Thetford, UK)
and administered inlra-arlerially. On the basis of previous studies,
we studied doses that are subsyslemic and act locally to produce
approximately 40% reduction, approximately 30% increase, and ap¬
proximately 20% reduction in forearm blood flow (FBF) in healthy
subjects after 60 minutes of infusion of ET-1 (5 pmol/min), BQ-123
(10 nmol/min), and BQ-788 (1 nmol/min), respectively.30 "2 In such
studies, by 60 minutes these doses produce maximal and sustained
responses.30'32 Pilot studies have suggested that higher doses may
evoke systemic hemodynamic effects.
Measurement of FBF. The combination of subsyslemic and locally
active intrabrachial artery infusions with bilateral FBF measure¬
ments using venous occlusion plethysmography is a powerful and
reproducible method of directly assessing in vivo vascular responses
to vasoactive mediators without invoking syslemic effects.33'34 All
studies were performed in a quiet, temperature-controlled room
maintained at 22 to 24°C. FBF was measured as previously de¬
scribed. 26'3,i
Study Design. Schematic diagrams of the 3 protocols applied in this
study are shown in Fig. 1. ET-1, BQ-123, and BQ-788 were admin¬
istered on 3 separate occasions, in random order, at least 1 week
apart. Subjects rested supine throughout each study. Strain gauges
and cuffs were applied, and the brachial artery of the nondominanl
arm cannulated. In all protocols, saline was infused for 30 minutes to
allow time for equilibration, with FBF measurements being made
every 10 minutes and the final measurement taken as the baseline
FBF. Thereafter, ET-1, BQ-123, or BQ-788 was infused for 60 min¬
utes at each of 2 incremental doses, and FBF was measured every 10
minutes.
Measurement ofSystemic Hemodynamics. Arterial blood pressure and
heart rate (HR) were measured in the noninfused arm using a non¬
invasive oscillomelric sphygmomanometer (Takeda UA 751, Takeda
Medical Inc, Tokyo, Japan) at 20-minule intervals throughout each
study.3'' The mean arterial pressure (MAP) was calculated according
to the formula; MAP (mm Hg) = diastolic arterial pressure + 1/3
pulse pressure.
Baseline cardiac functions, including HR, stroke volume, and car¬
diac output, were measured using a noninvasive thoracic electrical
bioimpedance method (BoMed NC-COM3; BoMed Medical Manu¬
facturer Ltd., Irvine, CA) as previously described.37 Bioimpedance is
a noninvasive and reproducible method for assessing systemic he¬
modynamic parameters, including cardiac output and systemic vas¬
cular resistance.38"40
Blond Assays. After 30 minutes of supine rest, 10 mL venous blood
was withdrawn from the control arm and admixed with 1 mL of 1%
disodium EDTA and 1,000 K1U aprolinin (Bayer AG, Leverkusen,
Germany). Blood samples were placed on ice and immediately cen-
trifuged at l,500g for 20 minutes. Plasma was frozen and stored at
—80°C until assayed. Following extraction using Bond Elut columns
(Varian, Harber City, CA), the plasma concentrations of ET-1 (Pen¬
insula Laboratories Europe Ltd., St. Helens, UK) and big ET-1 (Pen¬
insula Laboratories Europe Ltd.) were determined by radioimmuno¬
assay as previously described.41 The intra-assay coefficients of
variation for ET-1 and big ET-1 were 7.0% and 7.2%, respectively,
and the interassay coefficients of variation were 9.0% and 9.3%, re¬
spectively.
Measurement of Urinary Sodium Excretion. On the day before the
study, urine was collected for 24 hours to measure total volume and
Na+ concentration using flame photometry.
Data Analysis and Statistics. Plelhysmographic data were extracted
from the Chart™ (AD Instruments, Castle Hill, Australia), and data
files and FBFs were calculated for individual venous occlusion cuDT
inflations using a template spreadsheet (Excel v5.0; Microsoft, Red¬
mond, WA). Recordings from the first 60 seconds following inflation
of the wrist cuff were not included in the analysis because of the
variability in blood flow that this produces.42 Usually, the last 5 flow
recordings in each 3-minule period were calculated and averaged for
each arm. To reduce the variability of blood [low data, the ratio of
flows in both arms was calculated for each time point, thereby using
the noninfused arm as a contemporaneous control.33-34 The percent¬
age change in FBF was calculated as follows: % change in FBF =
100 X [(1,/NIi) - (Ii/Nlj,)]/(lj/Nlb); where 1, and Nl, are the blood
(lows in the infused and noninfused forearms, respectively, at a given
time point (t), and Ij, and NIb are the blood flows in the infused and
noninfused forearms, respectively, at baseline (b); time 0. FBF was
expressed in ml. X 100 mL tissue-1 X min-1.43
Protocol t: (duration ISUmin)
(30 minj (60 min) (60 min)
Saline for equilibration ET-1 (2 pmol/min) ET-1 (6 pmol/min)
LU * IFJ * IfJ LD LD Id IU LD LfJ [fj lu ID HJ ixJ id
Protocol 2: (duration. 150 min)
Fig. 1. Schematic diagram of the
study design. Three protocols, at
least 1 week apart, were undertaken
in random order, F = bilateral FBF
measurements, each for 3 minutes.
*Biood sampling. #Assessment of
electrical bioimpedancc.
(30 mm) (60 min) (60 min)
Saline for equilibration BQ-123 (3 nmol/min) BQ-123 (10 nmol/min)
LfJ • (fJ it LfJ
Protocol 3: (duration: 150
LfJ ill ID LzJ ID ID
nin)
ID LD LD ID LD Itl
(30 min) (60 min) (60 min)
Saline for equilibration BQ-788 (n.3 nmol/min) BQ-788 (I nmol/min)
ID « LfJ # jr. LU (fj LU LD LfJ LD IfJ [fl LfJ LfJ LfJ III
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Table 1. Subject Characteristics
Cirrhotic Patients Controls
Variable (n= 11) (n = 8)
Age (years) 52.1 ± 3.3 49.0 ± 4.9
Sex (male: female) 5:6 5:3
BM1 (kg.m-2) 24.3 ± 0.8 24.8 ± 1.3
BSA (m2) o+100 00 1+ o
Liver disease etiology —
ALD 4
PBC 5
ALD + HCV 1
Cryptogenic 1
Child-Pugh score 5.7 ± 0.2 —
Child grade A 11 —
Esophageal varices 11 —
Urinary Na+/24 h (mmol/L) 147.5 ± 20.8 173.9 ± 20.1
Results are expressed as mean ± SEM.
Abbreviations: BM1, body mass index; BSA, body surface area; ALD, alco¬
hol-induced liver disease; PBC, primary biliary cirrhosis; HCV, hepatitis C
virus.
Dala were expressed as mean ± SEM and examined by 2-faclor
ANOVA with repealed measures, regression analysis, and 2-lailed
paired and unpaired Sludenl's ( tests as appropriate. Statistical sig¬
nificance was taken at the 5% level.
RESULTS
A summary of baseline characteristics of the subjects is
shown in Table 1. Patients with cirrhosis were well matched
to the control subjects for age, sex, and body mass index. Six
patients (5 men and 1 woman) completed all 3 protocols; 1
female patient completed 2 protocols, and the remaining 4
studies were performed in 4 female patients. Therefore, the 24
studies were completed in 11 patients. No adverse effects were
observed in either patients or controls during or after the
studies. The 24-hour urinary Na+ excretion was similar in
both groups (Table 2).
Baseline Hemodynamics. As shown in Table 2, both cirrhotic
patients and healthy controls had similar baseline systemic
hemodynamics including HR, MAP, stroke index, cardiac in¬
dex, and total peripheral vascular resistive index. There was
no significant difference in baseline FBF (mL X 100 mL tis¬
sue"' X min"1) in the infused arm between patients with
cirrhosis and control subjects (2.8 ± 0.3 and 2.5 ± 0.3, re¬
spectively; Table 2). Throughout all protocols, there were no
Table 2. Basal Forearm and Systemic Hemodynamics and Plasma ET-1
and Big ET-1 Concentrations in Both Groups
Variable Cirrhotic Patients Controls
Heart rate (beat/min) 72 3 ± 2.7 65.8 ± 2.8
MAP (mm Hg) 93 9 4- 3.2 95.2 ± 4.2
Cardiac index (L X min-1 X m-2) 3.7 -+- 0.2 3.7 ± 0.4
Stroke index (mL X m-2) 54 3 ± 4.8 56.8 ± 4.7
TPVR1 (mm Hg X L-1 X min X m2) 25 8 -t- 1.2 28.3 ± 4.3
FBF infused arm (mL X 100 mL
tissue-1 X min-1) 2.8 + 0.3 2.5 ± 0.3
FBF non-infused arm (mL X 100 mL
tissue-1 X min-1) 2.9 + 0 3 2.3 ± 0.3
Plasma ET-1 (fmol/mL) 1.2 ± 0.1 1.2 ± 0.2
Plasma big ET-1 (fmol/mL) 7.6 ± 0.8 6.8 ± 1.8
Results are expressed as mean ± SEM.
Abbreviation: TPVR1, total peripheral vascular resistive index.
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Fit;. 2. Mean (SEM) percentage change in FBF in response to ET-1 infu¬
sions in cirrhotic patients (•) and healthy controls (O). P < .001 dose re¬
sponse and cirrhotics vs. controls by 2-way ANOVA with repeated measures.
significant changes in MAP, HR, or FBF in the noninfused
arm.
FBF Responses to ET-1 Infusions. ET-1 infusion caused a sig¬
nificant dose-dependent reduction in FBF both in cirrhotic
patients and in controls (P < .001, ANOVA for each group).
However, the vasoconstriction was significantly less in the
patients than in the controls (P < .001, 2-way ANOVA with
repeated measures; Fig. 2). The maximum reduction in
FBF after infusion of the first dose of ET-1 (2 pmol/mL) was
11.5 ± 5.3% and 25.4 ± 3.6% in the cirrhotic patients and
controls, respectively, and reached 25.0 ± 3.6% and 36.3 ±
5.2%, respectively, after infusion of the second dose (6 pmol/
mL; Fig. 2).
FBF Responses to BQ-123 Infusions. ETA receptor antagonism,
using BQ-123 infusion, produced a dose-dependent increase
in FBF in both cirrhotic patients and controls (P < .001,
ANOVA for each group). This vasodilator response, was sig¬
nificantly greater in the patients than the controls (P < .001,
2-way ANOVA with repeated measures). The maximum in¬
crease in FBF after infusion of the first dose of BQ-123 (3
nmol/min) was 30.0 ± 5.2% and 10.0 ± 2.2% in cirrhotic
patients and controls, respectively, and reached 47.7 ± 6.1%
and 37.1 ± 12.5%, respectively, after infusion of the second
dose (10 nmol/min; Fig. 3).
FBF Responses to BQ-788 Infusions. ETB receptor antagonism,
using BQ-788 infusion, produced a significant dose-depen¬
dent reduction in FBF in both the cirrhotic patients and con¬
trols (P < .001, ANOVA for each group). This vasoconstrictor
response was similar in the 2 groups (P = .62). The maximum
reduction in FBF after infusion of the first dose ofBQ-788 (0.3
nmol/mL) was 11.4 ± 5.8% and 14.2 ± 6.2% in cirrhotic
patients and controls, respectively, and reached 22.2 ± 7.5%
and 26.4 ± 9.2%, respectively, after infusion of the second
dose (1 nmol/mL; Fig. 4).
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Fig. 3. Mean (SEM) percentage change in FBF in response to BQ-123
(ETa receptor antagonist) infusions in cirrhotic patients (•) and healthy
controls (O). P < .001 dose response and cirrhotics vs. controls by 2-way
ANOVA with repeated measures.
Blood Assays. Basal plasma concentrations of ET-1 and big
ET-1 were similar in cirrhotic patients and controls (Table 2)
and correlated positively with each other (r = 0.82; P < .001).
DISCUSSION
In patients with well-compensated cirrhosis, portal hyper¬
tension, and normal plasma ET-1 concentrations, we have
shown peripheral vascular hyporesponsiveness to exogenous
ET-1 before the development of any systemic hemodynamic
abnormality. Moreover, these patients have an augmented re¬
sponse to ETa receptor antagonism, while retaining a normal
response to ETB receptor antagonism. These findings are con¬
sistent with an activated endothelin system in cirrhosis, a
greater contribution of ET-1 to basal forearm vascular tone
acting through the ETA receptor, and a potential counter-
regulatory role for ET-1 in the pathogenesis of the circulatory
disturbances of cirrhosis.
Patients with advanced cirrhosis and fluid reten-
tion17'21'21'26 have elevated plasma ET-1 concentrations and
are particularly high in those with hepatorenal syndrome.17
Moreover, plasma ET-1 concentrations correlate positively
with the severity of liver disease (measured by Child-Pugh
score),20-2,5'44 the hepatic blood flow (measured by D-sorbitol
infusion), and the hepatic venous pressure gradient,21 and
inversely with the liver cell mass (measured by galactose elim¬
ination capacity)25 and creatinine clearance.161"111 However,
because of its paracrine mode of action, the majority ofET-1 is
released abluminally to act on adjacent vascular smooth mus¬
cle and endothelial cells, and as a consequence, plasma ET-1
concentrations may not truly reflect the underlying activity of
the endothelin system.45 In the present study, we have con¬
firmed the previous findings of normal plasma ET-1 and big
ET-1 concentrations in patients with well-compensated cir-
rhosis1"'46'47 but have additionally shown evidence of func¬
tional abnormalities in the tonic activity of the endothelin
system. This suggests that perturbation of the endothelin sys¬
tem may precede the onset of detectable changes in plasma
ET-1 concentrations.
We report an impaired in vivo vasoconstrictor response to
exogenous ET-1 in patients with well-compensated cirrhosis
in the absence of a measurable abnormality in baseline FBF,
cardiac function, or systemic hemodynamics. This reduced
responsiveness to ET-1 may, in part, reflect a greater basal
ET-1 activity as suggested by the enhanced vasodilator re¬
sponse to BQ-123 infusion. Using the same forearm model we
have also shown impaired vasoconstrictor response to angio¬
tensin 11 in patients with early55 and advanced cirrhosis.26-55
This observation is in keeping with the impaired pressor re¬
sponses to both ET- 14K and angiotensin II4g in the rat model of
secondary biliary cirrhosis and portal hypertension. The
mechanisms underlying the reduced responsiveness to ET-1
remain unclear, but NO, and possibly other mediators, may be
involved.411-51 This is supported by the observations of in¬
creased NO production, and nitric oxide synthase activity, in
portal hypertension50 and by the reversal of the ET-14B and
angiotensin II4g hyporesponsiveness observed in the rat
model of cirrhosis after NO synthase inhibition.
This study has also shown, for the first time, that patients
with well-compensated cirrhosis exhibit an enhanced forearm
vasodilatation response to infusion of the ETA receptor antag¬
onist, BQ-123. This observation is consistent with a compen¬
sated vasodilated state, an activated endothelin system, and a
greater contribution of ET-1 to the maintenance of basal fore¬
arm vascular tone acting through the ETA receptor in these
patients. Interestingly, this forearm vasodilator response to
BQ-123 infusion has been shown to be largely reversed by
inhibiting endogenous NO production, but not by cyclo-oxy-
genase inhibition, in healthy subjects.52 Whether the en¬
hanced forearm vasodilatation observed in the present study
in patients with well-compensated cirrhosis is mediated
through a higher endogenous NO production is currently un¬
known.
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Fic;. 4. Mean (SEM) percentage change in FBF in response to BQ-788
(ETb receptor antagonist) infusions in cirrhotic patients (•) and healthy
controls (O). P < .001 dose response and P = .62 cirrhotic patients vs.
controls by 2-way ANOVA with repeated measures.
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In the present study, we have shown that patients with
well-compensated cirrhosis and healthy controls have similar
forearm vasoconstrictor responses to the infusion of the ETB
receptor antagonist BQ-788. The interpretation of this obser¬
vation is complex for several reasons. First, the relative pre¬
dominance of ETb receptor-mediated vasoconstriction or va¬
sodilatation12-16 will depend largely on the proportionate
expression of these receptors in the vascular smooth muscle
and endothelial cells. Selective cell-specific blockade of the
ETb receptors would be valuable to dissect out these relative
contributions but the techniques to address this issue do not
currently exist.52 Second, since the ETB receptor appears to
function as a clearance receptor,52 " the responses to BQ-788
are likely, at least in part, to represent the effect of ET-1 dis¬
placement on the ETa receptor. Thus, the vasoconstriction
after ETB receptor antagonism, by BQ-788, is the sum of the
unopposed action of endogenous ET-1 on the ETA receptors,
and the absence of its action on the ETB receptors. Third, it is
unlikely that stimulation of ETB receptors is the sole mecha¬
nism for the increased NO production in cirrhosis, since one
would have anticipated greater vasoconstriction in such pa¬
tients following selective ETB receptor antagonism. Further
studies are now needed to address the relationship between
NO production and ETB receptor stimulation, in patients with
cirrhosis.
The findings of the present study apply directly to the fore¬
arm circulation, but add to our understanding of the role of
ET-1 in regulation of peripheral vascular tone in cirrhosis and
are probably representative of the systemic resistance vascular
beds.'4 As yet, there are no reports of systemic studies assess¬
ing the actions of either exogenous or endogenous ET-1 in the
systemic and splanchnic circulations in patients with cirrho¬
sis, apart from a preliminary report of infusing the ETA recep¬
tor antagonist, BQ-123, in 3 patients with advanced cirrhosis
and hepatorenal syndrome. Interestingly, this study showed
an improvement in renal blood flow and creatinine clear¬
ance.54 However, on the basis of our study and the peripheral
vasodilatation hypothesis,7 if selective ETA receptor antago¬
nists were to exert their major effect on the splanchnic circu¬
lation, then they might further exacerbate portal hypertension
and systemic hypotension. Therefore, we believe that sys¬
temic studies are clearly needed to assess the clinical role of
ET-1 antagonists in patients with cirrhosis and portal hyper¬
tension.
One of the potential limitations of the present study is that
4 of the 11 patients had alcohol-induced liver disease. Indeed,
excessive and regular alcohol intake may alter the vascular
responses to exogenous vasopressor agents such as noradren¬
aline.2" In each phase of the present study, only 2 or 3 of 8
patients had alcohol-induced cirrhosis. All subjects were ab¬
stinent from alcohol for a minimum of 1 month as determined
by both clinical history and repeated random blood ethanol
testing. In our previous studies26-55 incorporating similar pa¬
tients, we have shown normal vascular responses to noradren¬
aline infusion. In addition, we have reevaluated the present
results following exclusion of patients with alcohol-induced
cirrhosis and have found consistent results without altering
the statistical significance or the magnitude of the effects of
the study findings.
In conclusion, the forearm circulation in patients with well-
compensated cirrhosis is hyporesponsive to exogenous ET-1,
despite the absence of any significant differences in basal sys¬
temic hemodynamic characteristics and normal circulating
ET-1 concentrations in these patients. The enhanced vasodi-
latory response to BQ-123 in cirrhotic patients suggests a
compensated vasodilated state, an activated endothelin sys¬
tem, and a greater contribution of ET-1 to the maintenance of
forearm basal vascular tone acting through the ETA receptor.
The mechanism underlying this hyporesponsiveness to ET-1
warrants further investigation.
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